tretinoin profile

Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (46)

tretinoin is involved in 46 pathway(s), involving a total of 8797 unique proteins and 3437 unique compounds

ID Source	ID
PubMed CID	444795
CHEMBL ID	38
CHEBI ID	15367
SCHEMBL ID	3145
SCHEMBL ID	19091395
MeSH ID	M0021879

Synonym
BIDD:PXR0081
BIDD:GT0483
MLS001076515
97950-17-9
retinoic acid, cis-
cis-retinoic acid
AB00052318-17
avita (0.025% gel)
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid
altreno (0.05% lotion)
all-trans-retinoic acid (atra)
renova (0.02% cream)
gtpl2644
aberel
2,6,8-nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-
wln: l6utj a1 b1u1y1&u2u1y1&u1vq c1 c1
tretinoin, all-trans-
alltrans-retinoic acid
vitamin a1 acid, all-trans-
tretinoin
airol
retionic acid
vesanoid (tn) (roche)
aknefug
retin-a
avita
nsc122758
retinoic acid, all-trans-
wln: l6utj a1 b1u1y1 & u2u1y1 & u1vq c1 c1
all trans-retinoic acid
nsc-122758
2,6,8-nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-e)-
dermairol
aknoten
vitamin a acid, all-trans-
.beta.-retinoic acid
eudyna
3,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
stieva-a
renova
retisol-a
CHEBI:15367 ,
vesanoid
(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
atralin
retinova
nexret
EU-0101061
retinoic acid, >=98% (hplc), powder
tretinoin (jan/usp/inn)
retin a (tn)
D00094
avita (tn)
tretinoin (tn)
renova (tn)
brn 2057223
beta-ra
a-acido (argentina)
vitamin a acid, trans-
tretinoine [inn-french]
aberela [norway]
hsdb 2169
acid a vit (belgium, netherlands)
all trans retinoic acid
nsc 122758
retin-a micro
avitoin [norway]
lgd 100057
einecs 206-129-0
15-apo-beta-caroten-15-oic acid
effederm
effederm [france]
cordes vas [germany]
tretinoinum [inn-latin]
ccris 3294
tretinoino [inn-spanish]
tretinoina [inn-spanish]
a-vitaminsyre [denmark]
acnavit [denmark]
3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-all-trans-tetraenoic acid
BSPBIO_000074
PRESTWICK2_000257
SPECTRUM5_001933
SPECTRUM5_001746
tretinon
PRESTWICK_424
tnp00194 ,
cas-302-79-4
3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2e,4e,6e,8e-tetraenoic acid
LMPR01090019
tretinoin/all-trans retinoic acid
NCGC00021808-15
NCGC00021808-14
BSPBIO_001500
PRESTWICK3_000257
IDI1_033970
IDI1_000903
BPBIO1_000082
2,4, 6,8-nonatetranoic acid, 3,7-dimethyl-9-(2,6, 6-trimethyl-1-cyclohexen-1-yl)-, (2e, 4e, 6e, 8e)-
(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
2,4,6,8-nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-e)-
retin a
retacnyl
retinoic acid, all-trans- (8ci)
cordes vas
atragen
epi-aberel
atra
vesnaroid
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid
all-trans-b-retinoic acid
all-trans-tretinoin
tretinoine (french) (einecs)
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
vitamin a acid
tretin m
302-79-4
beta-retinoic acid
retinoic acid
all-trans-beta-retinoic acid
all-trans-vitamin a acid
C00777
ro 1-5488
trans-retinoic acid
acide retinoique (french) (dsl)
(all-e)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
all-(e)-retinoic acid
all-trans-retinoic acid
agn 100335
all-trans-vitamin a1 acid
1N4H
DB00755
UPCMLD-DP097
NCGC00021808-09
NCGC00021808-06
NCGC00021808-05
smr000058245
MLS000028588 ,
SPECTRUM1502016
LOPAC0_001061
NCGC00021808-04
NCGC00021808-07
dtxsid7021239 ,
all-trans retinoic acid
cid_444795
NCGC00017280-06
bdbm31883
[3h]ra
[3h]vitamin a acid
[3h]retinoic acid
9-cis-retinoic acid (9cra)
chembl38 ,
[3h]tretinoin
at-ra
R 2625 ,
HMS2092N11
HMS1989K22
HMS2089D20
AC-6824
NCGC00017280-17
MLS002207234
AKOS000280845
L000833
MLS002222211
BMSE000562
2,4,6,8-nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-
oristar rna
kerlocal
retinoic acid, all trans
BML2-E05 ,
HMS1361K22
HMS1791K22
HMS502N05
sr-01000000239
SR-01000000239-14
R0064
all-trans-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
HMS1568D16
HMS1921D14
NCGC00017280-10
cpd000058245
NCGC00021808-11
HMS3263E04
HMS3259E11
HMS2095D16
tretinoin [usan:usp:inn:ban]
aberela
tretinoino
avitoin
unii-5688utc01r
betarretin
5688utc01r ,
acnavit
refissa
tretinoinum
a-vitaminsyre
tretinoina
NCGC00254179-01
tox21_300305
tox21_202330
NCGC00259879-01
MLS002548861
nsc759631
nsc-759631
pharmakon1600-01502016
tox21_110812
dtxcid001239
HMS2236N03
CCG-39912
NCGC00017280-07
NCGC00017280-18
NCGC00017280-16
NCGC00017280-08
NCGC00017280-20
NCGC00017280-12
NCGC00017280-19
NCGC00017280-15
NCGC00017280-05
NCGC00017280-09
HY-14649
CS-1269
BCPP000036
BP-20401
LP01061
tretinoin [vandf]
tretinoin [usp monograph]
tri-luma component tretinoin
tretinoin component of solage
ziana component tretinoin
tretinoin [inn]
tretinoin component of twyneo
retinoic acid [mi]
tretinoin [hsdb]
tretinoin [usan]
tretinoin [mart.]
altreno
twyneo component tretinoin
tretinoin [usp-rs]
tretinoin [ep monograph]
tretinoin [jan]
tretinoin [who-dd]
veltin component tretinoin
tretinoin component of ziana
tretinoin component of veltin
isotretinoin impurity a [ep impurity]
solage component tretinoin
tretinoin component of tri-luma
tretinoin [orange book]
retinoic acid [inci]
1CBR
S1653
BRD-K06926592-001-01-7
MLS006010222
NC00481
SCHEMBL3145
BRD-K71879491-001-22-6
tox21_110812_1
NCGC00017280-23
AB00052318-15
AB00052318-16
NCGC00261746-01
tox21_501061
Q-200610
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2e,4e,6e,8e,-nonatetraenoic acid
2,4,6,8-nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all trans)-
2,4,6,8-nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)--, (all trans)-
.beta.-all-trans-retinoic acid
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid-, (all trans)-
[all-e]-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
HMS3402K22
OPERA_ID_1055
AB00052318_19
AB00052318_18
mfcd00001551
GS-3578
SR-01000000239-6
tretinoin, united states pharmacopeia (usp) reference standard
beta-retinoate
acide retinoique (french)
(all-e)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
trans-retinoate
tretinoine (french)
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
tretinoin, european pharmacopoeia (ep) reference standard
tretinoin, pharmaceutical secondary standard; certified reference material
tretinoin; (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid; retinoic acid; isotretinoin impurity a
retinoic acid all trans
SR-01000000239-3
SR-01000000239-7
SR-01000000239-12
SR-01000000239-13
SR-01000000239-4
SR-01000000239-15
SBI-0051031.P003
isotretinoin;(2z,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
HMS3712D16
11-cis,13-cis-
SW203749-4
SCHEMBL19091395
all-trans retinoic acid (tretinoin)
HMS3675B09
vitamin-a-sa currencyure
all-(e)-retinoate
BCP01405
HMS3411B09
Q29417
BRD-K71879491-001-15-0
retinoicacid
SDCCGSBI-0051031.P004
NCGC00017280-38
lgd 1057; nsc 659772; panretin; panretyn; panrexin; toctino
A899883
bdbm323588
us10188615, at-ra
BR164493
tretinion
HY-14649G
CS-0626116
retinoic acid (gmp)
EN300-27107561
(8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
tretinoin (ep monograph)
retin-a-micro
tretinoinum (inn-latin)
isotretinoin impurity a (ep impurity)
tretinoino (inn-spanish)
tretinoin (usan:usp:inn:ban)
tretinoina (inn-spanish)
tretinoin cream
tretinoin (usp-rs)
d10ad01
tretinoine (inn-french)
l01xx14
tretinoin (usp monograph)
tretinoin (mart.)

Excerpt	Reference
"Alitretinoin is a systemic retinoid licensed for use in adult patients suffering from chronic hand eczema recalcitrant to potent topical steroids. "	( Knöpfel, N; Luchsinger, I; Schwieger-Briel, A; Theiler, M; Vogler, T; Wälchli, R; Weibel, L, 2020)
"Tretinoin (TRE) is a widely used retinoid for the topical treatment of acne, psoriasis, skin cancer and photoaging. "	( Katare, OP; Lohan, S; Negi, P; Raza, K; Sharma, G; Singh, B; Yachha, Y, 2013)
"Tretinoin is a drug widely used in the topical treatment of various dermatological diseases."	( Corrias, F; Fadda, AM; Lai, F; Pini, E; Pireddu, R; Sinico, C; Valenti, D, 2013)
"Tretinoin is a retinoid derivative that has an antiproliferative effect on several kinds of tumours. "	( Beck, RC; Begnini, KR; Campos, VF; Collares, T; de Leon, PM; Dellagostin, OA; Guterres, SR; Ourique, A; Pohlmann, AR; Schultze, E; Seixas, FK; Thurow, H; Yurgel, VC, 2014)
"Tretinoin (TRT) is a widely used retinoid for the topical treatment of acne, photo-aged skin, psoriasis and skin cancer which makes it a good candidate for topical formulation. "	( Abdelmalak, NS; Badawi, A; El Ramly, A; Elbayoumy, T; Rahman, SA; Sabry, N, 2015)
"Tretinoin-UDV is a promising delivery system for tretinoin dermal delivery without promoting skin irritation (unlike other commercial formulations), which is quite advantageous for therapeutic purpose."	( Ascenso, A; Bentley, MV; Euletério, C; Marques, HC; Oliveira, H; Praça, FG; Salgado, A; Santos, C; Simões, S, 2014)
"Alitretinoin is an effective treatment option for nail LP. "	( Alsenaid, A; Braun-Falco, M; Eder, I; Ruzicka, T; Wolf, R, 2014)
"Alitretinoin is an endogenous vitamin A derivative, 9-cis-retinoic acid. "	( D'Erme, AM; Gola, M; Milanesi, N, 2015)
"Tretinoin is known to be a pharmaceutical drug for treating acne vulgaris, keratosis pilaris, and acute promyelocytic leukemia. "	( Karthick, T; Singh, S; Tandon, P, 2017)
"Tretinoin is a mitogen by itself and also enhances the absorption of minoxidil which acts by enlarging the miniaturized hair follicles."	( Dhurat, RS; Jerajani, HR; Melkote, S; Palav, A, 2009)
"Tretinoin (Vesanoid) is an all-trans-retinoic acid, and is related to retinol (Vitamin A). "	( Olson, K; Su-Yin, A; Wiegand, T; Wong, J, 2009)
"Alitretinoin is an endogenous retinoid and acts as a pan-agonist at retinoid receptors, binding with high affinity to both retinoic acid receptors and retinoid X receptors (RXR). "	( Garnock-Jones, KP; Perry, CM, 2009)
"Alitretinoin is a new drug for systemic treatment of chronic hand eczema. "	( Agner, T; Hellgren, LI; Høgh, JK; Jemec, GB; Jungersted, JM, 2010)
"Alitretinoin is a novel agent which showed high clinical efficacy in patients with severe, refractory CHE."	( Blank, AA; Blank, PR; Szucs, TD, 2010)
"Alitretinoin is an endogenously occurring physiological vitamin A derivative (retinoid) that possesses strong anti-inflammatory and immunomodulatory activity."	( Alexandroff, AB; de Sica Chapman, A; English, J; Graham-Brown, R, 2011)
"Alitretinoin is an endogenous retinoid related to vitamin A. "	( Kovacs, P; Leese, PT; Meyer, I; Roos, B; Schmitt-Hoffmann, AH; Schoetzau, A; van de Wetering, J, 2012)
"Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoic acid receptor (RAR) subtypes alpha, beta, and gamma and retinoic X receptor (RXR) subtypes alpha, beta, and gamma."	( Baumann, L; Black, L; Bryde, J; Halem, M; Kerdel, F; Lazarus, M; Martin, LK; Pacheco, H; Vujevich, J, 2005)
"Isotretinoin has proved to be an effective drug; response to therapy has been seen in virtually 100 percent of patients treated."	( Eaton, ML; Robinson, LA; Rumsfield, JA; Tse, CS; West, DP, 1983)
"Isotretinoin is a new orally active retinoic acid derivative for the treatment of severe refractory nodulocystic acne. "	( Avery, GS; Brogden, RN; Heel, RC; Speight, TM; Ward, A, 1984)
"Tretinoin tocoferil is an alpha-tocopherol ester of all-trans retinoic acid (RA) and safely used in the treatment of skin ulcer. "	( Honma, Y; Kanatani, Y; Makishima, M; Yamamoto-Yamaguchi, Y, 1996)
"Tretinoin is a valuable drug when given at low doses to patients with lichen planus who failed to respond to other therapies."	( Bollag, W; Geiger, JM; Ott, F, 1996)
"Tretinoin tocoferil is an alpha-tocopherol ester of all-trans retinoic acid (ATRA) and safely used to treat skin ulcers. "	( Honma, Y; Makishima, M, 1997)
"Tretinoin-iontophoresis is an effective, noninvasive treatment of atrophic acne scars without causing disturbing side-effects."	( Donath, P; Hannes, J; Neumayer, R; Perl, S; Reiner, A; Schmidt, JB, 1999)
"Alitretinoin (9-cis RA) is an endogenous retinoid with high binding affinity for both RAR and RXR receptor families."	( Cato, A; Dancey, J; Eisenhauer, E; Huan, S; Jaunakais, D; Loewen, GR; Matthews, S; Miller, WH; Moore, M; Reyno, LM; Truglia, JA; Winquist, E, 2000)
"Isotretinoin is a potent retinoic acid used in the treatment of skin disorders. "	( Fedderson, DE; Franck, BH; Mann, TK; Rathmell, WK; Wiens, DJ, 1992)
"Tretinoin is a safe and highly effective agent for inducing complete remission in patients with acute promyelocytic leukemia. "	( Andreeff, M; Frankel, SR; Hittelman, WN; Itri, LM; Jakubowski, A; Miller, WH; Scheinberg, DA; Tafuri, A; Vyas, R; Warrell, RP, 1991)
"Isotretinoin (13-cis-RA) is a human teratogen and mouse embryos exposed to 13-cis-RA in vivo exhibit many of the same defects as humans. "	( Abbott, BD; Goulding, EH; Jetten, AM; Pratt, RM, 1988)
"Isotretinoin (Accutane) is a lately developed synthetic oral retinoid for treatment of severe forms of cystic acne resistant to therapy. "	( Bauermeister-Jasso, K; Enderer, K; Mahrle, G, 1985)
"Isotretinoin is a clinically effective short-term therapy for chronic or possibly for subacute cutaneous lupus erythematosus."	( Bell, JD; Cavallo, T; Daniels, JC; Jorizzo, JL; Newton, RC; Sanchez, RL; Solomon, AR, 1986)

Excerpt	Reference
"Alitretinoin has a similar pharmacology action to acitretin, but much shorter half-life (only four weeks), making it a far much more attractive option compared to acitretin for women of child-bearing age."	( Mannello, B; Menon, S; Pavlou, P; Simonacci, F; Verdolini, R, 2015)
"Alitretinoin has an anti-inflammatory and immunomodulatory mechanism of action."	( Molin, S; Ruzicka, T, 2008)
"Tretinoin cream has an excellent safety record; a local cutaneous hypervitaminosis A reaction is the only common problem."	( Ellis, CN; Goldfarb, MT; Voorhees, JJ; Weiss, JS, 1989)
"Isotretinoin, however, has a profound inhibitory effect on sebaceous gland size and function."	( Demers, LM; Lookingbill, DP; Shalita, AR; Tigelaar, RE, 1988)
"Tretinoin has been the backbone of APL therapy since the late 1990s and is only available as a liquid filled capsule."	( Fallon, MJ; Jared, JR; Przybylski, DJ, 2021)
"Alitretinoin has a similar pharmacology action to acitretin, but much shorter half-life (only four weeks), making it a far much more attractive option compared to acitretin for women of child-bearing age."	( Mannello, B; Menon, S; Pavlou, P; Simonacci, F; Verdolini, R, 2015)
"Alitretinoin has an anti-inflammatory and immunomodulatory mechanism of action."	( Molin, S; Ruzicka, T, 2008)
"Alitretinoin has been shown to be effective in a randomized controlled trial, and is currently the only treatment specifically licensed for the treatment of hand eczema."	( Aldridge, R; English, J; Gawkrodger, DJ; Kownacki, S; Statham, B; White, JM; Williams, J, 2009)
"Isotretinoin has proved to be an effective drug; response to therapy has been seen in virtually 100 percent of patients treated."	( Eaton, ML; Robinson, LA; Rumsfield, JA; Tse, CS; West, DP, 1983)
"Isotretinoin probably has multiple modes of action, including (1) inhibition of sebaceous gland activity, (2) inhibition of the growth of Propionibacterium acnes within the follicle, although the retinoid is not antibacterial, (3) inhibition of inflammation, and (4) alteration of the pattern of keratinization within the follicle, as demonstrated by light and ultrastructural studies."	( Nikolowski, J; Plewig, G; Wolff, HH, 1982)
"Tretinoin has been shown to stimulate the synthesis of collagen in photo-aged human and hairless mouse skin. "	( Kligman, LH; Sapadin, AN; Schwartz, E, 1996)
"Tretinoin has been thoroughly evaluated for its potential as an embryofetal developmental toxicant. "	( Christian, MS; Kochhar, DM, 1997)
"Isotretinoin, which has recently become available, is less irritating, but is probably somewhat less effective."	( Kligman, AM, 1997)
"Alitretinoin gel has significant antitumor activity as a topical treatment for AIDS-related KS lesions, substantially reduces the incidence of disease progression in treated lesions, and is generally well tolerated."	( Duvic, M; Friedman-Kien, AE; Galpin, JE; Groopman, J; Loewen, G; Looney, DJ; Miles, SA; Myskowski, PL; Scadden, DT; Stevens, V; Truglia, JA; Von Roenn, J; Yocum, RC, 2000)
"Tretinoin has been available in China for decades; adapalene became available in 1998."	( Li, GQ; Tu, P; Wong, WZ; Zheng, J; Zhu, XJ, 2001)
"Tretinoin has been previously shown in animal and clinical studies to stimulate epidermal cell production and to be effective in the treatment of solar keratoses. "	( Lever, L; Marks, R, 1990)
"Tretinoin has previously been used for the treatment of acne. "	( Ellis, CN; Goldfarb, MT; Voorhees, JJ; Weiss, JS, 1990)
"Tretinoin has been shown to be effective in the improvement of these visible signs."	( Goh, SH, 1990)
"Tretinoin cream has been used extensively to reverse the changes of photoaging. "	( Ellis, CN; Goldfarb, MT; Voorhees, JJ; Weiss, JS, 1989)
"Isotretinoin, however, has a profound inhibitory effect on sebaceous gland size and function."	( Demers, LM; Lookingbill, DP; Shalita, AR; Tigelaar, RE, 1988)
"Isotretinoin has decided advantages over previously reported therapies for gram-negative folliculitis."	( James, WD; Leyden, JJ, 1985)
"Isotretinoin has been found to be effective in the treatment of Gram-negative folliculitis. "	( Morello, JA; Sahm, DF; Simjee, S; Soltani, K, 1986)
"Tretinoin has been shown to promote and regulate cell proliferation and differentiation in the epithelium and may promote vascular proliferation."	( Bazzano, GS; Galen, W; Terezakis, N, 1986)

Excerpt	Reference
"As tretinoin can cause skin irritation, the herbal extract can be a better alternative treatment."	( Asawaworarit, P; Chuanchaiyakul, S; Kamanamool, N; Piyavechvirat, T; Udompataikul, M, 2017)
"Tretinoin may increase the efficacy of corticosteroids in this setting."	( Alinia, H; Feldman, SR; Mansoori, P; Moradi Tuchayi, S; Orscheln, CS; Taheri, A, 2015)
"Tretinoin is known to increase the percutaneous absorption of minoxidil and, therefore, to enhance the response of AGA to minoxidil."	( Eun, HC; Kim, KH; Kwon, OS; Lee, SH; Shin, HS; Won, CH, 2007)
"Tretinoin appears to enhance this effect of azelaic acid."	( Breathnach, AS, 1996)

Excerpt	Reference
"Tretinoin treatment significantly lowered skin resistance and elastance, which is a result that indicates higher distensibility of the skin. "	( Dematte, MF; Dolhnikoff, M; Ferreira, MC; Gemperli, R; Lanças, T; Saldiva, PH; Salles, AG, 2011)
"In tretinoin-treated mice and non-treated mice (controls), the mean (SD) thicknesses of granulation were 1.383 (697) micro m and 683 (413) micro m, the density of capillary vessels in granulation was 12.2 (5.5)% and 5.7 (3.9)%, respectively."	( Harii, K; Kurita, M; Momosawa, A; Ohura, N; Toyama, T, 2006)
"Tretinoin treatment produced a marked increase in the viable epidermal thickness and resulted in a more undulating dermoepidermal junction with prominent rete ridges. "	( Dogadkina, D; Kligman, AM; Lavker, RM, 1993)
"Tretinoin-treated skin had increased amounts of collagen and type III procollagen whereas irritant- and peeling agent-treated skins were similar to vehicle-treated controls."	( Kligman, LH; Sapadin, AN; Schwartz, E, 1996)
"Oral tretinoin: After oral treatment, in the absence of maternal toxicity, significantly more offspring of dams receiving 5 mg/kg or greater had supernumerary ribs, and offspring of the 10 mg/kg treatment group had a greater incidence of cleft palate than had control offspring."	( Carter, MW; Ford, WH; Mitala, JJ; Powers, WJ; Seegmiller, RE, 1997)
"Tretinoin treatment of acne and of nonacne conditions were equal at an age of 44."	( Feldman, SR; Fleischer, AB; McConnell, RC; Williford, PM, 1998)
"Six tretinoin topically-treated patients (0.25 mg daily of 0.1% tretinoin cream) were matched with five non-treated control patients comparing mucositis severity, duration and analgetic (morphine) requirements."	( Cohen, G; Elad, S; Galili, D; Garfunkel, AA; Or, R, 1997)
"Tretinoin-treated skin was smooth and pink, resembling that of younger mice."	( Capetola, RJ; Kligman, LH; Mezick, JA; Thorne, EG, 1992)
"Tretinoin treatment produced an improvement in the signs of extrinsic ageing compared with the vehicle-treated areas."	( Ellis, CN; Goldfarb, MT; Voorhees, JJ, 1990)
"Isotretinoin treatment had no influence on the isoelectric focusing pattern of apoprotein E isoforms and C apoproteins."	( Bros, U; Melnik, B; Plewig, G, 1987)
"The tretinoin-treated arms had 15.7 +/- 6.1 AK before treatment and 3.4 +/- 2.6 AK following therapy."	( Bercovitch, L, 1987)
"Treatment with tretinoin was immediately initiated."	( Goto, M; Hamasaki, Y; Isomura, N; Yamashita, Y, 2013)
"Treatment with tretinoin resulted in significantly greater improvement relative to placebo in clinical signs of photodamage (fine and coarse wrinkling, mottled hyperpigmentation, lentigines, and sallowness), overall photodamage severity, and investigator's global assessment of clinical response (p<0.05). "	( Bergfeld, W; Fisher, GJ; Gottlieb, AB; Grossman, R; Hammerberg, C; Hickman, J; Humeniuk, J; Kang, S; Kempers, S; Lebwohl, M; Lowe, N; McMichael, A; Milbauer, J; Nighland, M; Nyirady, J; Phillips, T; Powers, J; Rodriguez, D; Savin, R; Shavin, J; Sherer, D; Silvis, N; Weinstein, R; Weiss, J, 2005)
"Pretreatment with tretinoin did not enhance skin flap survival under the conditions of this study."	( Canady, JW; Thompson, SA, 1994)
"Drug treatment with tretinoin is associated with morphological and functional maturation of leukaemic promyelocytes and a progressive reduction in the occurrence of the characteristic t(15;17) chromosomal translocation."	( Gillis, JC; Goa, KL, 1995)
"Treatment with tretinoin before and after TCA did not significantly enhance the efficacy of the peel."	( Dzubow, L; Humphreys, TR; Kligman, A; Werth, V, 1996)
"Treatment with tretinoin for 4 months restored the elasticity, the glyphic markings, with a partial restoration of pigmentation."	( Kligman, AM; Pagnoni, A; Sadiq, I; Stoudemayer, T, 1999)
"Pretreatment with tretinoin before epidermal injury such as chemical peeling and dermabrasion has shown accelerated wound healing."	( Badiavas, E; Falanga, V; Paquette, D, 2001)
"Treatment with tretinoin brought about regression of the lesions."	( Kligman, AM; Mills, OH, 1975)
"Treatment with tretinoin (topical vitamine A acid) resulted in a severe inflammatory reactions in the lesions which persisted for four monthes and did not prevent a mild recurrence of the disease."	( Moss, HV, 1979)
"Mice treated with tretinoin also appeared to have increased amounts of elastic fibers and glycosaminoglycans."	( Capetola, RJ; Kligman, LH; Mezick, JA; Thorne, EG, 1992)
"Treatment with tretinoin resulted in a significant increase in the rate of healing in control but not in diabetic eyes."	( Hatchell, DL; Hatchell, MC; Stekiel, T; Ubels, JL, 1985)

Role	Description
keratolytic drug	A drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
antioxidant	A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
signalling molecule	A molecular messenger in which the molecule is specifically involved in transmitting information between cells. Such molecules are released from the cell sending the signal, cross over the gap between cells by diffusion, and interact with specific receptors in another cell, triggering a response in that cell by activating a series of enzyme controlled reactions which lead to changes inside the cell.
retinoid X receptor agonist	An agonist that selectively binds to and activates a retinoid X receptor.
anti-inflammatory agent	Any compound that has anti-inflammatory effects.
AP-1 antagonist	An antogonist that interferes with the action of activator protein 1 (AP-1).
retinoic acid receptor agonist	An agonist that selectively binds to and activates a retinoic acid receptor.
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
retinoic acid	A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).
vitamin A	Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Developmental Biology	727	30
Activation of HOX genes during differentiation	51	1
Activation of anterior HOX genes in hindbrain development during early embryogenesis	51	1
Metabolism	1496	1108
Metabolism of lipids	500	463
Fatty acid metabolism	113	203
Carnitine metabolism	10	13
The citric acid (TCA) cycle and respiratory electron transport	147	56
Pyruvate metabolism and Citric Acid (TCA) cycle	41	46
Pyruvate metabolism	20	26
Regulation of pyruvate dehydrogenase (PDH) complex	9	14
Biological oxidations	150	276
Phase I - Functionalization of compounds	69	175
Cytochrome P450 - arranged by substrate type	30	110
Vitamins	4	15
Miscellaneous substrates	3	15
Signaling Pathways	1269	117
Signaling by Nuclear Receptors	152	46
Signaling by Retinoic Acid	24	31
RA biosynthesis pathway	11	19
Retinol Metabolism	37	30
Vitamin A Deficiency	37	30
Disease	1278	231
Diseases of metabolism	69	121
Metabolic disorders of biological oxidation enzymes	6	47
Defective CYP26B1 causes RHFCA	1	4
Gene expression (Transcription)	902	49
RNA Polymerase II Transcription	728	42
Generic Transcription Pathway	608	39
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	33	1
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation	5	1
Transcriptional regulation of granulopoiesis	28	1
Gastrulation	118	1
Acute myeloid leukemia	0	9
Vitamin A1 and A5/X pathways	0	3
Formation of intermediate mesoderm	8	1
Kidney development	43	1
Formation of the nephric duct	18	1
Chicken limb development	1	1
Differentiation pathway	0	12
Cardiac progenitor differentiation	0	1
Pluripotent stem cell differentiation pathway	0	11
Dopaminergic neurogenesis	0	1
Nuclear receptors in lipid metabolism and toxicity	0	3
4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression	0	11
Vitamin A and carotenoid metabolism	0	20

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	8.9125	0.0447	17.8581	100.0000	AID485341
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	28.1838	0.1778	14.3909	39.8107	AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	39.8107	0.1259	19.1169	125.8920	AID2549
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	28.1838	5.6234	17.2929	31.6228	AID2323
Chain A, Cruzipain	Trypanosoma cruzi	Potency	35.7168	0.0020	14.6779	39.8107	AID1476
Luciferase	Photinus pyralis (common eastern firefly)	Potency	47.2810	0.0072	15.7588	89.3584	AID1224835; AID624030
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	23.9625	0.1000	20.8793	79.4328	AID488773; AID588453
pregnane X receptor	Rattus norvegicus (Norway rat)	Potency	37.6188	0.0251	27.9203	501.1870	AID651751
phosphopantetheinyl transferase	Bacillus subtilis	Potency	79.4328	0.1413	37.9142	100.0000	AID1490
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	56.0456	3.1890	29.8841	59.4836	AID1224846; AID1224894
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	3.9743	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
USP1 protein, partial	Homo sapiens (human)	Potency	67.8335	0.0316	37.5844	354.8130	AID504865
GLS protein	Homo sapiens (human)	Potency	0.2512	0.3548	7.9355	39.8107	AID624146
TDP1 protein	Homo sapiens (human)	Potency	15.3236	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	9.0323	0.0007	14.5928	83.7951	AID1259368; AID1259369; AID1259392
Microtubule-associated protein tau	Homo sapiens (human)	Potency	28.1274	0.1800	13.5574	39.8107	AID1460; AID1468
AR protein	Homo sapiens (human)	Potency	12.4064	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID588516; AID743035; AID743042; AID743054; AID743063
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	35.4813	0.1000	22.9075	100.0000	AID485364
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	32.4681	0.0112	12.4002	100.0000	AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	0.2512	0.0013	7.7625	44.6684	AID914; AID915
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	31.1877	0.0006	57.9133	22,387.1992	AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	24.0778	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	26.6795	0.5318	15.4358	37.6858	AID504845
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	19.4971	0.0123	7.9835	43.2770	AID1645841
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	7.0795	0.2818	9.7212	35.4813	AID2326
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	58.3079	0.0002	14.3764	60.0339	AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	11.0429	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	0.4110	0.0008	17.5051	59.3239	AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	11.9970	0.0015	30.6073	15,848.9004	AID1224819; AID1224820; AID1224821; AID1224823; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	28.3860	0.3758	27.4851	61.6524	AID588527; AID743217; AID743220; AID743239
pregnane X nuclear receptor	Homo sapiens (human)	Potency	42.8055	0.0054	28.0263	1,258.9301	AID1346982; AID720659
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	7.4771	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	27.5404	0.0123	8.9648	39.8107	AID1645842
Parkin	Homo sapiens (human)	Potency	3.6626	0.8199	14.8306	44.6684	AID720573
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	79.4328	0.7079	36.9043	89.1251	AID504333
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	22.1439	0.0010	24.5048	61.6448	AID588534; AID743212; AID743227
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	13.8468	0.0010	19.4141	70.9645	AID588536; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	31.6228	0.0237	23.2282	63.5986	AID588543
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	37.9025	0.0355	20.9770	89.1251	AID504332
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	39.1150	0.0007	23.0674	1,258.9301	AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	29.8493	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	21.3156	0.0016	28.0151	77.1139	AID1224843; AID1224895; AID1259385
activating transcription factor 6	Homo sapiens (human)	Potency	58.2993	0.1434	27.6121	59.8106	AID1159516
thyrotropin-releasing hormone receptor	Homo sapiens (human)	Potency	37.9117	0.1549	17.8702	43.6557	AID1346877
Caspase-7	Cricetulus griseus (Chinese hamster)	Potency	68.5199	0.0067	23.4960	68.5896	AID1346980
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	0.0224	0.5406	17.6392	96.1227	AID2364; AID2528
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	47.3935	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	39.8107	0.0060	26.1688	89.1251	AID488953
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	0.0028	0.0100	39.5371	1,122.0200	AID588547
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	3.2643	0.0041	9.9848	25.9290	AID504444
caspase-3	Cricetulus griseus (Chinese hamster)	Potency	68.5199	0.0067	23.4960	68.5896	AID1346980
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	30.6776	0.0003	23.4451	159.6830	AID743065; AID743066; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	49.6428	0.0420	27.3789	61.6448	AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	41.3145	0.0006	27.2152	1,122.0200	AID651741; AID720636; AID743202; AID743219
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	6.3903	0.0079	8.2332	1,122.0200	AID2551
geminin	Homo sapiens (human)	Potency	30.7052	0.0046	11.3741	33.4983	AID463097; AID624296
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	31.6228	0.0316	22.3146	100.0000	AID588579
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	0.1994	0.0056	12.3677	36.1254	AID624044
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	0.7943	0.1259	12.2344	35.4813	AID1458
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	39.8107	0.0316	10.2792	39.8107	AID884; AID885
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	19.9526	0.1778	24.7352	79.4328	AID488949
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	31.6228	0.2512	15.8432	39.8107	AID504327
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	0.2188	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	27.5404	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	27.5404	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	55.9471	0.0023	19.5956	74.0614	AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	0.2188	0.0015	51.7393	15,848.9004	AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	27.5404	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	31.1448	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	27.4122	0.0119	12.2221	68.7989	AID651632
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	27.5404	0.0123	8.9648	39.8107	AID1645842
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	33.8078	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Nuclear Receptor ROR-beta	Rattus norvegicus (Norway rat)	Ki	0.2800	0.2800	0.2800	0.2800	AID977610
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	71.5000	0.1100	7.1903	10.0000	AID1449628; AID1473738
Amyloid-beta precursor protein	Homo sapiens (human)	IC50 (µMol)	0.1800	0.0005	3.8895	10.0000	AID1695748
Adenosine receptor A3	Homo sapiens (human)	IC50 (µMol)	5.2750	0.0000	1.8940	8.5470	AID625196
Adenosine receptor A3	Homo sapiens (human)	Ki	2.9820	0.0000	0.9306	10.0000	AID625196
Retinoic acid receptor alpha	Homo sapiens (human)	IC50 (µMol)	2.2542	0.0008	0.9324	9.0000	AID198042; AID198043; AID198044; AID282378
Retinoic acid receptor alpha	Homo sapiens (human)	Ki	0.0688	0.0010	0.9485	6.5000	AID198057; AID200134; AID200139
60 kDa heat shock protein, mitochondrial	Homo sapiens (human)	IC50 (µMol)	5.3000	0.1700	4.5590	10.0000	AID1594139
Retinoic acid receptor beta	Homo sapiens (human)	IC50 (µMol)	0.7537	0.0009	0.4353	3.0000	AID198533; AID198534; AID199387; AID282379
Retinoic acid receptor beta	Homo sapiens (human)	Ki	0.0095	0.0007	1.5673	9.9010	AID198218; AID198222; AID198547
Retinoic acid receptor alpha	Mus musculus (house mouse)	IC50 (µMol)	0.0057	0.0050	0.0120	0.0310	AID197910; AID197911; AID197912
Retinoic acid receptor gamma	Homo sapiens (human)	IC50 (µMol)	0.0064	0.0005	0.0109	0.0260	AID199044; AID199045; AID199392
Retinoic acid receptor gamma	Homo sapiens (human)	Ki	0.0056	0.0000	1.9975	10.0000	AID198732; AID198738; AID199055; AID199058
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	5.2750	0.0002	1.8742	10.0000	AID625196
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.7458	0.0001	0.9490	10.0000	AID35839; AID625196
Alpha-1A adrenergic receptor	Bos taurus (cattle)	Ki	0.0004	0.0000	0.5072	3.7020	AID35839
Retinoic acid receptor gamma	Mus musculus (house mouse)	IC50 (µMol)	0.0040	0.0040	0.0040	0.0040	AID198890; AID198891
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Ki	0.0005	0.0001	0.7396	10.0000	AID41913
Retinoic acid receptor RXR-alpha	Homo sapiens (human)	IC50 (µMol)	1.0000	0.0060	0.4450	2.4000	AID199226
Retinoic acid receptor RXR-alpha	Homo sapiens (human)	Ki	0.2268	0.0004	0.5692	7.6320	AID199210; AID199640; AID35839
Retinoic acid receptor beta	Mus musculus (house mouse)	IC50 (µMol)	0.0050	0.0050	0.0050	0.0050	AID198366; AID198367
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0004	0.0000	0.5751	10.0000	AID35839
Mitogen-activated protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.5760	0.0003	1.6878	9.2000	AID625181
Retinoic acid receptor RXR-alpha	Mus musculus (house mouse)	IC50 (µMol)	18.0000	0.0820	0.0820	0.0820	AID199221; AID199509; AID199510
Retinoic acid receptor RXR-beta	Homo sapiens (human)	IC50 (µMol)	1.0000	0.0120	0.0120	0.0120	AID199362
Retinoic acid receptor RXR-beta	Homo sapiens (human)	Ki	0.3118	0.0005	0.1592	0.8810	AID199230; AID199807; AID41913
Indoleamine 2,3-dioxygenase 1	Mus musculus (house mouse)	IC50 (µMol)	301.3000	0.0060	1.6251	10.0000	AID717846
Nuclear receptor ROR-alpha	Homo sapiens (human)	IC50 (µMol)	0.1995	0.1995	1.5998	2.6000	AID1168690
Alpha-synuclein	Homo sapiens (human)	IC50 (µMol)	3.0000	0.1900	3.8204	9.8000	AID1695730
Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)	IC50 (µMol)	0.5233	0.3700	0.6740	0.9000	AID55119; AID55248; AID55249
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	IC50 (µMol)	0.3580	0.0001	1.1873	8.9125	AID625217
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	Ki	0.2280	0.0003	0.7693	10.0000	AID625217
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	5.2750	0.0000	1.8194	10.0000	AID625196
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.7458	0.0000	0.9650	10.0000	AID35839; AID625196
Retinoic acid receptor RXR-gamma	Homo sapiens (human)	IC50 (µMol)	0.3500	0.0040	0.1770	0.3500	AID199380
Retinoic acid receptor RXR-gamma	Homo sapiens (human)	Ki	0.1365	0.0014	0.1526	1.0000	AID199366; AID199967; AID73356
Nuclear receptor ROR-gamma	Homo sapiens (human)	IC50 (µMol)	0.1995	0.0600	1.9357	9.4100	AID1168688
10 kDa heat shock protein, mitochondrial	Homo sapiens (human)	IC50 (µMol)	5.3000	0.1700	4.5590	10.0000	AID1594139
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	IC50 (µMol)	0.8200	0.8200	3.9067	5.9000	AID1391263
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Ki	0.8200	0.8200	0.8200	0.8200	AID1693195
Thiosulfate sulfurtransferase	Homo sapiens (human)	IC50 (µMol)	91.0000	0.0600	3.9631	9.7000	AID1594135
60 kDa chaperonin	Escherichia coli	IC50 (µMol)	13.8500	0.0390	3.5552	9.8000	AID1594140; AID1594141
10 kDa chaperonin	Escherichia coli	IC50 (µMol)	13.8500	0.0390	3.5552	9.8000	AID1594140; AID1594141
Indoleamine 2,3-dioxygenase 2	Mus musculus (house mouse)	IC50 (µMol)	28.7000	1.5000	5.0875	8.2000	AID717845
Nuclear receptor ROR-beta	Homo sapiens (human)	IC50 (µMol)	12.6224	0.1259	5.0629	10.0000	AID1168686; AID1168691
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 1A2	Homo sapiens (human)	EC50 (µMol)	0.0005	0.0003	0.2069	2.0000	AID1372839
Cytochrome P450 3A4	Homo sapiens (human)	EC50 (µMol)	0.0015	0.0001	0.2328	3.2000	AID1372837
Retinoic acid receptor alpha	Homo sapiens (human)	EC50 (µMol)	0.1674	0.0002	0.1790	2.5119	AID1372902; AID1389198; AID1576232; AID1614975; AID166217; AID197906; AID197921; AID197922; AID197923; AID198028; AID198030; AID198031; AID200108; AID200110; AID35832; AID394810; AID396775; AID755403
Retinoic acid receptor alpha	Homo sapiens (human)	Kd	0.0102	0.0002	0.5268	9.5000	AID1799183; AID198045; AID198046; AID198049; AID198050; AID198053; AID198054; AID200130; AID200132; AID35831
Cytochrome P450 2D6	Homo sapiens (human)	EC50 (µMol)	0.0002	0.0002	0.8276	4.4400	AID1372842
Retinoic acid receptor beta	Homo sapiens (human)	EC50 (µMol)	0.0344	0.0003	0.2311	6.9000	AID1389199; AID1576232; AID1614976; AID198201; AID198203; AID198361; AID198377; AID198378; AID198381; AID198383; AID198521; AID198522; AID199386; AID257179; AID257180; AID394804; AID394806; AID396777; AID41910
Retinoic acid receptor beta	Homo sapiens (human)	Kd	0.0086	0.0002	0.2876	2.3000	AID1799183; AID198215; AID198217; AID198535; AID198536; AID198538; AID198539; AID198540; AID198542; AID198544; AID41909
Retinoic acid receptor alpha	Mus musculus (house mouse)	EC50 (µMol)	0.0082	0.0012	0.0208	0.0700	AID1372837; AID1602830; AID197908
Retinoic acid receptor alpha	Mus musculus (house mouse)	Kd	0.0150	0.0070	0.0110	0.0150	AID197913
Cytochrome P450 2C9	Homo sapiens (human)	EC50 (µMol)	0.0012	0.0008	0.4170	2.3000	AID1602831
Retinoic acid receptor gamma	Homo sapiens (human)	EC50 (µMol)	0.0116	0.0002	0.0613	0.6480	AID1389200; AID1576232; AID1614977; AID166227; AID198713; AID198715; AID198886; AID198898; AID198899; AID198902; AID198904; AID198905; AID199391; AID392142; AID394813; AID73353
Retinoic acid receptor gamma	Homo sapiens (human)	Kd	0.0103	0.0002	0.4245	3.8240	AID1799183; AID198728; AID198731; AID199046; AID199047; AID199049; AID199050; AID199051; AID199053; AID199054; AID254257; AID73352
Retinoic acid receptor gamma	Mus musculus (house mouse)	EC50 (µMol)	0.0004	0.0002	0.0044	0.0110	AID1372842; AID1602833
Retinoic acid receptor gamma	Mus musculus (house mouse)	Kd	0.0180	0.0170	0.0175	0.0180	AID198892
Retinoic acid receptor RXR-alpha	Homo sapiens (human)	EC50 (µMol)	0.6141	0.0001	0.3427	9.1000	AID167597; AID199222; AID199477; AID199479; AID199506; AID199629; AID199632
Retinoic acid receptor RXR-alpha	Homo sapiens (human)	Kd	0.0681	0.0004	0.5838	8.8000	AID1799444; AID199343; AID199492; AID199493; AID199636; AID199638
Retinoic acid receptor beta	Mus musculus (house mouse)	EC50 (µMol)	0.0012	0.0005	0.0033	0.0120	AID1372839; AID1602831; AID198365
Retinoic acid receptor beta	Mus musculus (house mouse)	Kd	0.0130	0.0070	0.0100	0.0130	AID198368
Cellular retinoic acid-binding protein 2	Mus musculus (house mouse)	Kd	0.0020	0.0020	0.0020	0.0020	AID55255; AID55256
Retinoic acid receptor RXR-alpha	Mus musculus (house mouse)	EC50 (µMol)	2.0000	0.0400	1.7180	5.0000	AID199219
Retinoic acid receptor RXR-alpha	Mus musculus (house mouse)	Kd	1.0000	0.0320	0.5160	1.0000	AID199511
Retinoic acid receptor RXR-beta	Homo sapiens (human)	EC50 (µMol)	1.0496	0.0008	0.5254	5.2000	AID199358; AID199785; AID199800; AID199801
Retinoic acid receptor RXR-beta	Homo sapiens (human)	Kd	0.0000	0.0025	0.0140	0.0350	AID199805
Retinoic acid receptor RXR-beta	Mus musculus (house mouse)	EC50 (µMol)	1.2110	0.0030	0.2782	1.2110	AID199788
Retinoic acid receptor RXR-beta	Mus musculus (house mouse)	Kd	0.6530	0.0030	0.1969	1.0000	AID199794; AID199795
Retinoic acid receptor RXR-gamma	Mus musculus (house mouse)	EC50 (µMol)	0.4835	0.0040	0.1900	0.9610	AID199373; AID199947
Retinoic acid receptor RXR-gamma	Mus musculus (house mouse)	Kd	0.3500	0.0030	0.0830	0.3500	AID199953
Cytochrome P450 2C19	Homo sapiens (human)	EC50 (µMol)	0.0006	0.0003	0.0060	0.0123	AID1602833
Retinoic acid receptor RXR-gamma	Homo sapiens (human)	EC50 (µMol)	0.8568	0.0001	0.2380	1.2250	AID199375; AID199945; AID199957; AID199960
Retinoic acid receptor RXR-gamma	Homo sapiens (human)	Kd	0.1530	0.0018	0.0616	0.3060	AID199954; AID199964
Nuclear receptor ROR-gamma	Homo sapiens (human)	EC50 (µMol)	18.0000	0.0200	0.7035	9.0000	AID1177731
Cellular retinoic acid-binding protein 1	Mus musculus (house mouse)	Kd	0.0004	0.0004	0.0004	0.0004	AID55252; AID55253
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Kd	0.8000	0.8000	0.8000	0.8000	AID1742093
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Ornithine decarboxylase	Mus musculus (house mouse)	ID50	0.0001	0.0001	0.0001	0.0001	AID151013
Ornithine decarboxylase	Rattus norvegicus (Norway rat)	ID50	0.0000	0.0000	0.0006	0.0022	AID150874
Retinoic acid receptor alpha	Homo sapiens (human)	EC30 (µMol)	0.0010	0.0003	0.0009	0.0013	AID47183; AID47184
Retinoic acid receptor alpha	Homo sapiens (human)	Relative EC30	0.0022	0.0010	0.0022	0.0034	AID47360; AID90247
Retinoic acid receptor alpha	Homo sapiens (human)	Relative IC50	0.0009	0.0008	0.0009	0.0010	AID197892; AID198065
Retinoic acid receptor beta	Homo sapiens (human)	EC30 (µMol)	0.0008	0.0007	0.0154	0.0480	AID47185; AID47186
Retinoic acid receptor beta	Homo sapiens (human)	Relative EC30	0.0016	0.0010	0.0016	0.0022	AID47362; AID90248
Retinoic acid receptor beta	Homo sapiens (human)	Relative IC50	0.0007	0.0005	0.0007	0.0010	AID198347; AID198555
Retinoic acid receptor gamma	Homo sapiens (human)	EC30 (µMol)	0.0002	0.0002	0.0459	0.1500	AID47187; AID47371
Retinoic acid receptor gamma	Homo sapiens (human)	Relative EC30	0.0006	0.0003	0.0006	0.0010	AID47364; AID90249
Retinoic acid receptor gamma	Homo sapiens (human)	Relative IC50	0.0007	0.0004	0.0007	0.0010	AID198871; AID199065
Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)	ID50	1.0000	0.8000	1.0500	1.6000	AID52066
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
cognition	Amyloid-beta precursor protein	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglial cell activation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
suckling behavior	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation involved in immune response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of translation	Amyloid-beta precursor protein	Homo sapiens (human)
protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
intracellular copper ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
endocytosis	Amyloid-beta precursor protein	Homo sapiens (human)
response to oxidative stress	Amyloid-beta precursor protein	Homo sapiens (human)
cell adhesion	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of epidermal growth factor-activated receptor activity	Amyloid-beta precursor protein	Homo sapiens (human)
Notch signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
axonogenesis	Amyloid-beta precursor protein	Homo sapiens (human)
learning or memory	Amyloid-beta precursor protein	Homo sapiens (human)
learning	Amyloid-beta precursor protein	Homo sapiens (human)
mating behavior	Amyloid-beta precursor protein	Homo sapiens (human)
locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
axo-dendritic transport	Amyloid-beta precursor protein	Homo sapiens (human)
cholesterol metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of cell population proliferation	Amyloid-beta precursor protein	Homo sapiens (human)
adult locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
visual learning	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglia development	Amyloid-beta precursor protein	Homo sapiens (human)
axon midline choice point recognition	Amyloid-beta precursor protein	Homo sapiens (human)
neuron remodeling	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite development	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of Wnt signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular matrix organization	Amyloid-beta precursor protein	Homo sapiens (human)
forebrain development	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection development	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of chemokine production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-6 production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of multicellular organism growth	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of neuron differentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of glycolytic process	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of JNK cascade	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Amyloid-beta precursor protein	Homo sapiens (human)
collateral sprouting in absence of injury	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of inflammatory response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of synapse structure or activity	Amyloid-beta precursor protein	Homo sapiens (human)
synapse organization	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular process controlling balance	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic assembly at neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
neuron apoptotic process	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
neuron cellular homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Amyloid-beta precursor protein	Homo sapiens (human)
response to interleukin-1	Amyloid-beta precursor protein	Homo sapiens (human)
modulation of excitatory postsynaptic potential	Amyloid-beta precursor protein	Homo sapiens (human)
NMDA selective glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of spontaneous synaptic transmission	Amyloid-beta precursor protein	Homo sapiens (human)
cytosolic mRNA polyadenylation	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Amyloid-beta precursor protein	Homo sapiens (human)
cellular response to amyloid-beta	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of presynapse assembly	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection maintenance	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of T cell migration	Amyloid-beta precursor protein	Homo sapiens (human)
central nervous system development	Amyloid-beta precursor protein	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
protein folding	60 kDa chaperonin	Escherichia coli K-12
response to radiation	60 kDa chaperonin	Escherichia coli K-12
response to heat	60 kDa chaperonin	Escherichia coli K-12
virion assembly	60 kDa chaperonin	Escherichia coli K-12
chaperone cofactor-dependent protein refolding	60 kDa chaperonin	Escherichia coli K-12
protein refolding	60 kDa chaperonin	Escherichia coli K-12
chaperone cofactor-dependent protein refolding	60 kDa chaperonin	Escherichia coli K-12
response to heat	60 kDa chaperonin	Escherichia coli K-12
inflammatory response	Adenosine receptor A3	Homo sapiens (human)
signal transduction	Adenosine receptor A3	Homo sapiens (human)
activation of adenylate cyclase activity	Adenosine receptor A3	Homo sapiens (human)
regulation of heart contraction	Adenosine receptor A3	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A3	Homo sapiens (human)
response to wounding	Adenosine receptor A3	Homo sapiens (human)
regulation of norepinephrine secretion	Adenosine receptor A3	Homo sapiens (human)
negative regulation of cell migration	Adenosine receptor A3	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	Adenosine receptor A3	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A3	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A3	Homo sapiens (human)
ureteric bud development	Retinoic acid receptor alpha	Homo sapiens (human)
neural tube closure	Retinoic acid receptor alpha	Homo sapiens (human)
liver development	Retinoic acid receptor alpha	Homo sapiens (human)
glandular epithelial cell development	Retinoic acid receptor alpha	Homo sapiens (human)
growth plate cartilage development	Retinoic acid receptor alpha	Homo sapiens (human)
protein phosphorylation	Retinoic acid receptor alpha	Homo sapiens (human)
germ cell development	Retinoic acid receptor alpha	Homo sapiens (human)
female pregnancy	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of cell population proliferation	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of cell population proliferation	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of translation	Retinoic acid receptor alpha	Homo sapiens (human)
hippocampus development	Retinoic acid receptor alpha	Homo sapiens (human)
prostate gland development	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of granulocyte differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
embryonic camera-type eye development	Retinoic acid receptor alpha	Homo sapiens (human)
regulation of myelination	Retinoic acid receptor alpha	Homo sapiens (human)
response to estradiol	Retinoic acid receptor alpha	Homo sapiens (human)
response to retinoic acid	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of type II interferon production	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of tumor necrosis factor production	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of interleukin-13 production	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of interleukin-4 production	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of interleukin-5 production	Retinoic acid receptor alpha	Homo sapiens (human)
response to vitamin A	Retinoic acid receptor alpha	Homo sapiens (human)
response to cytokine	Retinoic acid receptor alpha	Homo sapiens (human)
multicellular organism growth	Retinoic acid receptor alpha	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Retinoic acid receptor alpha	Homo sapiens (human)
regulation of apoptotic process	Retinoic acid receptor alpha	Homo sapiens (human)
apoptotic cell clearance	Retinoic acid receptor alpha	Homo sapiens (human)
response to ethanol	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of T-helper 2 cell differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of neuron differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of cell cycle	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of DNA-templated transcription	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of DNA-templated transcription	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Retinoic acid receptor alpha	Homo sapiens (human)
regulation of synaptic plasticity	Retinoic acid receptor alpha	Homo sapiens (human)
retinoic acid receptor signaling pathway	Retinoic acid receptor alpha	Homo sapiens (human)
positive regulation of binding	Retinoic acid receptor alpha	Homo sapiens (human)
ventricular cardiac muscle cell differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
Sertoli cell fate commitment	Retinoic acid receptor alpha	Homo sapiens (human)
limb development	Retinoic acid receptor alpha	Homo sapiens (human)
face development	Retinoic acid receptor alpha	Homo sapiens (human)
trachea cartilage development	Retinoic acid receptor alpha	Homo sapiens (human)
chondroblast differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of cartilage development	Retinoic acid receptor alpha	Homo sapiens (human)
cellular response to lipopolysaccharide	Retinoic acid receptor alpha	Homo sapiens (human)
cellular response to retinoic acid	Retinoic acid receptor alpha	Homo sapiens (human)
cellular response to estrogen stimulus	Retinoic acid receptor alpha	Homo sapiens (human)
regulation of hematopoietic progenitor cell differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of miRNA transcription	Retinoic acid receptor alpha	Homo sapiens (human)
cell differentiation	Retinoic acid receptor alpha	Homo sapiens (human)
hormone-mediated signaling pathway	Retinoic acid receptor alpha	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Retinoic acid receptor alpha	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
adhesion of symbiont to host	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of type II interferon production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
'de novo' protein folding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to unfolded protein	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to cold	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interferon-alpha production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of type II interferon production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-10 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-12 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-6 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein refolding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
B cell proliferation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
B cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of macrophage activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
negative regulation of apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
isotype switching to IgG isotypes	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein stabilization	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
chaperone-mediated protein complex assembly	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein maturation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
biological process involved in interaction with symbiont	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cellular response to interleukin-7	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein import into mitochondrial intermembrane space	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial unfolded protein response	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apoptotic mitochondrial changes	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ureteric bud development	Retinoic acid receptor beta	Homo sapiens (human)
glandular epithelial cell development	Retinoic acid receptor beta	Homo sapiens (human)
growth plate cartilage development	Retinoic acid receptor beta	Homo sapiens (human)
apoptotic process	Retinoic acid receptor beta	Homo sapiens (human)
signal transduction	Retinoic acid receptor beta	Homo sapiens (human)
striatum development	Retinoic acid receptor beta	Homo sapiens (human)
neurogenesis	Retinoic acid receptor beta	Homo sapiens (human)
regulation of myelination	Retinoic acid receptor beta	Homo sapiens (human)
negative regulation of chondrocyte differentiation	Retinoic acid receptor beta	Homo sapiens (human)
embryonic hindlimb morphogenesis	Retinoic acid receptor beta	Homo sapiens (human)
multicellular organism growth	Retinoic acid receptor beta	Homo sapiens (human)
positive regulation of apoptotic process	Retinoic acid receptor beta	Homo sapiens (human)
embryonic eye morphogenesis	Retinoic acid receptor beta	Homo sapiens (human)
embryonic digestive tract development	Retinoic acid receptor beta	Homo sapiens (human)
ventricular cardiac muscle cell differentiation	Retinoic acid receptor beta	Homo sapiens (human)
neural precursor cell proliferation	Retinoic acid receptor beta	Homo sapiens (human)
stem cell proliferation	Retinoic acid receptor beta	Homo sapiens (human)
negative regulation of stem cell proliferation	Retinoic acid receptor beta	Homo sapiens (human)
retinoic acid receptor signaling pathway	Retinoic acid receptor beta	Homo sapiens (human)
hormone-mediated signaling pathway	Retinoic acid receptor beta	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Retinoic acid receptor beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Retinoic acid receptor beta	Homo sapiens (human)
cell differentiation	Retinoic acid receptor beta	Homo sapiens (human)
negative regulation of apoptotic process	Retinoic acid receptor alpha	Mus musculus (house mouse)
spermatogenesis	Retinoic acid receptor alpha	Mus musculus (house mouse)
outflow tract septum morphogenesis	Retinoic acid receptor alpha	Mus musculus (house mouse)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
heparin binding	Amyloid-beta precursor protein	Homo sapiens (human)
enzyme binding	Amyloid-beta precursor protein	Homo sapiens (human)
identical protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
transition metal ion binding	Amyloid-beta precursor protein	Homo sapiens (human)
receptor ligand activity	Amyloid-beta precursor protein	Homo sapiens (human)
PTB domain binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein serine/threonine kinase binding	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor activator activity	Amyloid-beta precursor protein	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
magnesium ion binding	60 kDa chaperonin	Escherichia coli K-12
protein binding	60 kDa chaperonin	Escherichia coli K-12
ATP binding	60 kDa chaperonin	Escherichia coli K-12
isomerase activity	60 kDa chaperonin	Escherichia coli K-12
ATP hydrolysis activity	60 kDa chaperonin	Escherichia coli K-12
identical protein binding	60 kDa chaperonin	Escherichia coli K-12
unfolded protein binding	60 kDa chaperonin	Escherichia coli K-12
ATP-dependent protein folding chaperone	60 kDa chaperonin	Escherichia coli K-12
G protein-coupled adenosine receptor activity	Adenosine receptor A3	Homo sapiens (human)
mRNA regulatory element binding translation repressor activity	Retinoic acid receptor alpha	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Retinoic acid receptor alpha	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Retinoic acid receptor alpha	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Retinoic acid receptor alpha	Homo sapiens (human)
DNA-binding transcription repressor activity	Retinoic acid receptor alpha	Homo sapiens (human)
transcription coactivator binding	Retinoic acid receptor alpha	Homo sapiens (human)
retinoic acid binding	Retinoic acid receptor alpha	Homo sapiens (human)
chromatin binding	Retinoic acid receptor alpha	Homo sapiens (human)
DNA-binding transcription factor activity	Retinoic acid receptor alpha	Homo sapiens (human)
nuclear receptor activity	Retinoic acid receptor alpha	Homo sapiens (human)
signaling receptor binding	Retinoic acid receptor alpha	Homo sapiens (human)
protein binding	Retinoic acid receptor alpha	Homo sapiens (human)
zinc ion binding	Retinoic acid receptor alpha	Homo sapiens (human)
enzyme binding	Retinoic acid receptor alpha	Homo sapiens (human)
protein domain specific binding	Retinoic acid receptor alpha	Homo sapiens (human)
chromatin DNA binding	Retinoic acid receptor alpha	Homo sapiens (human)
histone deacetylase binding	Retinoic acid receptor alpha	Homo sapiens (human)
protein kinase B binding	Retinoic acid receptor alpha	Homo sapiens (human)
retinoic acid-responsive element binding	Retinoic acid receptor alpha	Homo sapiens (human)
mRNA 5'-UTR binding	Retinoic acid receptor alpha	Homo sapiens (human)
protein kinase A binding	Retinoic acid receptor alpha	Homo sapiens (human)
alpha-actinin binding	Retinoic acid receptor alpha	Homo sapiens (human)
heterocyclic compound binding	Retinoic acid receptor alpha	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Retinoic acid receptor alpha	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
lipopolysaccharide binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
p53 binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
DNA replication origin binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
single-stranded DNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
RNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
double-stranded RNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
high-density lipoprotein particle binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
isomerase activity	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP hydrolysis activity	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
enzyme binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ubiquitin protein ligase binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apolipoprotein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apolipoprotein A-I binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
unfolded protein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-folding chaperone binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP-dependent protein folding chaperone	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Retinoic acid receptor beta	Homo sapiens (human)
DNA binding	Retinoic acid receptor beta	Homo sapiens (human)
zinc ion binding	Retinoic acid receptor beta	Homo sapiens (human)
protein-containing complex binding	Retinoic acid receptor beta	Homo sapiens (human)
nuclear retinoid X receptor binding	Retinoic acid receptor beta	Homo sapiens (human)
heterocyclic compound binding	Retinoic acid receptor beta	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Retinoic acid receptor beta	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Retinoic acid receptor beta	Homo sapiens (human)
nuclear receptor activity	Retinoic acid receptor beta	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Retinoic acid receptor gamma	Homo sapiens (human)
DNA binding	Retinoic acid receptor gamma	Homo sapiens (human)
chromatin binding	Retinoic acid receptor gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Retinoic acid receptor gamma	Homo sapiens (human)
protein binding	Retinoic acid receptor gamma	Homo sapiens (human)
zinc ion binding	Retinoic acid receptor gamma	Homo sapiens (human)
nuclear retinoid X receptor binding	Retinoic acid receptor gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Retinoic acid receptor gamma	Homo sapiens (human)
nuclear receptor activity	Retinoic acid receptor gamma	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Retinoic acid receptor gamma	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Bos taurus (cattle)
vitamin D response element binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
transcription cis-regulatory region binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
transcription coregulator binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
retinoic acid binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
double-stranded DNA binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
DNA-binding transcription factor activity	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
nuclear steroid receptor activity	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
nuclear receptor activity	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
protein binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
zinc ion binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
enzyme binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
peptide binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
identical protein binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
nuclear vitamin D receptor binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
sequence-specific DNA binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
retinoic acid-responsive element binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
DNA binding domain binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
LBD domain binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
phosphotyrosine residue binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
DNA binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase 1	Homo sapiens (human)
MAP kinase activity	Mitogen-activated protein kinase 1	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Mitogen-activated protein kinase 1	Homo sapiens (human)
phosphatase binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
identical protein binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 1	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Retinoic acid receptor RXR-beta	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Retinoic acid receptor RXR-beta	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Retinoic acid receptor RXR-beta	Homo sapiens (human)
nuclear steroid receptor activity	Retinoic acid receptor RXR-beta	Homo sapiens (human)
nuclear receptor activity	Retinoic acid receptor RXR-beta	Homo sapiens (human)
protein binding	Retinoic acid receptor RXR-beta	Homo sapiens (human)
zinc ion binding	Retinoic acid receptor RXR-beta	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Retinoic acid receptor RXR-beta	Homo sapiens (human)
retinoic acid-responsive element binding	Retinoic acid receptor RXR-beta	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-alpha	Homo sapiens (human)
transcription coregulator binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
transcription corepressor binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
transcription coactivator binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
DNA binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-alpha	Homo sapiens (human)
protein binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
beta-catenin binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
oxysterol binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
sequence-specific DNA binding	Nuclear receptor ROR-alpha	Homo sapiens (human)
ligand-activated transcription factor activity	Nuclear receptor ROR-alpha	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-alpha	Homo sapiens (human)
fatty acid binding	Alpha-synuclein	Homo sapiens (human)
phospholipase D inhibitor activity	Alpha-synuclein	Homo sapiens (human)
SNARE binding	Alpha-synuclein	Homo sapiens (human)
magnesium ion binding	Alpha-synuclein	Homo sapiens (human)
transcription cis-regulatory region binding	Alpha-synuclein	Homo sapiens (human)
actin binding	Alpha-synuclein	Homo sapiens (human)
protein kinase inhibitor activity	Alpha-synuclein	Homo sapiens (human)
copper ion binding	Alpha-synuclein	Homo sapiens (human)
calcium ion binding	Alpha-synuclein	Homo sapiens (human)
protein binding	Alpha-synuclein	Homo sapiens (human)
phospholipid binding	Alpha-synuclein	Homo sapiens (human)
ferrous iron binding	Alpha-synuclein	Homo sapiens (human)
zinc ion binding	Alpha-synuclein	Homo sapiens (human)
lipid binding	Alpha-synuclein	Homo sapiens (human)
oxidoreductase activity	Alpha-synuclein	Homo sapiens (human)
kinesin binding	Alpha-synuclein	Homo sapiens (human)
Hsp70 protein binding	Alpha-synuclein	Homo sapiens (human)
histone binding	Alpha-synuclein	Homo sapiens (human)
identical protein binding	Alpha-synuclein	Homo sapiens (human)
alpha-tubulin binding	Alpha-synuclein	Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
tau protein binding	Alpha-synuclein	Homo sapiens (human)
phosphoprotein binding	Alpha-synuclein	Homo sapiens (human)
molecular adaptor activity	Alpha-synuclein	Homo sapiens (human)
dynein complex binding	Alpha-synuclein	Homo sapiens (human)
cuprous ion binding	Alpha-synuclein	Homo sapiens (human)
retinoic acid binding	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
retinoid binding	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
retinal binding	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
retinol binding	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
fatty acid binding	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G-protein alpha-subunit binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
GTPase activator activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
nuclear steroid receptor activity	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
protein binding	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
zinc ion binding	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
molecular condensate scaffold activity	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
nuclear receptor activity	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
retinoic acid-responsive element binding	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
protein binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
oxysterol binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
ligand-activated transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
RNA binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding chaperone	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
unfolded protein binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-folding chaperone binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
metal ion binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
cytoskeletal motor activity	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
beta-catenin binding	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
mitogen-activated protein kinase kinase binding	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
GTPase activating protein binding	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
tau protein binding	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
phosphoserine residue binding	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
phosphothreonine residue binding	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
phosphoprotein binding	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
ubiquitin ligase activator activity	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
thiosulfate sulfurtransferase activity	Thiosulfate sulfurtransferase	Homo sapiens (human)
5S rRNA binding	Thiosulfate sulfurtransferase	Homo sapiens (human)
3-mercaptopyruvate sulfurtransferase activity	Thiosulfate sulfurtransferase	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-beta	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Nuclear receptor ROR-beta	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-beta	Homo sapiens (human)
protein binding	Nuclear receptor ROR-beta	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-beta	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor ROR-beta	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-beta	Homo sapiens (human)
melatonin receptor activity	Nuclear receptor ROR-beta	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-beta	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular region	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
nuclear envelope lumen	Amyloid-beta precursor protein	Homo sapiens (human)
cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
mitochondrial inner membrane	Amyloid-beta precursor protein	Homo sapiens (human)
endosome	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum lumen	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi lumen	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi-associated vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cytosol	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
clathrin-coated pit	Amyloid-beta precursor protein	Homo sapiens (human)
cell-cell junction	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
membrane	Amyloid-beta precursor protein	Homo sapiens (human)
COPII-coated ER to Golgi transport vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
axon	Amyloid-beta precursor protein	Homo sapiens (human)
growth cone	Amyloid-beta precursor protein	Homo sapiens (human)
platelet alpha granule lumen	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
endosome lumen	Amyloid-beta precursor protein	Homo sapiens (human)
trans-Golgi network membrane	Amyloid-beta precursor protein	Homo sapiens (human)
ciliary rootlet	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic spine	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic shaft	Amyloid-beta precursor protein	Homo sapiens (human)
perikaryon	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
apical part of cell	Amyloid-beta precursor protein	Homo sapiens (human)
synapse	Amyloid-beta precursor protein	Homo sapiens (human)
perinuclear region of cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
presynaptic active zone	Amyloid-beta precursor protein	Homo sapiens (human)
spindle midzone	Amyloid-beta precursor protein	Homo sapiens (human)
recycling endosome	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular exosome	Amyloid-beta precursor protein	Homo sapiens (human)
receptor complex	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
cytoplasm	60 kDa chaperonin	Escherichia coli K-12
cytosol	60 kDa chaperonin	Escherichia coli K-12
membrane	60 kDa chaperonin	Escherichia coli K-12
GroEL-GroES complex	60 kDa chaperonin	Escherichia coli K-12
plasma membrane	Adenosine receptor A3	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A3	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Adenosine receptor A3	Homo sapiens (human)
dendrite	Adenosine receptor A3	Homo sapiens (human)
plasma membrane	Adenosine receptor A3	Homo sapiens (human)
synapse	Adenosine receptor A3	Homo sapiens (human)
nucleus	Retinoic acid receptor alpha	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor alpha	Homo sapiens (human)
transcription regulator complex	Retinoic acid receptor alpha	Homo sapiens (human)
nucleolus	Retinoic acid receptor alpha	Homo sapiens (human)
cytoplasm	Retinoic acid receptor alpha	Homo sapiens (human)
cytosol	Retinoic acid receptor alpha	Homo sapiens (human)
plasma membrane	Retinoic acid receptor alpha	Homo sapiens (human)
actin cytoskeleton	Retinoic acid receptor alpha	Homo sapiens (human)
dendrite	Retinoic acid receptor alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Retinoic acid receptor alpha	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Retinoic acid receptor alpha	Homo sapiens (human)
chromatin	Retinoic acid receptor alpha	Homo sapiens (human)
protein-containing complex	Retinoic acid receptor alpha	Homo sapiens (human)
nucleus	Retinoic acid receptor alpha	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
mitochondrial matrix	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular space	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cytoplasm	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrion	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial matrix	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
early endosome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cytosol	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
plasma membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
clathrin-coated pit	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cell surface	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
coated vesicle	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
secretory granule	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular exosome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sperm midpiece	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sperm plasma membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
migrasome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-containing complex	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
lipopolysaccharide receptor complex	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
nucleus	Retinoic acid receptor beta	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor beta	Homo sapiens (human)
cytoplasm	Retinoic acid receptor beta	Homo sapiens (human)
chromatin	Retinoic acid receptor beta	Homo sapiens (human)
nucleus	Retinoic acid receptor beta	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor alpha	Mus musculus (house mouse)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
nucleus	Retinoic acid receptor gamma	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor gamma	Homo sapiens (human)
cytoplasm	Retinoic acid receptor gamma	Homo sapiens (human)
membrane	Retinoic acid receptor gamma	Homo sapiens (human)
chromatin	Retinoic acid receptor gamma	Homo sapiens (human)
transcription regulator complex	Retinoic acid receptor gamma	Homo sapiens (human)
nucleus	Retinoic acid receptor gamma	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Bos taurus (cattle)
cytoplasm	Alpha-1A adrenergic receptor	Bos taurus (cattle)
plasma membrane	Alpha-1A adrenergic receptor	Bos taurus (cattle)
caveola	Alpha-1A adrenergic receptor	Bos taurus (cattle)
nuclear membrane	Alpha-1A adrenergic receptor	Bos taurus (cattle)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
nucleoplasm	Retinoic acid receptor gamma	Mus musculus (house mouse)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
nucleus	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
transcription regulator complex	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
mitochondrion	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
cytosol	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
chromatin	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
receptor complex	Retinoic acid receptor RXR-alpha	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor beta	Mus musculus (house mouse)
extracellular region	Mitogen-activated protein kinase 1	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 1	Homo sapiens (human)
nucleoplasm	Mitogen-activated protein kinase 1	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 1	Homo sapiens (human)
mitochondrion	Mitogen-activated protein kinase 1	Homo sapiens (human)
early endosome	Mitogen-activated protein kinase 1	Homo sapiens (human)
late endosome	Mitogen-activated protein kinase 1	Homo sapiens (human)
endoplasmic reticulum lumen	Mitogen-activated protein kinase 1	Homo sapiens (human)
Golgi apparatus	Mitogen-activated protein kinase 1	Homo sapiens (human)
centrosome	Mitogen-activated protein kinase 1	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 1	Homo sapiens (human)
cytoskeleton	Mitogen-activated protein kinase 1	Homo sapiens (human)
plasma membrane	Mitogen-activated protein kinase 1	Homo sapiens (human)
caveola	Mitogen-activated protein kinase 1	Homo sapiens (human)
focal adhesion	Mitogen-activated protein kinase 1	Homo sapiens (human)
pseudopodium	Mitogen-activated protein kinase 1	Homo sapiens (human)
azurophil granule lumen	Mitogen-activated protein kinase 1	Homo sapiens (human)
synapse	Mitogen-activated protein kinase 1	Homo sapiens (human)
mitotic spindle	Mitogen-activated protein kinase 1	Homo sapiens (human)
ficolin-1-rich granule lumen	Mitogen-activated protein kinase 1	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 1	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 1	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor RXR-alpha	Mus musculus (house mouse)
nucleus	Retinoic acid receptor RXR-beta	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor RXR-beta	Homo sapiens (human)
nucleolus	Retinoic acid receptor RXR-beta	Homo sapiens (human)
cytosol	Retinoic acid receptor RXR-beta	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Retinoic acid receptor RXR-beta	Homo sapiens (human)
chromatin	Retinoic acid receptor RXR-beta	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
nucleus	Nuclear receptor ROR-alpha	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-alpha	Homo sapiens (human)
nucleolus	Nuclear receptor ROR-alpha	Homo sapiens (human)
chromatin	Nuclear receptor ROR-alpha	Homo sapiens (human)
nucleus	Nuclear receptor ROR-alpha	Homo sapiens (human)
platelet alpha granule membrane	Alpha-synuclein	Homo sapiens (human)
extracellular region	Alpha-synuclein	Homo sapiens (human)
extracellular space	Alpha-synuclein	Homo sapiens (human)
nucleus	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
mitochondrion	Alpha-synuclein	Homo sapiens (human)
lysosome	Alpha-synuclein	Homo sapiens (human)
cytosol	Alpha-synuclein	Homo sapiens (human)
plasma membrane	Alpha-synuclein	Homo sapiens (human)
cell cortex	Alpha-synuclein	Homo sapiens (human)
actin cytoskeleton	Alpha-synuclein	Homo sapiens (human)
membrane	Alpha-synuclein	Homo sapiens (human)
inclusion body	Alpha-synuclein	Homo sapiens (human)
axon	Alpha-synuclein	Homo sapiens (human)
growth cone	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle membrane	Alpha-synuclein	Homo sapiens (human)
perinuclear region of cytoplasm	Alpha-synuclein	Homo sapiens (human)
postsynapse	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber	Alpha-synuclein	Homo sapiens (human)
protein-containing complex	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
axon terminus	Alpha-synuclein	Homo sapiens (human)
neuronal cell body	Alpha-synuclein	Homo sapiens (human)
cytosol	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
axon	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
neuron projection	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
cell body fiber	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
nucleus	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
cytosol	Cellular retinoic acid-binding protein 1	Gallus gallus (chicken)
nucleoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cytoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
nucleoplasm	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
cytoplasm	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
chromatin	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Retinoic acid receptor RXR-gamma	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear body	Nuclear receptor ROR-gamma	Homo sapiens (human)
chromatin	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
mitochondrion	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
membrane	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular exosome	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial matrix	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
glutamatergic synapse	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
postsynaptic cytosol	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
nucleoplasm	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
nuclear speck	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
midbody	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
ciliary basal body	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)
extracellular space	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrial matrix	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Nuclear receptor ROR-beta	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-beta	Homo sapiens (human)
chromatin	Nuclear receptor ROR-beta	Homo sapiens (human)
nucleus	Nuclear receptor ROR-beta	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (916)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID199967	Inhibition of [3H]9-cis-RA binding to Retinoid X receptor RXR gamma	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID767629	Inhibition of MMP9 activity in human HT1080 cells at 1 uM after 24 hrs	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID1372840	Ratio of relative EC50 for mouse Gal4-fused RARbeta-LBD expressed in COS-7 cells to relative EC50 for mouse Gal4-fused RARalpha-LBD expressed in COS-7 cells	2018	Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4	Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
AID1630298	Selectivity index, ratio of agonist activity at human RARalpha expressed in HEK293 cells assessed as increase in RARE-mediated transcription relative to bexarotene to agonist activity at human RXRalpha expressed in human HCT116 cells assessed as increase	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-
AID444826	Induction of dendrite out growth in IL-4/GMCSF-stimulated mouse P19 cells assessed as dendrite length at 100 nM after 48 hrs by light microscopy	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID3329	Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
AID199051	Binding constant for baculovirus-expressed Retinoic acid receptor RAR gamma	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors.
AID767646	Reduction of MMP2 mRNA level in human HT1080 cells at 1 uM after 24 hrs by RT-PCR analysis relative to control	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID334327	Induction of morphological transformation of rat ASK cells into astrocytes at 100 uM after 1 hr by light microscopy in presence of fetal calf serum
AID1695730	Inhibition of alpha-synuclein fibril formation (unknown origin) incubated for 24 hrs to 7 days by thioflavin S based fluorescence assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID198054	Inhibition of [3H]ATRA binding to baculovirus expressed Retinoic acid receptor RAR alpha	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Identification of retinoic acid receptor beta subtype specific agonists.
AID1152398	Activation of RAR in mouse F9 cells assessed as increase in CYP26A1 mRNA level at 0.01 uM after 48 hrs by RT-PCR analysis	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID478134	Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Liposomal formulation of retinoids designed for enzyme triggered release.
AID334311	Induction of morphological transformation of rat ASK cells into astrocytes after 1 hr by light microscopy
AID192004	Initial DMBA-induced mammary tumor volume in rat after retinoid treatment at 2 mmol/kg diet	2002	Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17	An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID1537941	Induction of granulocytic differentiation in human NB4 cells assessed as increase in CD14 positive cells at 10 to 30 uM after 6 days by FITC staining based flow cytometry analysis	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
AID197912	Inhibition of binding to retinoid A receptor RAR alpha	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID199792	Inhibition of binding to murine Retinoid X receptor RXR beta	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
AID220402	Inhibition of ZR-75-1 retinoid sensitive breast carcinoma cell proliferation at 1 uM	2000	Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12	4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID282375	Growth inhibition of human MDA-MB-231 cells up to 10 uM after 6 days by MTT assay	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID444965	Induction of neurite outgrowth in human SK-N-SH cells at 2 to 5 uM after 48 hrs by crystal violet staining	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID198886	Transcriptional activation of Retinoic acid receptor RAR gamma	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID81670	Differentiating activity of compound in HL60 cells at conc 0.0003 ug/mL	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.
AID1168691	Inverse agonist activity at RORbeta (unknown origin) by M1H assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID47185	Transcriptional activation in CV-1 cells expressing RAR beta receptor	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID90249	Transcriptional activation in COS cells expressing RAR-gamma	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.
AID199477	Transcriptional activation of Retinoid X receptor RXR alpha	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID73354	Percent transcriptional activation of RAR gamma compared to 1 mM ATRA	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID93765	Concentration required for 50% reduction in absolute cell number in human sebaceous cell assay	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID365034	Induction of apoptosis in human HL60R cells at 1.0 uM after 24 hrs by acridine orange staining	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID124619	In vivo the maximum tolerated dose in six CD-1 mice at a oral dose of 10 mg/kg/day was determined	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID252630	NBT positivity against human leukemia cell line HL-60 at 2*E-9 M	2005	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13	Cell differentiation inducers derived from thalidomide.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID199330	The concentration required to inhibit the binding of [3H]ATRA to retinoic acid receptor in human promyelocytic leukemia cells	1995	Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16	A novel type of retinoic acid receptor antagonist: synthesis and structure-activity relationships of heterocyclic ring-containing benzoic acid derivatives.
AID166118	Percentage inhibition of cholesterol-3-sulfate activity rabbit at 10 nM.	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID288573	Induction of terminal differentiation in mouse F9 cells assessed by measuring secreted plasminogen activator activity after 3 days	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and
AID1389207	Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as increase in TUJ1 expression at 10 uM measured up to 3 weeks by immunofluorescence method	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID186911	Effect on total mammary tumor volume in female rats on day 14 after a diet additive of 2 mmol/kg (+/-S.E) (p<0.05)	2001	Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12	An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID198539	Binding affinity towards retinoic acid receptor beta was determined using [3H]ATRA (5 nM) as radioligand	2001	Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6	Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID150723	Inhibition of tumor promoter (TPA) -induced mouse epidermal ornithine decarboxylase (ODC) activity at 17 nmol dose level	1981	Journal of medicinal chemistry, May, Volume: 24, Issue:5	Aromatic retinoic acid analogues. Synthesis and pharmacological activity.
AID1537905	Induction of granulocytic differentiation in human HL60 cells assessed as increase in CD11b-APC-Cy7 positive cells at 10 to 30 uM after 6 days by flow cytometry analysis	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
AID199210	Agonistic activity towards retinoid X receptor-alpha	1997	Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26	Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID198046	Binding affinity for baculovirus-expressed Retinoic acid receptor RAR alpha	1996	Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16	Identification of a retinoic acid receptor alpha subtype specific agonist.
AID1181357	Inhibition of mushroom tyrosinase using L-tyrosine as substrate at 50 uM by spectrophotometry relative to control	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Effect of p-aminophenols on tyrosinase activity.
AID198536	Binding affinity for baculovirus-expressed Retinoic acid receptor RAR beta	1996	Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16	Identification of a retinoic acid receptor alpha subtype specific agonist.
AID1199794	Growth inhibition of human CWR22Rv1 cells by MTT assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID404778	Increase in transcriptional activity of RARalpha receptor epressed in human HaCaT cells co-transfected with DR5-tk-CAT reporter plasmid assessed as beta-galactosidase activity by CAT-ELISA	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.
AID197922	Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID1588449	Induction of differentiation of human HL60 cells assessed as increase in CEBPA mRNA expression at 1 uM by QT-PCR analysis	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.
AID1464518	Induction of apoptosis in human IMR32 cells assessed as decrease in Bcl-2 mRNA expression level at 4 uM after 24 hrs by real-time PCR method relative to control
AID199479	Transcriptional activation in CV-1 cells expressing human Retinoid X receptor RXR-alpha	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID288572	Reversal of keratinization in vitamin A-deficient hamster trachea after 10 days by TOC assay	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and
AID1136169	Reversal of keratinized lesions in vitamin A deficient hamster tracheal organ culture assessed as cultures with keratin and keratohyaline granules at 0.1 uM after 7 days (Rvb = 93%)	1977	Journal of medicinal chemistry, Jul, Volume: 20, Issue:7	Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID47360	Relative transcriptional activation in CV-1 cells expressing RAR alpha receptor compared to ATRA	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID394804	Agonist activity at RARbeta2 expressed in mouse NIH3T3 cells by R-SAT assay	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
AID1136175	Increase in RNA content in mouse epidermal cells at 10 nM after 3 days	1977	Journal of medicinal chemistry, Jul, Volume: 20, Issue:7	Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID717845	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID82341	Relative activity against human promyelocytic leukemia HL-60 cells.	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60.
AID1389199	Transactivation of GST-tagged RARbeta LBD (unknown origin) assessed as fluorescein-labelled coactivator peptide recruitment measured after 4 hrs by TR-FRET analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID47184	Transcriptional activation in CV-1 cells expressing RAR alpha receptor	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Syntheses and evaluation of naphthalenyl- and chromenyl-pyrrolyl-benzoic acids as potent and selective retinoic acid receptor alpha agonists.
AID429391	Cell cycle arrest in human LNCAP cells assessed as accumulation at S phase after 48 hrs by flow cytometry	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth.
AID1168686	Inverse agonist activity at recombinant N-terminally GST-tagged RORbeta ligand binding domain (unknown origin) expressed in Escherichia coli incubated for 1 hr by FRET assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID199222	Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID46878	Relative percent binding to cellular retinoic acid binding protein (CRABP) in chick embryo skin.	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Terminal bifunctional retinoids. Synthesis and evaluations related to cancer chemopreventive activity.
AID492805	Cell cycle arrest in human NB4 cells assessed as increase in accumulation at pre-G1 phase at 1 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID396440	Toxicity against human dermal fibroblasts assessed as cell viability at 10 uM relative to control	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Synthesis and in vitro biological activity of retinyl polyhydroxybenzoates, novel hybrid retinoid derivatives.
AID1464523	Reduction in N-myc mRNA expression level in human IMR32 cells at 4 uM after 8 hrs by real-time PCR method
AID81845	Compound was evaluated for the retinoid-induced differentiation of the human myeloid leukemia cell line HL-60 using trans-retinoic acid as the standard.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Novel heteroarotinoids: synthesis and biological activity.
AID1602831	Transactivation of GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.
AID282379	Displacement of [11,12-3H]ARTA from RARbeta	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID84153	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-11 (M) in experiment D	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID288760	Inhibition of TPA-induced Epstein-Barr virus early antigen activation assessed as EBV-EA induction in Raji cells at 320 nM after 48 hrs relative to TPA	2007	Journal of natural products, Jun, Volume: 70, Issue:6	Cancer chemopreventive effects of cycloartane-type and related triterpenoids in in vitro and in vivo models.
AID197915	Percent inhibition of [3H]ATRA binding to mouse Retinoic acid receptor RAR alpha	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID124884	Mortality determined for the toxicity of the compound. - indicates that no signs of toxicity was found	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID717840	Inhibition of mouse Tdo2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 100 uM after 45 mins by spectrophotometric analysis relative to control	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID264886	Plasma concentration in CD1 mouse at 5 mg/kg, po after 2 hrs co-administered with 3-[6-(2-dimethylamino- 1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]- 2,2-dimethyl-propionic acid at 10 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
AID767630	Antiinvasive activity in human HT1080 cells assessed as reduction of cell number at 1 uM after 22 hrs by matrigel invasion assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID81669	Differentiation activity was determined by evaluation of NBT reduction activity of HL-60 cells, % of NBT positive cells determined	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
AID85334	In vitro inhibitory activity tested for reverse keratinization of epithelial cells in hamster trachael organ assay at 10E-9 M concentration; (Activity culture/total culture 419/474)	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Syntheses and activities of antioxidant derivatives of retinoic acids.
AID198542	In vitro binding affinity for Retinoic acid receptor RAR beta	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID152332	percent aggregation of mouse embryonal carcinoma (P19) cells 10e -6M concentration in culture medium	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzoates and beta-ionylideneacetamidobenzoates with retinoidal activity.
AID1199788	Growth inhibition of human SKBR3 cells by MTT assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID1537917	Antiproliferative activity against human HL60 cells assessed as reduction in viability at 1 to 30 uM after 3 days by SRB assay	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
AID1695748	Inhibition of amyloid beta (1 to 40) (unknown origin) incubated for 24 hrs to 7 days by thioflavin S based fluorescence assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID198534	Binding affinity for Retinoic acid receptor beta	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Syntheses and evaluation of naphthalenyl- and chromenyl-pyrrolyl-benzoic acids as potent and selective retinoic acid receptor alpha agonists.
AID129754	Percent decrease in average number of papillomas at dose 170 nmol *-p<0.001	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID254257	Dissociation constant for Retinoic acid receptor gamma	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Ligand recognition by RAR and RXR receptors: binding and selectivity.
AID83974	Activity of compound the was expressed as ratio of active hamster tracheal organ cultures(TOC) to the total cultures at 10e-12 M concentration; 3/19	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID755409	Transactivation of Gal4-fused RARalpha (unknown origin) expressed in African green monkey COS1 cells at 100 nM by luciferase reporter gene assay relative to DMSO-treated control	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.
AID199794	Dissociation constant for binding to Retinoid X receptor beta	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID198535	Ability to displace 3[H](all-E)-retinoic acid (5 nM) from beta retinoic acid receptor (beta RAR) using transactivation assay	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	High affinity retinoic acid receptor antagonists: analogs of AGN 193109.
AID1594144	Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1742093	Binding affinity to Pin1 (unknown origin) preincubated for 2 hrs followed by UV irradiation for 15 mins by SDS-PAGE gel based photoaffinity labelling method	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Targeting Protein Folding: A Novel Approach for the Treatment of Pathogenic Bacteria.
AID38344	Inhibition of LPS-induced mouse B-lymphocyte proliferation (Mean of IC50/ATRA IC50)	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.
AID1168688	Inverse agonist activity at RORgammaT (unknown origin) by M1H assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID394803	Agonist activity at RARbeta2 expressed in mouse NIH3T3 cells by R-SAT assay relative to Am-580	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
AID1588453	Induction of differentiation of human HL60 cells assessed as increase in CD11b positive cells at 1 uM after 7 days by flow cytometric analysis (Rvb = 3.94%)	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.
AID128377	Tested for relative activity in a 20-week anti-papilloma experiment in female CD-1 mice at dose 1.7 nmol	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID186912	Effect on total mammary tumor volume in female rats on day 21 after a diet additive of 2 mmol/kg (+/-S.E) (p<0.05)	2001	Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12	An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID197903	Relative IC50 for human RAR-alpha receptor as IC50(compound) divided by IC50(ATRA)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID282372	Growth inhibition of human MCF7 cells after 6 days by MTT assay	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID1464493	Growth inhibition of human IMR32 cells at 0.01 uM after 72 hrs by MTT assay relative to control
AID210129	Percent inhibition of BrdU incorporation into T-47D cells	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID624608	Specific activity of expressed human recombinant UGT1A4	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID548961	Antioxidant activity of the compound assessed as reducing activity of DPPH at 0.1 mM after 60 mins	2010	Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23	Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID1372902	Transactivation of human Gal4-DBD-fused RARalpha-LBD expressed in HEK293T cells after 16 to 24 hrs by FRET based beta-lactamase reporter gene assay	2018	Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4	Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
AID199386	Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID82156	HL-60 differentiation-inducing activity at a dose of 10e-9 M	2001	Bioorganic & medicinal chemistry letters, May-21, Volume: 11, Issue:10	Structure-Activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei.
AID84706	Dose for reversal of keratinization in epithelium of 50% of retinoid-deficient hamster tracheas in organ culture in experiment D	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID406411	Protection against Bacillus anthracis lethal toxin-mediated cytotoxicity in mouse RAW264.7 cells assessed as change in viability at 0.125 to 12.5 uM relative to toxin-treated control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Amiodarone and bepridil inhibit anthrax toxin entry into host cells.
AID197917	Inhibition of [3H]CD 367 binding to Retinoic acid receptor RAR alpha	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID678721	Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID199509	Inhibition of [3H]-ATRA binding to mouse Retinoic acid receptor RXR alpha	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID198366	Inhibition of murine Retinoic acid receptor RAR beta	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
AID334334	Induction of cAMP production in rat ASK cells assessed per 10'6 cells at 50 uM after 1 hr by radioimmunoassay
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID404773	Decrease in collagenase expression in Coll-CAT gene transfected human HaCaT cells co-transfected with c-Jun relative to control	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.
AID199805	Inhibition of [3H]-9-cis RA binding to Retinoid X receptor RXR beta	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Stereoselective synthesis and receptor activity of conformationally defined retinoid X receptor selective ligands.
AID288765	Cell viability of Raji cells at 320 nM	2007	Journal of natural products, Jun, Volume: 70, Issue:6	Cancer chemopreventive effects of cycloartane-type and related triterpenoids in in vitro and in vivo models.
AID429393	Induction of apoptosis in human LNCAP cells assessed as apoptotic cells after 48 hrs using Annexin-V-FITC/PI staining by flow cytometry	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth.
AID610870	Induction of apoptosis in human HeLa cells plated on serum free media for 24 hrs assessed as caspase 3 cleavage at 10 uM after 12 hrs	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid.
AID358152	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 1000 molar ratio after 48 hrs relative to TPA
AID193324	% change in the mean tumor volume in female rats on 21 days after a diet additive of 2 mmol/kg of the compound	2001	Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12	An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID1199795	Growth inhibition of human PC3 cells by MTT assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID124894	mortality determined for the toxicity of the compound. - indicates that no signs of toxicity was found	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID250165	Evaluated for mean value of the fluorescence intensity of CD11c-PE expressing NB4 cells at day 6	2004	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16	Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID166117	Percentage inhibition of cholesterol-3-sulfate activity in rabbit at 0.1 nM.	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID82154	HL-60 differentiation-inducing activity at a dose of 10e-8 M	2001	Bioorganic & medicinal chemistry letters, May-21, Volume: 11, Issue:10	Structure-Activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei.
AID1588437	Induction of differentiation of human HL60 cells assessed as morphological changes at 1 uM after 7 days by NBT reduction assay	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.
AID503304	Antiproliferative activity against human PC3 cells at 5 uM after 120 hrs by MTT assay relative to DMSO	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID198538	Inhibition of [3H]RA binding to retinoic acid receptor RAR beta	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Stereoselective synthesis and receptor activity of conformationally defined retinoid X receptor selective ligands.
AID199962	Percent transcriptional activation relative to ATRA in CV-1 cells expressing Retinoid X receptor RXR gamma	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID548958	Inhibition of soybean lipoxygenase at 0.05 mM	2010	Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23	Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID209496	Percent survivors at dose 67 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID199219	Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID717844	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID84704	Dose for reversal of keratinization in epithelium of 50% of retinoid-deficient hamster tracheas in organ culture in experiment B	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID264882	AUC(0-tz) in CD1 mouse at 5 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
AID198895	Relative activity against Retinoic acid receptor gamma at 10e-6 M with respect to 10e-6 M of trans-RA	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID679999	TP_TRANSPORTER: transepithelial transport (basal to apical) in mdr1a-expressing LLC-PK1 cell	1998	Archives of biochemistry and biophysics, Feb-15, Volume: 350, Issue:2	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.
AID700887	Binding affinity to bovine serum albumin turn at 0.5 mM by circular dichroism analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID198347	Inhibition of [3H]ATRA binding to Retinoic acid receptor beta	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID80939	The ability to induce differentiation of HL-60 cells relative to that of retinoic acid	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids.
AID288576	Antiproliferative activity against HMVE cells	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and
AID82162	Effective dose for induction of HL-60 cell differentiation	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID199510	Inhibition of binding to murine Retinoid X receptor RXR alpha	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
AID700894	Binding affinity to bovine serum albumin beta-antiparallel (1692 to 1680 cm'-1) at 0.1 mM after 2 hrs by FTIR spectroscopic analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID209485	Percent survivors at dose 600 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID150562	Inhibition of skin tumor promoter -induced mouse epidermal ornithine decarboxylase (ODC) activity on TPA-induced mouse epidermis at a dose of 1.7(nmol)	1980	Journal of medicinal chemistry, Sep, Volume: 23, Issue:9	Retinoic acid analogues. Synthesis and potential as cancer chemopreventive agents.
AID1602830	Transactivation of GAL4-fused mouse RARalpha-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.
AID199795	Inhibition of [3H]9-cis-RA binding to mouse Retinoid X receptor RXR beta	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID394805	Activity at RARbeta1 expressed in mouse NIH3T3 cells by R-SAT assay relative to Am-580	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1372839	Transactivation of mouse Gal4-fused RARbeta-LBD expressed in COS-7 cells after 1 day by bright-Glo reagent based assay	2018	Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4	Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
AID199800	Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR beta	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID198373	Retinoid activity at 10 e-5 M (E)-RA against Retinoic acid receptor beta for gene transcriptional activation in transfected CV-1 cells	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID670306	Activation of proteasome in human HT1080 cells expressing FLAG-tagged cIAP1 assessed as induction of CRABP-2 protein degradation at 10 uM after 6 hrs by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13	Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist.
AID444968	Induction of neurite outgrowth in human U87 cells at 2 to 5 uM after 48 hrs by crystal violet staining	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID284543	Growth inhibition of human HepG2 cells at 4 uM after 68 hrs relative to control	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID198713	Transcriptional activation of Retinoic acid receptor RAR gamma	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID199945	Transcriptional activation of Retinoid X receptor RXR gamma	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID284542	Growth inhibition of human estrogen receptor deficient adriamycin-resistant MCF7 cells at 4 uM after 68 hrs relative to control	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
AID198522	Effective concentration against Retinoic acid receptor beta	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID198043	Inhibition of [3H]ATRA-Hl60 binding to Retinoic acid receptor alpha	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID311158	Neurogenesis in TOPRO+ human neural stem cells at 1 uM relative to control	2007	Journal of natural products, Aug, Volume: 70, Issue:8	Panaxadiol glycosides that induce neuronal differentiation in neurosphere stem cells.
AID1192179	Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6	Synthesis and evaluation of the diarylthiourea analogs as novel anti-cancer agents.
AID680127	TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells	1998	Archives of biochemistry and biophysics, Feb-15, Volume: 350, Issue:2	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID198065	Relative binding affinity for Retinoic acid receptor alpha as IC50/IC50(ATRA)	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID365035	Induction of apoptosis in human MDA-MB-231 cells at 1.0 uM after 96 hrs by acridine orange staining	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID199380	Binding affinity against retinoic Acid X gamma receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1389205	Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as increase in PAX6 mRNA expression at 10 uM by RT-PCT analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID1389210	Induction of neuronal differentiation in human SH-SY5Y cells assessed as increase in RARalpha mRNA expression at 10 uM by RT-PCR analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID257179	Transcriptional activity against RARbeta2	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
AID198044	Binding affinity for Retinoic acid receptor alpha	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Syntheses and evaluation of naphthalenyl- and chromenyl-pyrrolyl-benzoic acids as potent and selective retinoic acid receptor alpha agonists.
AID299632	Neuronal differentiation activity assessed as increase in number of neurons at 0.1 uM in relative to control	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Dual bioactivity of resveratrol fatty alcohols: differentiation of neural stem cells and modulation of neuroinflammation.
AID84157	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-12 (M) in experiment C	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID198905	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Identification of retinoic acid receptor beta subtype specific agonists.
AID1165245	Antiangiogenic activity in chicken chorioallantoic membrane assessed as inhibition of blood vessel formation (Rvb = 23%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Development of a novel class of mitochondrial ubiquinol-cytochrome c reductase binding protein (UQCRB) modulators as promising antiangiogenic leads.
AID1168690	Inverse agonist activity at RORalpha (unknown origin) by M1H assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID128192	Antitumor activity in Mouse Skin Papilloma model	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID198547	Inhibition of [3H]ATRA binding to Retinoic acid receptor RAR beta	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID198042	Binding affinity against retinoic Acid alpha receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID396775	Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID755403	Activation of RXRalpha (unknown origin) by CAT reporter gene assay	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.
AID394808	Activity at RARalpha expressed in mouse NIH3T3 cells by R-SAT assay relative to Am-580	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
AID198555	Inhibition of [3H]ATRA-Hl60 binding to Retinoic acid receptor beta relative to ATRA	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID197906	Transcriptional activation of Retinoic acid receptor RAR alpha	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID334333	Induction of morphological transformation of rat ASK cells into astrocytes at 100 uM after 1 hr by light microscopy in presence of colchicine
AID1594140	Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID730055	Antiangiogenic activity in chicken embryo chorioallantoic membrane model assessed as reduction of capillary formation at 2 ug/egg after 4 days	2013	Journal of natural products, Jan-25, Volume: 76, Issue:1	Bioassay-guided isolation of proanthocyanidins with antiangiogenic activities.
AID29811	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1168683	Inverse agonist activity at human recombinant N-terminally 6xHis-tagged RORgamma ligand binding domain (unknown origin) expressed in Escherichia coli incubated for 1 hr by FRET assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID282366	Inhibition of ATRA hydroxylase in Syrian golden hamster liver microsome assessed ATRA metabolism using [11.12-3H]-ATRA	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID209482	Percent survivors at dose 300 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID429387	Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth.
AID548960	Antioxidant activity of the compound assessed as reducing activity of DPPH at 0.1 mM after 20 mins	2010	Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23	Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID129753	Percent decrease in average number of papillomas at dose 17 nmol *-p<0.001	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID198904	Transcriptional activation of Retinoic acid receptor RAR gamma	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID1054847	Inhibition of human recombinant TTR Y78F mutant-mediated fibrillogenesis at 40 uM after 30 mins by turbidimetric assay relative to control	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID700900	Binding affinity to bovine serum albumin alpha-helix at 0.5 mM by circular dichroism analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID124622	In vivo the maximum tolerated dose in six CD-1 mice at a oral dose of 30 mg/kg/day was determined	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID567893	Antiproliferative activity against human MCF7 cells expressing estrogen receptor assessed as cell growth inhibition 50 uM after 72 hrs by WST-1 assay relative to control	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Syntheses, antiproliferative activity and theoretical characterization of acitretin-type retinoids with changes in the lipophilic part.
AID199629	Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR alpha	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID1728100	Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
AID198872	Agonistic activity on Retinoic acid receptor gamma by transcriptional activation in COS-1 cells incubated at 10e-6 M	2001	Bioorganic & medicinal chemistry letters, May-21, Volume: 11, Issue:10	Structure-Activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei.
AID198377	Ability to inhibit TTNPB-induced transactivation at retinoic acid receptor beta	2001	Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6	Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.
AID610872	Growth inhibition of estrogen receptor-deficient human SKBR3 cells at 1 uM after 216 hrs by MTT assay relative to control in presence of 5% serum	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid.
AID166226	Retinoid activity at 10 e-5 M (E)-RA against RAR-gamma receptor for gene transcriptional activation in transfected CV-1 cells	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID150573	Inhibition of TPA-induced ODC activity as percentage of the average no. of papillomas / mouse in groups of control mice was determined using papilloma assay	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Cancer chemopreventive 3-substituted-4-oxoretinoic acids.
AID767647	Induction of RECK mRNA expression in human HT1080 cells at 1 uM after 24 hrs by RT-PCR analysis relative to control	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID678724	TP_TRANSPORTER: tissue concentration in mdr1a(-/-) mouse	1998	Archives of biochemistry and biophysics, Feb-15, Volume: 350, Issue:2	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.
AID35832	Effective concentration for retinoic acid receptor RAR alpha transcriptional activation	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID82975	In vitro apoptotic activity in HL60 cells	2001	Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14	Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells.
AID365036	Induction of apoptosis in human MDA-MB-231 cells at 2.0 uM after 96 hrs by acridine orange staining	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID201644	Percent inhibition of BrdU incorporation into SK-BR-3 cells	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID670305	Activation of proteasome in human HT1080 cells expressing FLAG-tagged cIAP1 assessed as induction of cIAP1 protein degradation at 10 uM after 6 hrs by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13	Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1594145	Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID26304	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1501679	Induction of neuronal differentiation in human SH-SY5Y cells assessed as neurite bearing cells at 10 uM followed by culture medium replacement for every three days for 10 days by inverted-phase microscopic analysis relative to control	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease.
AID199046	Ability to displace 3[H](all-E)-retinoic acid (5 nM) from Retinoic acid receptor gamma using transactivation assay	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	High affinity retinoic acid receptor antagonists: analogs of AGN 193109.
AID610811	Growth inhibition of ERalpha-negative and ERbeta-positive human A549 cells at 10 uM after 72 hrs	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid.
AID109743	Lowest daily intraperitoneal dose causing hypervitaminosis A symptoms was determined in a 2-week period in mice	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Retinoids at the threshold: their biological significance and therapeutic potential.
AID199960	Effective concentrations against Retinoic acid receptor RXR-gamma	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID55252	Inhibition of [3H]ATRA binding to murine Cytoplasmic retinoic acid binding protein (CRABP) type 1	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID250241	Ability to induce maturation and cell death of NB4 cells labelled with V-FITC on day 3	2004	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16	Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID1614975	Agonist activity RARalpha (unknown origin) assessed as induction of receptor transactivation	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID198354	Relative EC30 for human RAR-beta receptor as EC30(compound) divided by EC30(ATRA)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID123837	Skin scaling determined for the toxicity of the compound. - indicates that no signs of toxicity was found	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID1464487	Growth inhibition of human SK-N-AS cells by MTT assay
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID392141	Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay relative to all-trans retinoic acid	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID334323	Cytotoxicity against rat ASK cells at 150 uM
AID1069747	Antagonist activity at Gal4-fused RXRalpha (unknown origin) transfected in HEK293 cells assessed as CD3254-induced transcriptional activity at 4 uM by luciferase/beta-galactosidase reporter gene assay relative to CD3254-treated control	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.
AID1152396	Activation of RAR in human HepG2 cells assessed as increase in CAR mRNA level at 1 uM after 24 hrs by RT-PCR analysis	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID80929	The ability to induce differentiation of human promyelocytic leukemia HL-60 cell line to mature granulocyte	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids.
AID198902	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID697853	Inhibition of horse BChE at 2 mg/ml by Ellman's method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1069749	Agonist activity at Gal4-fused RXRalpha (unknown origin) transfected in HEK293 cells assessed as induction of transcriptional activity at 4 uM after 24 hrs by luciferase/beta-galactosidase reporter gene assay relative to control	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.
AID82980	In vitro inhibition of HL60 cell proliferation	2001	Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14	Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells.
AID1464489	Growth inhibition of human SK-N-AS cells at 1 uM after 72 hrs by MTT assay relative to control
AID730060	Antiangiogenic activity in chicken embryo chorioallantoic membrane model assessed as inhibition of blood vessels growth at 2 ug/egg after 4 days	2013	Journal of natural products, Jan-25, Volume: 76, Issue:1	Bioassay-guided isolation of proanthocyanidins with antiangiogenic activities.
AID150874	Inhibitory effect of compound on the induction of ornithine decarboxylase in CD-1 mouse.	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID378960	Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID1633432	Induction of neurogenesis in human SH-SY5Y cells assessed as upregulation of MAP-2 mRNA at 10 uM incubated for 24 hrs by RT-PCR analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID198216	Inhibition of [3H]-ATRA binding to baculovirus expressed RAR beta receptor	1997	Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16	Identification of highly potent retinoic acid receptor alpha-selective antagonists.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID68788	Ability to induce differentiation of mouse F9 embryonal carcinoma cells.	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Terminal bifunctional retinoids. Synthesis and evaluations related to cancer chemopreventive activity.
AID1389202	Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as effect on TRA160 expression at 10 uM after 7 days by flow cytometric analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID334325	Induction of morphological transformation of rat ASK cells into astrocytes at 25 uM after 1 hr by light microscopy in presence of fetal calf serum
AID84156	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-12 (M) in experiment B	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID378961	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID478129	Inhibition of sPLA2 from Naja mossambica mossambica by fluorescence technique	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Liposomal formulation of retinoids designed for enzyme triggered release.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID81285	Concentration required for 50% inhibition of differentiation-inducing activity against human promyelocytic leukemia cell line HL-60	1992	Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3	Base-catalyzed isomerization of retinoic acid. Synthesis and differentiation-inducing activities of 14-alkylated all-trans-, 13-cis-, and 20,14-retro-retinoic acids.
AID81281	Transglutaminase activity in HL-60 cdm-1 cells	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID700890	Binding affinity to bovine serum albumin beta-sheet (1640 to 1610 cm'-1) at 0.1 mM after 2 hrs by FTIR spectroscopic analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID199642	Transcriptional activation of Retinoid X receptor RXR alpha; NA is Not Active	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID83823	Activity of compound the was expressed as ratio of active hamster tracheal organ cultures(TOC) to the total cultures at 10e-10 M concentration; 18/19	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID1136174	Increase in RNA content in mouse epidermal cells at 0.1 uM after 3 days	1977	Journal of medicinal chemistry, Jul, Volume: 20, Issue:7	Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID1136170	Reversal of keratinized lesions in vitamin A deficient hamster tracheal organ culture assessed as cultures with keratin and keratohyaline granules at 10 nM after 7 days (Rvb = 93%)	1977	Journal of medicinal chemistry, Jul, Volume: 20, Issue:7	Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID73352	Binding affinity for retinoic acid receptor RAR gamma	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID1199786	Growth inhibition of human MDA-MB-231 cells by MTT assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID548963	Antiinflammatory activity in Fisher rat assessed as inhibition of carrageenan-induced paw oedema at 0.01 mmol/kg, po measured after 3.5 hrs	2010	Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23	Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID755405	Transactivation of full-length RXRbeta (unknown origin) expressed in African green monkey COS1 cells at 1000 nM by luciferase reporter gene assay	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.
AID41913	Binding affinity for retinoic acid receptor RAR beta	2002	Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17	An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID198533	Inhibition of [3H]-ATRA-Hl60 binding to Retinoic acid receptor beta	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID378957	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio relative to TPA	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID700888	Binding affinity to bovine serum albumin beta-sheet at 0.5 mM by circular dichroism analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID1633436	Induction of neurogenesis in human SH-SY5Y cells assessed as stimulation of neurite outgrowth at 10 uM incubated for 72 hrs by phase contrast microscopic analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID123012	Antitumor activity in CD-1 female mouse skin Papilloma assay at 15.3 nmol dose; 7/10 tumor-free mice	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid.
AID199053	In vitro binding affinity for Retinoic acid receptor RAR gamma	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID124883	mortality determined for the toxicity of the compound. - indicates that no signs of toxicity was found	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID198371	Inhibition of [3H]CD 367 binding to Retinoic acid receptor RAR beta	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID1192180	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6	Synthesis and evaluation of the diarylthiourea analogs as novel anti-cancer agents.
AID1069750	Agonist activity at Gal4-fused RARalpha (unknown origin) transfected in HEK293 cells assessed as induction of transcriptional activity at 4 uM after 6 hrs by luciferase/beta-galactosidase reporter gene assay relative to control	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.
AID209342	Mortality range in days at dose 300 umol/kg day; 10-14	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID697852	Inhibition of electric eel AChE at 2 mg/ml by Ellman's method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1389213	Transactivation of RARbeta in human SH-SY5Y cells assessed as increase in CYP26A1 mRNA expression at 10 uM measured after 4 to 12 hrs by RT-PCR analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID264880	Plasma concentration in CD1 mouse at 5 mg/kg, po after 2 hrs	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
AID1281290	Induction of cell differentiation in human HL60 cells at 0.1 to 10 uM measured after 3 days by NBT/MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents.
AID55250	Inhibition of chick skin Cytoplasmic retinoic acid binding protein at 100-fold excess ligand	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID700885	Binding affinity to bovine serum albumin by fluorescence spectroscopy analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID101800	Inhibition of MDA-MB-231 retinoid resistant breast carcinoma cell proliferation at 1 uM	2000	Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12	4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID91939	The compound was tested for the normalized percent inhibition of CFU-GM colony growth of JMML cells of patient J83 at a concentration of 10E-7 M.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1070215	Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
AID610871	Growth inhibition of estrogen receptor-deficient human SKBR3 cells at 1 uM after 144 hrs by MTT assay relative to control in presence of 5% serum	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid.
AID200110	Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR alpha	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID90248	Transcriptional activation in COS cells expressing RAR-beta	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.
AID199371	Relative EC30 for human RXR-gamma receptor as EC30(compound) divided by EC30(9-cis-RA)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID199230	Agonistic activity towards retinoid X receptor-beta	1997	Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26	Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID199625	Relative activity against Retinoic acid receptor RXR-alpha at 10e-6 M retinoid relative to 10e-6 M of 9-cis-RA.	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID82828	Induction of transglutaminase (TGase) activity in HL-60 cells	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID250913	Agonist activity for Retinoic acid receptor gamma as photons in presence and absence of ligand	2004	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16	Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID201645	Inhibition of ER-negative human breast cancer cell SK-BR-3 proliferation	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID150868	The percent inhibition was determined by mouse skin ornithine decarboxylase (ODC) assay using [14C]-ornithine	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID199638	Relative activity against Retinoid X receptor RXR-alpha compared to 9-cis-RA	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors.
AID200398	Growth inhibition of Cloudman S91 Melanoma cells at 1 uM drug concentration.	1982	Journal of medicinal chemistry, Aug, Volume: 25, Issue:8	Affinity therapeutics. 1. Selective incorporation of 2-thiouracil derivatives in murine melanomas. Cytostatic activity of 2-thiouracil arotinoids, 2-thiouracil retinoids, arotinoids, and retinoids.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID35839	Binding affinity for retinoic acid receptor RAR alpha	2002	Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17	An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID198732	Agonistic activity towards retinoic acid receptor-gamma	1997	Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26	Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID84150	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-11 (M) in experiment A	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID123030	Antitumor activity in CD-1 female mouse skin Papilloma assay at 15.3 nmol dose	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid.
AID1633430	Induction of neurogenesis in human SH-SY5Y cells assessed as upregulation of GAP43 mRNA at 10 uM incubated for 24 hrs by RT-PCR analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID257182	Efficacy against RARbeta1	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
AID767628	Inhibition of MMP2 activity in human HT1080 cells at 1 uM after 24 hrs	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1625190	Antiangiogenic activity in chicken fertilized egg chorioallantoic membrane at 3 uM after 48 hrs by stereomicroscopic analysis relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Antiangiogenic Activity of Compounds Isolated from Anarrhinum pedatum.
AID150728	Percent inhibition of TPA-induced ornithine decarboxylase activity	1981	Journal of medicinal chemistry, Oct, Volume: 24, Issue:10	Retinoic acid analogues with ring modifications. Synthesis and pharmacological activity.
AID47183	Transcriptional activation in CV-1 cells expressing RAR alpha receptor	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID198357	Relative IC50 for human RAR-beta receptor human RAR-beta receptor as IC50(compound) divided by IC50(ATRA)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID90247	Transcriptional activation in COS cells expressing RAR-alpha	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.
AID654485	Growth inhibition of human HuCCT1 cells at 10 uM after 72 hrs by MTT assay relative to control	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID128380	Tested for relative activity in a 20-week anti-papilloma experiment in female CD-1 mice at dose 17 nmol	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID198383	Transcriptional activation of Retinoic acid receptor RAR beta	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID41909	Binding affinity for retinoic acid receptor RAR beta	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID548959	Antioxidant activity against AAPH-induced lipid peroxidation assessed as inhibition of conjugated diene hydroperoxide production at 0.1 mM by UV spectrophotometry	2010	Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23	Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID91935	The compound was tested for the normalized percent inhibition of CFU-GM colony growth of JMML cells of patient J43 at a concentration of 10E-7 M.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID1785047	Induction of neurogenesis in human SH-SY5Y cells assessed as induction of MAP2 mRNA expression at 10 uM measured after 24 hrs by RT-PCR analysis relative to control	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
AID1564796	Induction of differentiation in human HL60 cells assessed as increase in CD11b positive cells at 2 uM incubated for 48 hrs by 7-AAD staining-based flow cytometric analysis	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	Synthesis and evaluation of 2-carboxy indole derivatives as potent and selective anti-leukemic agents.
AID624611	Specific activity of expressed human recombinant UGT1A8	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1693195	Inhibition of GST-tagged Pin1 (unknown origin) using Suc-Ala-pSer-Pro-Phe-pNA, Suc-Ala-Glu-Pro-Phe-pNA or Suc-Ala-Ala-Pro-Phe-pNA as substrate preincubated with enzyme for 0.5 to 2 hrs followed by substrate addition by chymotrypsin coupled assay	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Design, synthesis and biological evaluation of novel thiazole-based derivatives as human Pin1 inhibitors.
AID199226	Binding affinity against retinoic Acid X alpha receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID610869	Growth inhibition of human HeLa cells at 1 uM after 96 hrs by MTT assay in presence of 5% serum	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid.
AID1181358	Inhibition of mushroom tyrosinase using L-DOPA as substrate at 50 uM by spectrophotometry relative to control	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Effect of p-aminophenols on tyrosinase activity.
AID1389206	Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as increase in A2B5 expression at 10 uM measured after 7 days by immunofluorescence method	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID84705	Dose for reversal of keratinization in epithelium of 50% of retinoid-deficient hamster tracheas in organ culture in experiment C	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID755406	Transactivation of full-length RXRalpha (unknown origin) expressed in African green monkey COS1 cells at 1000 nM by luciferase reporter gene assay	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.
AID288763	Inhibition of TPA-induced Epstein-Barr virus early antigen activation assessed as EBV-EA induction in Raji cells at 0.32 nM after 48 hrs relative to TPA	2007	Journal of natural products, Jun, Volume: 70, Issue:6	Cancer chemopreventive effects of cycloartane-type and related triterpenoids in in vitro and in vivo models.
AID199387	Binding affinity against retinoic Acid beta receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID1192177	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6	Synthesis and evaluation of the diarylthiourea analogs as novel anti-cancer agents.
AID378962	Scavenging activity against (+/-)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide-induced NO generation in human Chang liver cells	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID1248104	Induction of cell differentiation in human HL60 cells at 0.1 uM incubated for 72 hrs by NBT dye based assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
AID198898	Ability to inhibit TTNPB-induced transactivation at retinoic acid receptor gamma	2001	Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6	Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.
AID288761	Inhibition of TPA-induced Epstein-Barr virus early antigen activation assessed as EBV-EA induction in Raji cells at 32 nM after 48 hrs relative to TPA	2007	Journal of natural products, Jun, Volume: 70, Issue:6	Cancer chemopreventive effects of cycloartane-type and related triterpenoids in in vitro and in vivo models.
AID1372843	Ratio of relative EC50 for mouse Gal4-fused RARgamma-LBD expressed in COS-7 cells to relative EC50 for mouse Gal4-fused RARalpha-LBD expressed in COS-7 cells	2018	Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4	Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
AID1625191	Antiangiogenic activity in chicken fertilized egg chorioallantoic membrane assessed as reduction in capillary formation at 3 uM after 48 hrs by stereomicroscopic analysis	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Antiangiogenic Activity of Compounds Isolated from Anarrhinum pedatum.
AID284544	Growth inhibition of human DU145 cells at 4 uM after 68 hrs relative to control	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
AID198715	Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR gamma	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID82163	Ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes.	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60.
AID166122	cross-linked envelope inhibition assay was performed at 10 nM compound concentration	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID444824	Induction of dendrite out growth in IL-4/GMCSF-stimulated human U937 cells assessed as dendrite length at 100 nM after 48 hrs by light microscopy	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID1168689	Inverse agonist activity at RORgammaT (unknown origin) by M1H assay relative to control	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID197910	Inhibition of [3H]ATRA binding to mouse Retinoic acid receptor RAR alpha	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID132681	Inhibition of Chondrogenesis in day 11 embryonic limb bud cells	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID1728101	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
AID1069743	Agonist activity at recombinant GST-tagged RXRalpha LBD (unknown origin) assessed as induction of biotinylated SRC-1-676-700 coactivator recruitment after 4 hrs by TR-FRET assay (Rvb = 148 +/- 7%)	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.
AID84155	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-12 (M) in experiment A	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID124216	Antitumor activity in CD-1 female mouse skin Papilloma assay at 15.3 nmol dose	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID199511	Dissociation constant for binding to Retinoid X receptor alpha	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID84148	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-10 (M) in experiment D	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID91937	The compound was tested for the normalized percent inhibition of CFU-GM colony growth of JMML cells of patient J83 at a concentration of 10E-6 M.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID1136176	Increase in RNA content in mouse epidermal cells at 1 nM after 3 days	1977	Journal of medicinal chemistry, Jul, Volume: 20, Issue:7	Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID343204	Growth inhibition of human PC3 cells after 5 days by MTT assay	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
AID73356	Binding affinity for retinoic acid receptor RAR gamma	2002	Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17	An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID209492	Percent survivors at dose 300 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID394811	Activity at RARgamma expressed in mouse NIH3T3 cells by R-SAT assay relative to Am-580	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
AID481444	Octanol-water partition coefficient, log P of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID264881	Plasma concentration in CD1 mouse at 5 mg/kg, po after 8 hrs	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
AID1785045	Induction of neurogenesis in human SH-SY5Y cells assessed as induction of GAP-43 mRNA expression at 10 uM measured after 24 hrs by RT-PCR analysis relative to control	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
AID444825	Cytotoxicity against human U937 cells after 3 days by trypan blue exclusion assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID197921	Ability to inhibit TTNPB-induced transactivation at retinoic acid receptor alpha	2001	Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6	Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID264887	Plasma concentration in CD1 mouse at 5 mg/kg, po after 8 hrs co-administered with 3-[6-(2-dimethylamino- 1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]- 2,2-dimethyl-propionic acid at 10 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
AID22293	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID334320	Induction of morphological transformation of rat ASK cells into astrocytes at 50 uM after 1 hr by light microscopy in absence of fetal calf serum
AID1177731	Inverse agonist activity at human RoRc-LBD fusion protein with GST expressed in BL-21 (BL3) cells assessed as SRC1 coactivator peptide recruitment	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc).
AID55249	Tested for its ability to inhibit the binding of (all-E-)-RA to cytoplasmic retinoic acid-binding protein (CRABP) from chick skin	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID209484	Percent survivors at dose 33 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID478133	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Liposomal formulation of retinoids designed for enzyme triggered release.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID199807	Inhibition of [3H]9-cis-RA binding to Retinoid X receptor RXR beta	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID264888	AUC(0-tz) in CD1 mouse at 5 mg/kg, po co-administered with 3-[6-(2-dimethylamino- 1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]- 2,2-dimethyl-propionic acid at 10 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
AID198049	Inhibition of [3H]RA binding to retinoic acid receptor RAR alpha	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Stereoselective synthesis and receptor activity of conformationally defined retinoid X receptor selective ligands.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID41910	Effective concentration for retinoic acid receptor RAR beta transcriptional activation	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID197898	Relative EC30 for human RAR-alpha receptor as EC30(compound) divided by EC30(ATRA)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID334329	Induction of morphological transformation of rat ASK cells into astrocytes at 6.2 uM after 1 hr by light microscopy in presence of colchicine
AID624606	Specific activity of expressed human recombinant UGT1A1	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID81842	The ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes relative to retinoic acid was determined by nitro blue tetrazolium (NBT) reduction assay	1994	Journal of medicinal chemistry, May-13, Volume: 37, Issue:10	Retinobenzoic acids. 6. Retinoid antagonists with a heterocyclic ring.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1204583	Antiproliferative activity against human NB4 cells assessed as decrease in cell viability at 1 uM after 96 hrs by trypan blue exclusion test	2015	European journal of medicinal chemistry, Jun-15, Volume: 98	Synthesis and antiproliferative activity of α-branched α,β-unsaturated ketones in human hematological and solid cancer cell lines.
AID404775	Induction of CRABP 2 mRNA expression in human normal fibroblast at 1 uM by Western blot relative to control	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.
AID84151	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-11 (M) in experiment B	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID755404	Transactivation of full-length RXRgamma (unknown origin) expressed in African green monkey COS1 cells at 1000 nM by luciferase reporter gene assay	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.
AID209490	Percent survivors at dose 200 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID198528	Percent transcriptional activation relative to ATRA in CV-1 cells expressing Retinoic acid receptor RAR beta	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID717846	Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID429390	Cell cycle arrest in human LNCAP cells assessed as accumulation at G0/G1 phase after 48 hrs by flow cytometry	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth.
AID82339	Activity relative to retinoic acid in differentiating promyelocytic leukemic HL-60 cells	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4'-carboxylic acids.
AID1389200	Transactivation of GST-tagged RARgamma LBD (unknown origin) assessed as fluorescein-labelled coactivator peptide recruitment measured after 4 hrs by TR-FRET analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID755399	Selectivity ratio of EC50 for retinoic acid receptor (unknown origin) to EC50 for retinoid X receptor (unknown origin)	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.
AID209340	Mortality range in days at dose 200 umol/kg day; 14-15	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID199634	Percent transcriptional activation relative to ATRA in CV-1 cells expressing Retinoid X receptor RXR alpha	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID200131	Inhibition of [3H]ATRA binding to baculovirus expressed RAR alpha receptor	1997	Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16	Identification of highly potent retinoic acid receptor alpha-selective antagonists.
AID198873	Agonistic activity on Retinoic acid receptor gamma by transcriptional activation in COS-1 cells incubated at 10e-7 M	2001	Bioorganic & medicinal chemistry letters, May-21, Volume: 11, Issue:10	Structure-Activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei.
AID334328	Induction of morphological transformation of rat ASK cells into astrocytes at 150 uM after 1 hr by light microscopy in presence of fetal calf serum
AID1199787	Growth inhibition of human MDA-MB-468 cells by MTT assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID199785	Transcriptional activation of Retinoid X receptor RXR beta	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID199058	Inhibition of [3H]ATRA binding to Retinoic acid receptor RAR gamma	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID610246	Growth inhibition of ERalpha-negative and ERbeta-positive human HT-29 cells at 10 uM after 72 hrs in presence of 10% FCS	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid.
AID120248	Topical irritation induced by RAR alpha-selective retinoid Am-580 in mice; ND denotes not determined.	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID288574	Inhibition of TPA-induced ornithine decarboxylase in mouse dorsal epidermis applied topically after 1 hr	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and
AID84861	Reversal of keratinization in vitamin A deficient hamster trachea culture	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	N-(Retinoyl)amino acids. Synthesis and chemopreventive activity in vitro.
AID198730	Inhibition of [3H]ATRA binding to baculovirus expressed RAR gamma receptor	1997	Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16	Identification of highly potent retinoic acid receptor alpha-selective antagonists.
AID654483	Growth inhibition of human MIAPaCa2 cells at 10 uM after 72 hrs by MTT assay relative to control	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID1594135	Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID82989	Effect on monocyte associated antigen CD14 expression in differentiating HL-60 cells	2001	Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14	Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID186913	Effect on total mammary tumor volume in female rats on day 7 after a diet additive of 2 mmol/kg (+/-S.E) (p<0.05)	2001	Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12	An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID1372901	Ratio of relative EC50 for human Gal4-DBD-fused RARgamma-LBD expressed in HEK293T cells to relative EC50 for human Gal4-DBD-fused RARalpha-LBD expressed in HEK293T cells	2018	Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4	Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1501668	Induction of neuronal differentiation in human SH-SY5Y cells assessed as extensive neurites formation at 10 uM followed by culture medium replacement for every three days for 10 days by inverted-phase microscopic analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease.
AID548962	Cytotoxicity against RAMEC assessed as cell viability after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23	Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID396448	Anti-aging activity in human dermal fibroblasts assessed as inhibition rate of MMP1 expression at 10 uM relative to control	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Synthesis and in vitro biological activity of retinyl polyhydroxybenzoates, novel hybrid retinoid derivatives.
AID41911	Percent transcriptional activation of RAR beta compared to 1 mM ATRA	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID47371	Transcriptional activation in CV-1 cells expressing RAR gamma receptor	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID1192182	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6	Synthesis and evaluation of the diarylthiourea analogs as novel anti-cancer agents.
AID1248101	Growth inhibition of human HL60 cells at 0.1 uM incubated for 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
AID140255	Percentage papilloma reduction (81) at 45.9 nmol dose 1 hr prior to TPA	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID199065	Inhibition of [3H]ATRA-Hl60 binding to Retinoic acid receptor gamma relative to ATRA	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID1686025	Agonist activity at human RAR	2016	Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19	Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID392142	Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID250912	Agonist activity for Retinoic acid receptor alpha as photons in presence and absence of ligand	2004	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16	Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID198381	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID198030	Transcriptional activation of Retinoic acid receptor RAR alpha	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID44377	Antitumor activity in CD-1 female mouse skin Papilloma assay	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid.
AID84147	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-10 (M) in experiment C	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID1391263	Inhibition of human N-terminal His6-tagged Pin1 PPIase activity expressed in Escherichia coli BL21 using Suc-Ala-Glu-cis-Pro-Phe-4-nitroanilide as substrate preincubated for 10 mins followed by substrate addition monitored for 90 secs by protease enzyme c	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID82170	Differentiation inducing activity towards human promyelocytic leukemia cell line HL-60 assayed by nitroblue tetrazolium reduction	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4'-carboxylic acids.
AID1614976	Agonist activity RARbeta (unknown origin) assessed as induction of receptor transactivation	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID210130	Inhibition of ER positive human breast cancer cell T-47D proliferation	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID1400149	Induction of differentiation of human NB4 cells assessed as increase in CD11b positive cells at 0.1 uM by flow cytometric analysis relative to control	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia.
AID199375	Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID404776	Induction of CRABP 2 mRNA expression in human normal fibroblast at 10 uM by Western blot relative to control	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID358156	Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hrs by trypan blue assay
AID1069744	Agonist activity at recombinant GST-tagged RXRalpha LBD (unknown origin) assessed as induction of fluorescein labeled D22 coactivator recruitment after 4 hrs by TR-FRET assay relative to control	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.
AID1464519	Induction of apoptosis in human IMR32 cells assessed as decrease in Bcl-2 mRNA expression level at 4 uM after 8 hrs by real-time PCR method
AID1464503	Cell cycle arrest in human SK-N-AS cells at 4 uM up to 72 hrs by propidium iodide staining based flow cytometry
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID199617	Percent inhibition of [3H]ATRA binding to mouse Retinoic acid receptor RXR alpha	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID198365	Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR beta	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID210107	Inhibition of T47D retinoid sensitive breast carcinoma cell proliferation at 1 uM	2000	Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12	4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID334326	Induction of morphological transformation of rat ASK cells into astrocytes at 50 uM after 1 hr by light microscopy in presence of fetal calf serum
AID199957	Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR gamma	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID38343	Inhibition of LPS-induced mouse B-lymphocyte proliferation. The result is expressed as relative IC50 i.e., IC50 of compound/all-trans retinoic acid IC50.	2002	Bioorganic & medicinal chemistry letters, Jul-08, Volume: 12, Issue:13	A library construction of 2,5-disubstituted pyrrole compounds by using solid/solution-phase syntheses.
AID198050	Binding affinity towards retinoic acid receptor alpha was determined using [3H]ATRA (5 nM) as radioligand	2001	Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6	Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.
AID84160	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-9 (M)	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID99416	Effective dose for differentiation -inducing activity against human promyelocytic leukemia cells	1988	Journal of medicinal chemistry, Nov, Volume: 31, Issue:11	Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity.
AID198521	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Identification of retinoic acid receptor beta subtype specific agonists.
AID396443	Anti-aging activity in human dermal fibroblasts assessed as expression rate of procollagen type 1 formation at 10 uM relative to control	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Synthesis and in vitro biological activity of retinyl polyhydroxybenzoates, novel hybrid retinoid derivatives.
AID199045	Binding affinity against Retinoic acid receptor gamma	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Syntheses and evaluation of naphthalenyl- and chromenyl-pyrrolyl-benzoic acids as potent and selective retinoic acid receptor alpha agonists.
AID1372900	Ratio of relative EC50 for human Gal4-DBD-fused RARbeta-LBD expressed in HEK293T cells to relative EC50 for human Gal4-DBD-fused RARalpha-LBD expressed in HEK293T cells	2018	Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4	Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
AID668898	Inhibition of nitrite level in LPS-induced mouse RAW264.7 cells at 5 uM by Griess assay relative to LPS treated control	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis and effects of some novel tetrahydronaphthalene derivatives on proliferation and nitric oxide production in lipopolysaccharide activated Raw 264.7 macrophages.
AID1464491	Growth inhibition of human IMR32 cells at 0.1 uM after 72 hrs by MTT assay relative to control
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1537922	Inhibition of colony formation in human NB4 cells at 30 uM preincubated for 72 hrs followed by compound washout and measured after 7 to 10 days	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
AID209494	Percent survivors at dose 33 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID247011	Effective concentration required for induction of differentiation of HL-60 cells into mature granulocytes.	2004	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16	Design and synthesis of cyclic urea compounds: a pharmacological study for retinoidal activity.
AID250242	Ability to induce maturation and cell death of NB4 cells labelled with V-FITC on day 6	2004	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16	Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID700884	Binding affinity to bovine serum albumin by fluorescence quenching assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID199049	Inhibition of [3H]RA binding to retinoic acid receptor RAR gamma	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Stereoselective synthesis and receptor activity of conformationally defined retinoid X receptor selective ligands.
AID700886	Binding affinity to bovine serum albumin random coil at 0.5 mM by circular dichroism analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID209349	Mortality range in days at dose 600 umol/kg day; 7-13	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID334331	Induction of morphological transformation of rat ASK cells into astrocytes at 25 uM after 1 hr by light microscopy in presence of colchicine
AID1136177	Increase in RNA content in mouse epidermal cells at 0.1 nM after 3 days	1977	Journal of medicinal chemistry, Jul, Volume: 20, Issue:7	Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID254266	Dissociation constant for Retinoid X receptor alpha; NAA = Not an active agonist	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Ligand recognition by RAR and RXR receptors: binding and selectivity.
AID1537937	Induction of granulocytic differentiation in human NB4 cells assessed as increase in CD11b-APC-Cy7 positive cells at 10 to 30 uM after 6 days by flow cytometry analysis	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
AID198871	Inhibition of [3H]ATRA binding to Retinoic acid receptor gamma	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.
AID700891	Binding affinity to bovine serum albumin random coil (1648 to 1641 cm'-1) at 0.1 mM after 2 hrs by FTIR spectroscopic analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID198028	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID334321	Induction of morphological transformation of rat ASK cells into astrocytes at 100 uM after 1 hr by light microscopy in absence of fetal calf serum
AID1199793	Growth inhibition of human LNCAP cells by MTT assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID82977	In vitro apoptotic activity against HL60 cells after 48 hr of treatment.	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Programmed cell death (PCD) associated with the stilbene motif of arotinoids: discovery of novel apoptosis inducer agents possessing activity on multidrug resistant tumor cells.
AID197908	Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR alpha	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID1537940	Induction of granulocytic differentiation in human HL60 cells assessed as increase in CD14-FITC positive cells at 10 to 30 uM after 6 days by flow cytometry analysis	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
AID199221	Inhibition of binding to retinoid X receptor RXR alpha	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID334317	Induction of morphological transformation of rat ASK cells into astrocytes at 6.2 uM after 1 hr by light microscopy in absence of fetal calf serum
AID334332	Induction of morphological transformation of rat ASK cells into astrocytes at 50 uM after 1 hr by light microscopy in presence of colchicine
AID47186	Transcriptional activation in CV-1 cells expressing RAR beta receptor	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Syntheses and evaluation of naphthalenyl- and chromenyl-pyrrolyl-benzoic acids as potent and selective retinoic acid receptor alpha agonists.
AID1389212	Induction of neuronal differentiation in human SH-SY5Y cells assessed as increase in RARbeta mRNA expression at 10 uM measured after 4 to 12 hrs by RT-PCR analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID1537918	Antiproliferative activity against human NB4 cells assessed as reduction in viability at 1 to 30 uM after 3 days by SRB assay	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
AID288764	Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs	2007	Journal of natural products, Jun, Volume: 70, Issue:6	Cancer chemopreventive effects of cycloartane-type and related triterpenoids in in vitro and in vivo models.
AID35831	Binding affinity fo retinoic acid receptor RAR alpha	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID1464512	Induction of apoptosis in human SK-N-AS cells assessed as caspase-3 activity at 4 uM after 8 to 24 hrs by CPP32 based colorimetric assay
AID81835	Granulocytic marker CD11b expression in HL-60 cell differentiation assay	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID1389203	Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as effect on A2B5 expression at 10 uM after 7 days by flow cytometric analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID199947	Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR gamma	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID197923	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors.
AID198215	Apparent binding constant for Retinoic acid receptor beta in HeLa cellGAL-4 transactivation assay	1996	Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12	Retinoic acid receptor beta,gamma-selective ligands: synthesis and biological activity of 6-substituted 2-naphthoic acid retinoids.
AID1372842	Transactivation of mouse Gal4-fused RARgamma-LBD expressed in COS-7 cells after 1 day by bright-Glo reagent based assay	2018	Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4	Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
AID755401	Induction of human HL60 cell differentiation into myeloid cells at 100 nM after 4 days by NBT reduction assay relative to control	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.
AID198201	Transcriptional activation of Retinoic acid receptor RAR beta	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID1389211	Induction of neuronal differentiation in human SH-SY5Y cells assessed as increase in RARgamma mRNA expression at 10 uM by RT-PCR analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID1192181	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6	Synthesis and evaluation of the diarylthiourea analogs as novel anti-cancer agents.
AID1389198	Transactivation of GST-tagged RARalpha LBD (unknown origin) assessed as fluorescein-labelled coactivator peptide recruitment measured after 4 hrs by TR-FRET analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID47362	Relative transcriptional activation in CV-1 cells expressing RAR beta receptor compared to ATRA	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID1372837	Transactivation of mouse Gal4-fused RARalpha-LBD expressed in COS-7 cells after 1 day by bright-Glo reagent based assay	2018	Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4	Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
AID444967	Induction of neurite outgrowth in mouse Neuro2a cells at 2 to 5 uM after 48 hrs by crystal violet staining	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID334319	Induction of morphological transformation of rat ASK cells into astrocytes at 25 uM after 1 hr by light microscopy in absence of fetal calf serum
AID200134	Agonistic activity towards retinoic acid receptor-alpha	1997	Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26	Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID1544148	Induction of neurite outgrowth in human SH-SY5Y cells assessed as increase in neurite length of more than 50 micrometer by measuring cell differentiation at 1 uM incubated for 6 days by Giemsa staining based phase contrast microscopic analysis relative to	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Profiling withanolide A for therapeutic targets in neurodegenerative diseases.
AID282378	Displacement of [11,12-3H]ARTA from RARalpha	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID199373	Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR gamma	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID1594139	Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID394813	Activity at RARgamma expressed in mouse NIH3T3 cells by R-SAT assay	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
AID84146	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-10 (M) in experiment B	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID1576232	Agonist activity at RAR (unknown origin) by Alpha Screen assay	2019	MedChemComm, Aug-01, Volume: 10, Issue:8	Dissecting the allosteric FXR modulation: a chemical biology approach using guggulsterone as a chemical tool.
AID234938	Transcriptional activation in CV-1 cells expressing retinoid A receptor alpha (RAR alpha) and retinoid X receptor alpha (RXR alpha)	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID199392	Binding affinity against retinoic Acid gamma receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID84152	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-11 (M) in experiment C	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID358157	Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio after 48 hrs by trypan blue assay
AID81673	Differentiating activity of compound in HL60 cells at conc 0.03 ug/mL	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.
AID524796	Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID429388	Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay in the presence of 1 uM RARalpha selective antagonist Ro415253	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth.
AID264884	Plasma concentration in CD1 mouse at 5 mg/kg, po after 8 hrs co-administered with 3-[6-(2-dimethylamino- 1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]- 2,2-dimethyl-propionic acid at 10 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
AID81837	Monocytic marker CD14 expression in HL-60 cell differentiation assay	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID82988	Effect on granulocyte associated antigen CD11b expression in diffrentiating HL-60 cells	2001	Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14	Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells.
AID166216	Retinoid activity at 10 e-5 M (E)-RA against RAR-alpha receptor for gene transcriptional activation in transfected CV-1 cells	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID284545	Growth inhibition of human HL60 cells at 4 uM after 72 hrs relative to control	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
AID198544	Inhibition of [3H]ATRA binding to baculovirus expressed Retinoic acid receptor RAR beta	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Identification of retinoic acid receptor beta subtype specific agonists.
AID1056039	Induction of cell differentiation in human SH-SY5Y cells assessed as neural-like differentiation at 10 uM after 6 days using beta3-tubulin and NF200 staining by microscopic analysis	2013	European journal of medicinal chemistry, , Volume: 70	Azetidinone-retinoid hybrids: synthesis and differentiative effects.
AID404774	Decrease in collagenase expression in Coll-CAT gene transfected human HaCaT cells co-transfected with c-Jun and retinoic acid receptor relative to control	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.
AID1168687	Inverse agonist activity at recombinant N-terminally GST-tagged RORbeta ligand binding domain (unknown origin) expressed in Escherichia coli incubated for 1 hr by FRET assay relative to control	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID343205	Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
AID700892	Binding affinity to bovine serum albumin alpha-helix (1660 to 1650 cm'-1) at 0.1 mM after 2 hrs by FTIR spectroscopic analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID264883	Plasma concentration in CD1 mouse at 5 mg/kg, po after 2 hrs co-administered with 3-[6-(2-dimethylamino- 1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]- 2,2-dimethyl-propionic acid at 10 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
AID674570	Induction of rat C/EBPalpha expression transfected in human U937 cells after 24 hrs by luciferase reporter gene assay relative to control	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID334324	Induction of morphological transformation of rat ASK cells into astrocytes at 12.5 uM after 1 hr by light microscopy in presence of fetal calf serum
AID68786	Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID198057	Inhibition of [3H]ATRA binding to Retinoic acid receptor RAR alpha	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID717843	Selectivity ratio of IC50 for mouse Ido1 to IC50 for mouse Ido2	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID674571	Induction of rat C/EBPalpha expression transfected in human HL60 cells after 24 hrs by luciferase reporter gene assay relative to control	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID311156	Neurogenesis in GFAP+ human neural stem cells at 1 uM relative to control	2007	Journal of natural products, Aug, Volume: 70, Issue:8	Panaxadiol glycosides that induce neuronal differentiation in neurosphere stem cells.
AID481440	Dissociation constant, pKa of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID38341	Compound was evaluated for its inhibition of LPS-induced mouse B-lymphocyte proliferation. The result is expressed as relative IC50 i.e., IC50 of compound / All Trans Retinoic Acid IC50	2002	Bioorganic & medicinal chemistry letters, Jul-08, Volume: 12, Issue:13	A library construction of 2,5-disubstituted pyrrole compounds by using solid/solution-phase syntheses.
AID378956	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio relative to TPA	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID47364	Relative transcriptional activation in CV-1 cells expressing RAR gamma receptor compared to ATRA	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID199954	Inhibition of [3H]-9-cis-RA binding to human Retinoid X receptor RXR gamma	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID1136171	Reversal of keratinized lesions in vitamin A deficient hamster tracheal organ culture assessed as cultures with keratin and keratohyaline granules at 1 nM after 7 days (Rvb = 93%)	1977	Journal of medicinal chemistry, Jul, Volume: 20, Issue:7	Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID198728	Apparent binding constant against Retinoic acid receptor gamma in HeLa cell GAl-4 transactivation assay	1996	Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12	Retinoic acid receptor beta,gamma-selective ligands: synthesis and biological activity of 6-substituted 2-naphthoic acid retinoids.
AID199343	Inhibition of binding to human Retinoic acid receptor RXR DEF domain	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID209480	Percent survivors at dose 200 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID1742094	Terminal half life in human at 30 mg/m2, po administered twice daily for 28 days by HPLC analysis	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Targeting Protein Folding: A Novel Approach for the Treatment of Pathogenic Bacteria.
AID1389201	Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as effect on SSEA3 expression at 10 uM after 7 days by flow cytometric analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID200139	Binding affinity to retinoic acid receptor alpha using [3H]CD 367 as radioligand	1995	Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26	Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID1602834	Selectivity ratio of EC50 for GAL4-fused mouse RARgamma-LBD expressed in COS-7 cells to EC50 for GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.
AID199493	Inhibition of binding to human Retinoid X receptor RXR alpha	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
AID83834	Activity of compound the was expressed as ratio of active hamster tracheal organ cultures(TOC) to the total cultures at 10e-11 M concentration; 10/20	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID394806	Activity at RARbeta1 expressed in mouse NIH3T3 cells by R-SAT assay	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
AID378959	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio relative to TPA	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID166217	Effective concentration against RAR-alpha receptor	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID250164	Evaluated for mean value of the fluorescence intensity of CD11c-PE expressing NB4 cells at day 3	2004	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16	Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID150718	Inhibition of the induction of ornithine decarboxylase in mouse epidermis by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (ODC) at dose 1.7 nmol	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID55255	Inhibition of [3H]ATRA binding to murine Cytoplasmic retinoic acid binding protein (CRABP) type 2	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID481446	Effective permeability across human jejunum	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID317384	Inhibition of UVB irradiation-induced MMP1 production in human dermal fibroblasts after 48 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Biflavonoids isolated from Selaginella tamariscina regulate the expression of matrix metalloproteinase in human skin fibroblasts.
AID114326	Antipapilloma activity was determined after intraperitoneal administration in mice	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Retinoids at the threshold: their biological significance and therapeutic potential.
AID199050	Binding affinity towards retinoic acid receptor gamma was determined using [3H]ATRA (5 nM) as radioligand	2001	Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6	Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.
AID334322	Induction of morphological transformation of rat ASK cells into astrocytes at 6.2 uM after 1 hr by light microscopy in presence of fetal calf serum
AID199044	Inhibition of [3H]ATRA-Hl60 binding to Retinoic acid receptor gamma	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
AID198874	Agonistic activity on Retinoic acid receptor gamma by transcriptional activation in COS-1 cells incubated at 10e-8 M	2001	Bioorganic & medicinal chemistry letters, May-21, Volume: 11, Issue:10	Structure-Activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei.
AID1192004	Induction of CYP26A1 expression in human HL60 cells at 0.1 uM after 72 hrs	2015	Bioorganic & medicinal chemistry, Mar-15, Volume: 23, Issue:6	Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1).
AID198037	Percent transcriptional activation relative to ATRA in CV-1 cells expressing Retinoic acid receptor RAR alpha	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID198367	Inhibition of binding to retinoid A receptor RAR beta	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID199632	Effective concentration against Retinoic acid receptor RXR-alpha	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID209495	Percent survivors at dose 600 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID1389215	Induction of neuronal differentiation in human SH-SY5Y cells assessed as increase in RARbeta mRNA expression at 0.001 to 1 uM measured after 8 hrs by RT-PCR analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID129752	Percent decrease in average number of papillomas at dose 1.7 nmol *-p<0.01	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID767631	Toxicity in human HT1080 cells assessed as reduction of cell growth at 1 uM after 24 hrs	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID144634	Induction of NB4 cell differentiation	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID199039	Percent transcriptional activation relative to ATRA in CV-1 cells expressing Retinoic acid receptor RAR gamma	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID199217	Relative IC50 for human RXR-alpha receptor as IC50(compound) divided by IC50(9-cis-RA)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID1602833	Transactivation of GAL4-fused mouse RARgamma-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID198361	Transcriptional activation of Retinoic acid receptor RAR beta	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID1281291	Induction of cell differentiation in human HL60 cells at 0.1 to 10 uM measured after 5 days by NBT/MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents.
AID82827	Percent differentiation of human promyelocytic leukemia (HL60) cells at 10e -6M concentration in culture medium	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzoates and beta-ionylideneacetamidobenzoates with retinoidal activity.
AID124618	In vivo maximum tolerated dose in six CD-1 mice was determined at a oral dose of 0 mg/kg/day	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID396776	Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay relative to all-trans retinoic acid	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID52070	Inhibition of binding of [3H]all-trans-retinoic acid to cellular retinoic acid binding protein at 3 uM compound concentration, in rat	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID198218	Agonistic activity towards retinoic acid receptor-beta	1997	Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26	Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID139988	In vitro inhibition of chondrogenesis in mouse embryo limb bud cells	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID199391	Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID47187	Transcriptional activation in CV-1 cells expressing RAR gamma receptor	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Syntheses and evaluation of naphthalenyl- and chromenyl-pyrrolyl-benzoic acids as potent and selective retinoic acid receptor alpha agonists.
AID81671	Differentiating activity of compound in HL60 cells at conc 0.003 ug/mL	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.
AID1694714	Inhibition of SIRT1 in human SH-SY5Y cells assessed as increase in acetylated p53 level at 10 uM by Western blot analysis
AID252973	Percent cell proliferation of human leukemia cell line HL-60 at 2*E-9 M	2005	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13	Cell differentiation inducers derived from thalidomide.
AID198378	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors.
AID668899	Inhibition of nitrite level in LPS-induced mouse RAW264.7 cells at 50 uM by Griess assay relative to LPS treated control	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis and effects of some novel tetrahydronaphthalene derivatives on proliferation and nitric oxide production in lipopolysaccharide activated Raw 264.7 macrophages.
AID198222	Binding affinity to retinoic acid receptor beta using [3H]CD 367 as radioligand	1995	Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26	Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID199953	Dissociation constant for binding to Retinoid X receptor gamma	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID192003	Final DMBA-induced mammary tumor volume in rat after retinoid treatment at 2 mmol/kg diet	2002	Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17	An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID199047	Binding affinity for baculovirus-expressed Retinoic acid receptor RAR gamma	1996	Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16	Identification of a retinoic acid receptor alpha subtype specific agonist.
AID1464522	Reduction in N-myc mRNA expression level in human IMR32 cells at 4 uM after 24 hrs by real-time PCR method relative to control
AID524795	Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID198368	Dissociation constant for binding to Retinoic acid receptor beta	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID668900	Cytotoxicity against mouse RAW264.7 cells at 5 uM by MTT assay	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis and effects of some novel tetrahydronaphthalene derivatives on proliferation and nitric oxide production in lipopolysaccharide activated Raw 264.7 macrophages.
AID420836	Inhibition of Dictyostelium discoideum AX2 RNase P by double reciprocal plot	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Preparation of spermine conjugates with acidic retinoids with potent ribonuclease P inhibitory activity.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID767623	Reduction of MMP9 mRNA level in human HT1080 cells at 1 uM after 24 hrs by RT-PCR analysis relative to control	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID444827	Cytotoxicity against mouse P19 cells after 3 days by trypan blue exclusion assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID198053	In vitro binding affinity for Retinoic acid receptor RAR alpha	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID282380	Displacement of [11,12-3H]ARTA from RARgamma	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID186910	Effect on total mammary tumor volume in female rats on day 1 after a diet additive of 2 mmol/kg (+/-S.E) (p<0.05)	2001	Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12	An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID82984	In vitro cytotoxicity against HL60 cells.	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Programmed cell death (PCD) associated with the stilbene motif of arotinoids: discovery of novel apoptosis inducer agents possessing activity on multidrug resistant tumor cells.
AID282383	Reduction of tumor growth in MCF7 cells xenografted ovariectomized mouse at 0.033 mmol/kg, sc for 6 weeks relative to control	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID199640	Inhibition of [3H]9-cis-RA binding to Retinoid X receptor RXR alpha	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID154429	Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50%	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
AID199216	Relative EC30 for human RXR-alpha receptor as EC30(compound) divided EC30(9-cis-RA)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID55256	Binding affinity for mouse Cytoplasmic retinoic acid binding protein type 2	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
AID230712	Ratio of the ED50 of compound to that of ED50 of retinoic acid, expressed as relative activity	1988	Journal of medicinal chemistry, Nov, Volume: 31, Issue:11	Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity.
AID199366	Agonistic activity towards retinoid X receptor-gamma	1997	Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26	Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
AID198045	Ability to displace 3[H](all-E)-retinoic acid (5 nM) from alpha retinoic acid receptor (alpha RAR) using transactivation assay	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	High affinity retinoic acid receptor antagonists: analogs of AGN 193109.
AID55253	Binding affinity for mouse Cytoplasmic retinoic acid binding protein type 1	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
AID524791	Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID429392	Cell cycle arrest in human LNCAP cells assessed as accumulation at G2/M phase after 48 hrs by flow cytometry	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth.
AID84703	Dose for reversal of keratinization in epithelium of 50% of retinoid-deficient hamster tracheas in organ culture in experiment A	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID311154	Neurogenesis in TUJ+MAP2+ human neural stem cells at 1 uM relative to control	2007	Journal of natural products, Aug, Volume: 70, Issue:8	Panaxadiol glycosides that induce neuronal differentiation in neurosphere stem cells.
AID755407	Transactivation of Gal4-fused RARgamma (unknown origin) expressed in African green monkey COS1 cells at 100 nM by luciferase reporter gene assay relative to DMSO-treated control	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.
AID282384	Antiproliferative effect against human MCF7 cells	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1537939	Induction of granulocytic differentiation in human NB4 cells assessed as increase in CD11c-APC positive cells at 10 to 30 uM after 6 days by flow cytometry analysis	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
AID199803	Percent transcriptional activation relative to ATRA in CV-1 cells expressing Retinoid X receptor RXR beta	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
AID1464490	Growth inhibition of human IMR32 cells at 0.1 uM after 24 hrs by MTT assay relative to control
AID198876	Relative EC30 for human RAR-gamma receptor as EC30(compound) divided by EC30(ATRA)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID81836	Granulocytic marker CD11b expression in HL-60 cell differentiation assay	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID668901	Cytotoxicity against mouse RAW264.7 cells at 50 uM by MTT assay	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis and effects of some novel tetrahydronaphthalene derivatives on proliferation and nitric oxide production in lipopolysaccharide activated Raw 264.7 macrophages.
AID288577	Inhibition of HMVE cell proliferation at 0.5 uM relative to control	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and
AID1602832	Selectivity ratio of EC50 for GAL4-fused mouse RARalpha LBD expressed in COS-7 cells to EC50 for GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.
AID1194830	Agonist activity at RARalpha (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 0.01 to 0.1 uM after 48 hrs by luciferase reporter gene assay	2015	Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9	Xanthones from the roots of Maclura cochinchinensis var. gerontogea and their retinoic acid receptor-α agonistic activity.
AID52066	Concentration of compound required to inhibit binding of 2.5 uM [3H]all-trans-retinoic acid by 50% in chick	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID73353	Effective concentration for retinoic acid receptor RAR gamma transcriptional activation	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID44524	Differentiation-inducing activity of the compound. ED1/3 value was obtained from the percentage of the differentiated cells (CD11b-positive cells).	1995	Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16	A novel type of retinoic acid receptor antagonist: synthesis and structure-activity relationships of heterocyclic ring-containing benzoic acid derivatives.
AID444966	Induction of neurite outgrowth in human SH-SY5Y cells at 2 to 5 uM after 48 hrs by crystal violet staining	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID1633431	Induction of neurogenesis in human SH-SY5Y cells assessed as upregulation of N-myc mRNA at 10 uM incubated for 24 hrs by RT-PCR analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID80927	Compound was tested for differentiation-inducing activity against human promyelocytic leukemia cell line HL-60	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Retinobenzoic acids. 4. Conformation of aromatic amides with retinoidal activity. Importance of trans-amide structure for the activity.
AID91942	The compound was tested for the normalized percent inhibition of CFU-GM colony growth of JMML cells of patient J84 at a concentration of 10E-7 M.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID166227	Effective concentration against RAR-gamma receptor	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID167597	Effective concentration against RXR-alpha receptor	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID257181	Efficacy against RARbeta2	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
AID197892	Inhibition of [3H]ATRA binding to Retinoic acid receptor alpha	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.
AID199506	Transcriptional activation of Retinoid X receptor RXR alpha	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID334318	Induction of morphological transformation of rat ASK cells into astrocytes at 12.5 uM after 1 hr by light microscopy in absence of fetal calf serum
AID197911	Inhibition of murine Retinoic acid receptor RAR alpha	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
AID1785046	Induction of neurogenesis in human SH-SY5Y cells assessed as induction of N-myc mRNA expression at 10 uM measured after 24 hrs by RT-PCR analysis relative to control	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
AID84158	Percent activity in the Hamster tracheal organ culture assay at concentration 10e-12 (M) in experiment D	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide a
AID84854	Molarity required to effect reversal of keratinization in 50% of cultures.	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID91933	The compound was tested for the normalized percent inhibition of CFU-GM colony growth of JMML cells of patient J43 at a concentration of 10E-6 M.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID199054	Inhibition of [3H]ATRA binding to baculovirus expressed Retinoic acid receptor RAR gamma	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Identification of retinoic acid receptor beta subtype specific agonists.
AID209486	Percent survivors at dose 67 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID68777	In vitro promotion of plasminogen activator secretion from F9 (murine teratocarcinoma) cells.	1995	Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26	Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID358154	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 100 molar ratio after 48 hrs relative to TPA
AID282376	Growth inhibition of human LNCaP cells after 6 days by MTT assay	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID478132	Cytotoxicity against human MT3 cells after 48 hrs by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Liposomal formulation of retinoids designed for enzyme triggered release.
AID378958	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio relative to TPA	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID481441	Aqueous diffusivity at 37C	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID81453	Cytostatic activity against HL-60 cells	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
AID198899	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors.
AID624613	Specific activity of expressed human recombinant UGT1A10	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID55248	Inhibition of [3H]ATRA binding to chick skin Cytoplasmic retinoic acid binding protein	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID624612	Specific activity of expressed human recombinant UGT1A9	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID151013	Compound was evaluated for the ability to inhibit the phorbol ester induced increase of mouse epidermal ornithine decarboxylase (ODC) activity by 50% when administered topically using ODC assay.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Novel heteroarotinoids: synthesis and biological activity.
AID1614977	Agonist activity RARgamma (unknown origin) assessed as induction of receptor transactivation	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID133247	Tested for relative activity in a 20-week anti-papilloma experiment in female CD-1 mice at dose 170 nmol	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID131561	Retinoid dose which inhibits 50% of skin papilloma was determined by a probit analysis	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID288762	Inhibition of TPA-induced Epstein-Barr virus early antigen activation assessed as EBV-EA induction in Raji cells at 3.2 nM after 48 hrs relative to TPA	2007	Journal of natural products, Jun, Volume: 70, Issue:6	Cancer chemopreventive effects of cycloartane-type and related triterpenoids in in vitro and in vivo models.
AID1537921	Inhibition of colony formation in human HL60 cells at 30 uM preincubated for 72 hrs followed by compound washout and measured after 7 to 10 days	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
AID199191	Inhibition of [3H]-retinoic acid binding to murine retinoic acid receptor RAR alpha	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid.
AID1588444	Induction of differentiation of human HL60 cells assessed as increase in CEBPA mRNA expression at by QT-PCR analysis	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.
AID124621	In vivo the maximum tolerated dose in six CD-1 mice at a oral dose of 2.5 mg/kg/day was determined	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.
AID235613	Therapeutic index calculated as the ratio of hypervitaminosis A dose to the ED50 dose	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Retinoids at the threshold: their biological significance and therapeutic potential.
AID198892	Dissociation constant for binding to Retinoic acid receptor gamma	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID717841	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as assessed as residual activity at 100 uM after 45 mins by spectrophotometric analysis relative to control	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID150571	In vivo inhibition of ornithine de-carboxylase (ODC) activity induced by 12-0-tetradecanoylphorbol 13-acetate (TPA) in mouse skin	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Cancer chemopreventive 3-substituted-4-oxoretinoic acids.
AID198217	Inhibition of [3H]-ATRA binding to human Retinoic acid receptor RAR beta	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID198031	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Identification of retinoic acid receptor beta subtype specific agonists.
AID1168685	Inverse agonist activity at recombinant N-terminally 6xHis-tagged RORgamma ligand binding domain (unknown origin) expressed in Escherichia coli incubated for 1 hr by FRET assay relative to control	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID1187717	Inhibition of lipid peroxidation in rat liver microsomes	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Inhibitory effects of p-alkylaminophenol on melanogenesis.
AID257180	Transcriptional activity against RARbeta1	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
AID755402	Induction of human HL60 cell differentiation into myeloid cells at 10 nM after 4 days by NBT reduction assay relative to control	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.
AID1586851	Displacement of DC271 from CRABP2 (unknown origin) at 200 to 1600 nM by fluorescence assay	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Novel Fluorescence Competition Assay for Retinoic Acid Binding Proteins.
AID1191998	Growth inhibition of human HL60 cells at 0.1 uM after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Mar-15, Volume: 23, Issue:6	Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1).
AID429394	Antiproliferative activity against human LNCAP cells assessed as maximal effect at 10 uM after 48 hrs by MTT assay	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth.
AID654484	Growth inhibition of human HuCCT1 cells at 4 uM after 72 hrs by MTT assay relative to control	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID392144	Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay relative to all-trans retinoic acid	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1501684	Induction of neuronal differentiation in human SH-SY5Y cells assessed as decrease in cell proliferation at 10 uM followed by culture medium replacement for every three days for 10 days by inverted-phase microscopic analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease.
AID199355	Relative EC30 for human RXR-beta receptor as EC30(compound) divided by EC30(9-cis-RA)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID150722	Inhibition of tumor promoter (TPA) -induced mouse epidermal ornithine decarboxylase (ODC) activity at 1.7 nmol dose level	1981	Journal of medicinal chemistry, May, Volume: 24, Issue:5	Aromatic retinoic acid analogues. Synthesis and pharmacological activity.
AID55119	Inhibition of binding to chick skin Cytoplasmic retinoic acid binding protein	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
AID250903	Agonist activity for Retinoic acid receptor beta as photons in presence and absence of ligand	2004	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16	Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID282377	Growth inhibition of human PC3 cells after 6 days by MTT assay	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID365033	Induction of apoptosis in human HL60R cells at 0.1 uM after 24 hrs by acridine orange staining	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID209352	Percent survivors at dose 100 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID481442	Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1389209	Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as increase in cytokeratin 8 expression at 10 uM measured up to 3 weeks by immunofluorescence method	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID1464492	Growth inhibition of human IMR32 cells at 0.4 uM after 72 hrs by MTT assay relative to control
AID365040	Growth inhibition of HMVE cells at 0.5 uM after 72 hrs by alamar blue method	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID199055	Binding affinity against Retinoic acid receptor gamma	2001	Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12	An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID52208	Inhibition of [3H]-retinoic acid binding to Cellular retinoic acid-binding protein (CRABP) from chick embryo skin	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid.
AID101948	Effect on MDA-MB-231 cell proliferation with compound 8; Significant inhibition	2000	Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12	sp2-bridged diaryl retinoids: effects of bridge-region substitution on retinoid X receptor (RXR) selectivity.
AID170874	Percentage change in DMBA-induced mammary tumor in rats; no new tumors, partial regression in 10/10 tumors	2002	Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17	An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID199788	Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR beta	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID1588436	Induction of apoptosis in human HL60 cells at 1 uM after 7 days	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.
AID198731	Inhibition of [3H]ATRA binding to human Retinoic acid receptor RAR gamma	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID396777	Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID1464507	Cell cycle arrest in human SK-N-AS cells assessed as accumulation at sub-G1 phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometry
AID1136165	Activity against chemically-induced skin papillomas in Swiss albino mouse assessed as change in total papilloma diameter at 40 mg/kg/day, ip administered five times per week for 2 weeks measured on day 14	1977	Journal of medicinal chemistry, Jul, Volume: 20, Issue:7	Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID210789	Percentage inhibition of Transglutaminase activity in rabbit at 10 nM.	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID755408	Transactivation of Gal4-fused RARbeta (unknown origin) expressed in African green monkey COS1 cells at 100 nM by luciferase reporter gene assay relative to DMSO-treated control	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.
AID406759	Cytotoxicity against human MON cells after 3 days by MTS assay	2008	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13	Design and synthesis of 4-HPR derivatives for rhabdoid tumors.
AID334330	Induction of morphological transformation of rat ASK cells into astrocytes at 12.5 uM after 1 hr by light microscopy in presence of colchicine
AID81291	In vitro for the differentiation induction activity determined in the human myeloid leukemic cell line HL-60	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
AID91944	The compound was tested for the normalized percent inhibition of CFU-GM colony growth of JMML cells of patient J84 at a concentration of 10e-8 M.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID1152400	Induction of RAR-mediated differentiation of human HL60 cells at 1 uM after 4 days by NBT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID199492	Inhibition of [3H]9-cis-RA binding to human Retinoid X receptor RXR alpha	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID1136173	Increase in RNA content in mouse epidermal cells at 1 uM after 3 days	1977	Journal of medicinal chemistry, Jul, Volume: 20, Issue:7	Dihydroretinoic acids and their derivatives. Synthesis and biological activity.
AID200108	Transcriptional activation of Retinoic acid receptor RAR alpha	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID101950	Effect on MDA-MB-231 cell proliferation; No effect	2000	Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12	sp2-bridged diaryl retinoids: effects of bridge-region substitution on retinoid X receptor (RXR) selectivity.
AID1054848	Inhibition of human recombinant TTR Y78F mutant-mediated fibrillogenesis after 30 mins by turbidimetric assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID481439	Absolute bioavailability in human	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1389216	Transactivation of RARbeta in human SH-SY5Y cells assessed as increase in CYP26A1 mRNA expression at 0.001 to 1 uM measured after 8 hrs by RT-PCR analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1588433	Induction of differentiation of human HL60 cells assessed as morphological changes at 1 uM after 7 days by Wright-Giemsa staining based assay	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.
AID90845	Relative activity expressed as mean of ratio of effective dose of retinoic acid against HL-60 cell versus the compound	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Retinobenzoic acids. 4. Conformation of aromatic amides with retinoidal activity. Importance of trans-amide structure for the activity.
AID199636	Inhibition of [3H]-9-cis RA binding to Retinoid X receptor RXR gamma	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Stereoselective synthesis and receptor activity of conformationally defined retinoid X receptor selective ligands.
AID1537938	Induction of granulocytic differentiation in human HL60 granulocytic assessed as increase in CD11c-APC positive cells at 10 to 30 uM after 6 days by flow cytometry analysis	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
AID199801	Effective concentrations against Retinoic acid receptor RXR-beta	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID624610	Specific activity of expressed human recombinant UGT1A7	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID81292	The ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes was determined by nitro blue tetrazolium (NBT) reduction assay	1994	Journal of medicinal chemistry, May-13, Volume: 37, Issue:10	Retinobenzoic acids. 6. Retinoid antagonists with a heterocyclic ring.
AID1192001	Induction of cell differentiation of human HL60 cells at 0.1 uM after 72 hrs by NBT dye based assay	2015	Bioorganic & medicinal chemistry, Mar-15, Volume: 23, Issue:6	Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1).
AID1192178	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6	Synthesis and evaluation of the diarylthiourea analogs as novel anti-cancer agents.
AID82153	HL-60 differentiation-inducing activity at a dose of 10e-7 M	2001	Bioorganic & medicinal chemistry letters, May-21, Volume: 11, Issue:10	Structure-Activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei.
AID199964	Inhibition of [3H]-9-cis RA binding to Retinoid X receptor RXR gamma	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Stereoselective synthesis and receptor activity of conformationally defined retinoid X receptor selective ligands.
AID91941	The compound was tested for the normalized percent inhibition of CFU-GM colony growth of JMML cells of patient J84 at a concentration of 10E-6 M.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID199950	Inhibition of binding to murine Retinoid X receptor RXR gamma	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
AID429395	Induction of necrosis in human LNCAP cells	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth.
AID1718426	Neurotrophic activity in rat N2a cells assessed as increase in NGF-mediated neurite outgrowth at 10 uM incubated for 24 hrs by cell imaging analysis relative to control	2021	Bioorganic & medicinal chemistry letters, 01-01, Volume: 31	Neurotrophic isoindolinones from the fruiting bodies of Hericium erinaceus.
AID1594134	Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID198203	Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR beta	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID198875	Agonistic activity on Retinoic acid receptor gamma by transcriptional activation in COS-1 cells incubated at 10e-9 M	2001	Bioorganic & medicinal chemistry letters, May-21, Volume: 11, Issue:10	Structure-Activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID610247	Growth inhibition of ERalpha-negative and ERbeta-positive human PC3 cells at 10 uM after 12 to 14 days relative to control	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid.
AID197913	Dissociation constant for binding to Retinoic acid receptor alpha	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID717842	Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as residual activity at 100 uM after 45 mins by spectrophotometric analysis relative to control	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1389204	Induction of neuronal differentiation in human TERA2.cl.SP12 cells assessed as increase in NeuroD1 mRNA expression at 10 uM by RT-PCT analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
AID700893	Binding affinity to bovine serum albumin turn (1680 to 1660 cm'-1) at 0.1 mM after 2 hrs by FTIR spectroscopic analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID1594137	Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID210769	Inhibitory dose against tracheal organ culture reversal of keratinization	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444969	Induction of neurite outgrowth in mouse P19 cells at 2 to 5 uM after 48 hrs by crystal violet staining	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.
AID68787	Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID200132	Inhibition of [3H]ATRA binding to human Retinoic acid receptor RAR alpha	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
AID114618	Inhibition of tumor-promoter-induced ornithine decarboxylase in TPA-treated female hairless mice	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID198540	Binding constant for baculovirus-expressed Retinoic acid receptor RAR beta	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors.
AID1594141	Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID654482	Growth inhibition of human MIAPaCa2 cells at 4 uM after 72 hrs by MTT assay relative to control	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID700889	Binding affinity to bovine serum albumin at 0.125 mM after 2 hrs by FTIR spectroscopic analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Binding sites of retinol and retinoic acid with serum albumins.
AID82831	Induction of HL-60 cells differentiation over 4 days	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID1204584	Cell cycle arrest at G0/G1 phase in human NB4 cells at 1 uM by flow cytometry	2015	European journal of medicinal chemistry, Jun-15, Volume: 98	Synthesis and antiproliferative activity of α-branched α,β-unsaturated ketones in human hematological and solid cancer cell lines.
AID198881	Relative IC50 for human RAR-gamma receptor as IC50(compound) divided by IC50(ATRA)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.
AID548957	Inhibition of soybean lipoxygenase at 0.1 mM	2010	Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23	Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID167596	Retinoid activity at 10 e-5 M (9Z)- RA against RXR-alpha receptor for gene transcriptional activation in transfected CV-1 cells	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID365039	Growth inhibition of HMVE cells after 72 hrs by alamar blue method	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and
AID1199785	Growth inhibition of human MCF7 cells by MTT assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID282373	Growth inhibition of human T47D cells after 6 days by MTT assay	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID198890	Inhibition of binding to murine Retinoic acid receptor RAR gamma	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
AID199358	Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID151015	Compound was evaluated for the percentage inhibition of test retinoid as compared to the control by ODCassay	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Novel heteroarotinoids: synthesis and biological activity.
AID199362	Binding affinity against retinoic Acid X beta receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID200130	Apparent binding constant against Retinoic acid receptor alpha in HeLa cell GAl-4 transactivation assay	1996	Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12	Retinoic acid receptor beta,gamma-selective ligands: synthesis and biological activity of 6-substituted 2-naphthoic acid retinoids.
AID198738	Binding affinity to retinoic acid receptor (RAR) gamma using [3H]CD 367 as radioligand	1995	Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26	Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID284541	Growth inhibition of human estrogen receptor expressing MCF7 cells at 4 uM after 68 hrs relative to control	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
AID1588445	Induction of differentiation of human HL60 cells assessed as increase in CEBPE mRNA expression at 1 uM by QT-PCR analysis	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.
AID1464488	Growth inhibition of human SK-N-AS cells at 1 uM after 24 hrs by MTT assay relative to control
AID394810	Activity at RARalpha expressed in mouse NIH3T3 cells by R-SAT assay	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
AID209488	Percent survivors at dose 100 umol/kg day	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Conformationally restricted retinoids.
AID264885	AUC(0-tz) in CD1 mouse at 5 mg/kg, po co-administered with 3-[6-(2-dimethylamino- 1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]- 2,2-dimethyl-propionic acid at 10 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
AID198891	Inhibition of binding to retinoid A receptor RAR gamma	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID35834	Percent transcriptional activation of RAR alpha compared to 1 mM ATRA	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1346788	Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors)	1995	Molecular and cellular biology, Jul, Volume: 15, Issue:7	Activation of retinoid X receptors induces apoptosis in HL-60 cell lines.
AID1346788	Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors)	1993	Proceedings of the National Academy of Sciences of the United States of America, Jan-01, Volume: 90, Issue:1	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids.
AID1346726	Human Testicular receptor 4 (2C. Testicular receptors)	2011	The Journal of biological chemistry, Jan-28, Volume: 286, Issue:4	The orphan nuclear receptor TR4 is a vitamin A-activated nuclear receptor.
AID1346740	Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)	1993	Proceedings of the National Academy of Sciences of the United States of America, Jan-01, Volume: 90, Issue:1	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids.
AID1346786	Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID1346788	Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors)	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID1346740	Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
AID1346786	Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)	2000	Current pharmaceutical design, Jan, Volume: 6, Issue:1	Therapeutic applications for ligands of retinoid receptors.
AID1346740	Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)	1994	Molecular and cellular biology, Jan, Volume: 14, Issue:1	Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping.
AID1346790	Human Peroxisome proliferator-activated receptor-beta/delta (1C. Peroxisome proliferator-activated receptors)	2003	The Journal of biological chemistry, Oct-24, Volume: 278, Issue:43	Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta.
AID1346788	Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors)	2000	Journal of molecular biology, Sep-08, Volume: 302, Issue:1	Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
AID1346777	Human RAR-related orphan receptor-beta (1F. Retinoic acid-related orphans)	2003	Nature structural biology, Oct, Volume: 10, Issue:10	All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta.
AID1346788	Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors)	2000	Current pharmaceutical design, Jan, Volume: 6, Issue:1	Therapeutic applications for ligands of retinoid receptors.
AID1346786	Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)	1994	Molecular and cellular biology, Jan, Volume: 14, Issue:1	Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping.
AID1346740	Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)	2000	Journal of molecular biology, Sep-08, Volume: 302, Issue:1	Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
AID1346786	Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)	2000	Journal of molecular biology, Sep-08, Volume: 302, Issue:1	Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
AID1346786	Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)	1995	Molecular and cellular biology, Jul, Volume: 15, Issue:7	Activation of retinoid X receptors induces apoptosis in HL-60 cell lines.
AID1346740	Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)	1995	Molecular and cellular biology, Jul, Volume: 15, Issue:7	Activation of retinoid X receptors induces apoptosis in HL-60 cell lines.
AID1346740	Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)	2000	Current pharmaceutical design, Jan, Volume: 6, Issue:1	Therapeutic applications for ligands of retinoid receptors.
AID1346788	Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors)	1994	Molecular and cellular biology, Jan, Volume: 14, Issue:1	Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1799444	Ligand Binding Assay from Article 10.1016/s1074-5521(98)90083-7: \\Engineering novel specificities for ligand-activated transcription in the nuclear hormone receptor RXR.\\	1998	Chemistry & biology, Jan, Volume: 5, Issue:1	Engineering novel specificities for ligand-activated transcription in the nuclear hormone receptor RXR.
AID1799183	Retinoid Competition Binding Assay from Article 10.1006/jmbi.2000.4032: \\Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.\\	2000	Journal of molecular biology, Sep-08, Volume: 302, Issue:1	Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1811	Experimentally measured binding affinity data derived from PDB	2003	Nature structural biology, Oct, Volume: 10, Issue:10	All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2003	Nature structural biology, Oct, Volume: 10, Issue:10	All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3534 (15.49)	18.7374
1990's	6536 (28.64)	18.2507
2000's	6054 (26.53)	29.6817
2010's	5288 (23.17)	24.3611
2020's	1410 (6.18)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,083 (4.58%)	5.53%
Reviews	1,986 (8.40%)	6.00%
Case Studies	1,372 (5.80%)	4.05%
Observational	15 (0.06%)	0.25%
Other	19,198 (81.16%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (221)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy & Safety of Clindamycin Phosphase 1.2% and Tretinoin 0.025% Gel vs. Vehicle for the Treatment of Acne and Acne-Induced Post Inflammatory Hyperpigmentation in Patients With Skin of Color[NCT01111994]	Phase 4	30 participants (Anticipated)	Interventional	2009-11-30	Active, not recruiting
Azacitidine in Combination With or Without All-trans Retinoic Acid in Newly Diagnosed Unfit Acute Myeloid Leukemia or Intermediate,High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria[NCT05175508]	Phase 2/Phase 3	180 participants (Anticipated)	Interventional	2021-05-01	Recruiting
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation[NCT01237808]	Phase 3	144 participants (Actual)	Interventional	2011-03-31	Completed
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System[NCT00867178]	Phase 1	33 participants (Actual)	Interventional	2009-02-25	Completed
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma[NCT01208454]	Phase 1	29 participants (Actual)	Interventional	2010-12-31	Completed
A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens[NCT04700176]	Phase 2	43 participants (Anticipated)	Interventional	2022-05-02	Recruiting
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING CLINDAMYCIN PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL (ACTAVIS MID-ATLANTIC LLC) TO ZIANA® (CLINDAMYCIN PHOSPHATE 1.2% AND TRETINOIN 0.025%) GEL (MEDICIS[NCT01257906]		1,225 participants (Actual)	Interventional	2010-05-31	Completed
A Phase 1 and Phase 2 Study of Daratumumab in Combination With All-trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma[NCT02751255]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2016-07-06	Completed
A Phase IV, Open-Label Study Evaluating the Use of Solodyn (Minocycline HCL Extended-Release Tablets), Ziana, and Triaz Foaming Cloths as Combination Acne Therapy Prior to Treatment With Isotretinoin[NCT01206348]	Phase 4	97 participants (Actual)	Interventional	2010-09-30	Completed
In-vivo Non-invasive Skin Imaging Pilot Study to Assess the Effects of Tretinoin Cream Using Multi-photon Microscopy and Multi-spectral Imaging[NCT02410980]	Early Phase 1	15 participants (Actual)	Interventional	2015-08-31	Completed
A Phase II Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma[NCT03999684]	Phase 2	18 participants (Actual)	Interventional	2019-08-05	Completed
An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis[NCT03359174]	Phase 2	2 participants (Actual)	Interventional	2018-05-29	Terminated(stopped due to low recruitment)
Comparison Of The Outcome Of Treatment Of Topical 15% Trichloroacetic Acid Versus Topical 0.05% Tretinoin In The Treatment Of Acanthosis Nigricans[NCT06008327]		80 participants (Actual)	Interventional	2022-08-01	Completed
A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome[NCT05281965]	Early Phase 1	20 participants (Anticipated)	Interventional	2022-04-01	Recruiting
Pilot Open-label Trial of Nivolumab Combined With Chemotherapy in Refractory Myelodysplastic Syndromes.[NCT03259516]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2017-05-25	Terminated(stopped due to Slow recruitment rate)
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients[NCT00392327]	Phase 3	379 participants (Actual)	Interventional	2007-03-26	Active, not recruiting
A Study of the RevLite Q-Switched Nd:YAG Laser System With Smart Infinite (SI) Handpiece for the Treatment of Refractory Mixed Type Melasma[NCT01335581]		18 participants (Actual)	Interventional	2011-04-30	Completed
Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML[NCT01161550]	Phase 1	11 participants (Actual)	Interventional	2010-11-30	Completed
Comparison Of The Efficacy Of Combination Of TAM Formula Versus Kligman Formula For Melasma At Tertiary Care Hospital,Karachi.[NCT06013540]	Phase 2	122 participants (Actual)	Interventional	2022-08-01	Active, not recruiting
Phase II Trial of Atragen and Interferon Alfa-2b in Patients With Advanced Renal Cell Carcinoma[NCT00003656]	Phase 2	26 participants (Actual)	Interventional	1999-01-31	Completed
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid[NCT02339740]	Phase 3	158 participants (Actual)	Interventional	2015-07-21	Active, not recruiting
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris[NCT03761784]	Phase 3	424 participants (Actual)	Interventional	2018-12-21	Completed
A Phase 1B Study Repurposing ATRA as Stromal Targeting Agent Along With Gemcitabine and Nab-Paclitaxel for Pancreatic Cancer (STAR_PAC)[NCT03307148]	Phase 1	29 participants (Actual)	Interventional	2016-01-15	Completed
A Phase 1b, Multicenter, Open-Label, Parallel-Group, Maximal Use Systemic Exposure (MUSE) Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Compared to Retin-A® 0.1% in Subjects With Moderate to Severe Acne Vulgaris[NCT04059523]	Phase 1	62 participants (Actual)	Interventional	2019-06-27	Completed
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma[NCT01175356]	Phase 1	99 participants (Actual)	Interventional	2010-10-04	Active, not recruiting
A Randomized Phase 2 Clinical Trial to Evaluate the Activity of ATRA in Combination With Anastrozole in Pre-operative Phase of Operable HR-positive/HER2-negative Early Breast Cancer (ATRA)[NCT04113863]	Phase 2	112 participants (Anticipated)	Interventional	2019-06-18	Recruiting
Pembrolizumab and All-Trans Retinoic Acid in Combination Treatment of Advanced Melanoma[NCT03200847]	Phase 1/Phase 2	26 participants (Actual)	Interventional	2017-10-31	Active, not recruiting
Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)[NCT01409161]	Phase 2	151 participants (Anticipated)	Interventional	2011-10-05	Recruiting
A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients[NCT00969722]	Phase 2	1 participants (Actual)	Interventional	2009-08-31	Terminated(stopped due to Lack of enrollment.)
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris[NCT03761810]	Phase 3	434 participants (Actual)	Interventional	2018-12-14	Completed
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME[NCT03878524]	Phase 1	2 participants (Actual)	Interventional	2020-04-01	Active, not recruiting
A National Phase I Study of Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors[NCT03611595]	Phase 1	18 participants (Anticipated)	Interventional	2018-08-28	Recruiting
S0521, A Randomized Trial of Maintenance Versus Observation for Patients With Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III[NCT00492856]	Phase 3	105 participants (Actual)	Interventional	2007-06-01	Completed
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma[NCT04385277]	Phase 2	34 participants (Actual)	Interventional	2020-12-31	Active, not recruiting
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue[NCT00026312]	Phase 3	1,449 participants (Actual)	Interventional	2001-10-18	Active, not recruiting
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)[NCT03126916]	Phase 3	724 participants (Anticipated)	Interventional	2018-05-14	Active, not recruiting
Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia[NCT01226303]	Phase 3	300 participants (Anticipated)	Interventional	2009-01-31	Recruiting
A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing TRETINOIN CREAM, 0.05% to RETIN-A® (TRETINOIN) CREAM, 0.05% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris[NCT03433378]	Early Phase 1	700 participants (Actual)	Interventional	2017-08-04	Completed
Clinical Efficacy and Safety of DLAAG Protocol in the Treatment of Refractory/Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess: a Multicenter, Single-arm, Prospective Clinical Study[NCT03356080]	Phase 2	50 participants (Anticipated)	Interventional	2017-07-07	Recruiting
The Combination of Low-dose Rituximab and All-trans Retinoic Acid as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial[NCT03304288]	Phase 2	168 participants (Actual)	Interventional	2017-10-11	Active, not recruiting
Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin[NCT01349556]		0 participants (Actual)	Interventional	2011-05-31	Withdrawn(stopped due to Study withdrawn due to volunteer disinterest in participating.)
Optimum Induction Therapy of Low-risk Acute Promyelocytic Leukemia With All Oral Drugs[NCT05832320]		74 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Phase I/II Study of Lenalidomide (Revlimid), All-trans Retinoic Acid (ATRA) and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma[NCT01985477]	Phase 1	2 participants (Actual)	Interventional	2013-12-31	Terminated(stopped due to Terminated Phase I due to slow accrual without progression to Phase II.)
Phase I/II Pilot Trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) and no Intensive Treatment is Possible[NCT02261779]	Phase 1/Phase 2	16 participants (Anticipated)	Interventional	2014-09-30	Recruiting
Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome[NCT00002479]	Phase 2	0 participants	Interventional	1991-10-31	Completed
Effect of Retinoic Acid Supplementation on the HDL-Associated Paraoxonase 1 Activity in Subjects With Hypercholesterolemia: A Randomized, Double-Blinded, Placebo-Controlled Trial[NCT02497833]	Early Phase 1	130 participants (Actual)	Interventional	2014-11-30	Completed
An Open-Label, Multi-Center, Single-Arm, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-Risk Neuroblastoma[NCT05373901]	Phase 1	8 participants (Actual)	Interventional	2022-06-07	Active, not recruiting
Interferon Alpha (NSC# 377523) Plus 13-Cis-Retinoic Acid Modulation Of BCL-2 Plus Paclitaxel For Recurrent Small Cell Lung Cancer[NCT00062010]	Phase 2	37 participants (Actual)	Interventional	2004-05-26	Completed
A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia[NCT00482833]	Phase 3	276 participants (Actual)	Interventional	2007-08-31	Completed
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma[NCT06172296]	Phase 3	478 participants (Anticipated)	Interventional	2024-02-14	Not yet recruiting
The Lipid Profile of the Skin Surface in Acne[NCT02180425]		30 participants (Actual)	Observational	2013-11-30	Completed
A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of CT Gel in Subjects With Acne Vulgaris[NCT00689117]	Phase 3	1,649 participants (Actual)	Interventional	2008-04-30	Completed
Solar Lentigines Treatment With the Triple Combination Cream (Hydroquinone 4%, Tretinoin 0.05%, and Fluocinolone Acetonide 0.01%). Randomized, Double Blind, Controlled Trial.[NCT00975312]	Phase 2	22 participants (Actual)	Interventional	2008-08-31	Completed
Split-Face, Randomized, Open-Label Study of Sequential Treatment With Tri-Luma® Cream With Intense Pulsed Light (IPL) vs. a Mild Inactive Control Cream With Intense Pulsed Light (IPL) in Subjects With Melasma[NCT00669071]	Phase 4	56 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Enrollment closed)
An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products (Retin-A Micro Gel, 0.04% Pump and Epiduo Gel) Using a Split-Face Model[NCT00952523]	Phase 4	162 participants (Actual)	Interventional	2009-07-31	Completed
Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes[NCT00382200]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2006-07-31	Completed
Phase IIb Randomised Clinical Trial Repurposing ATRA as a Stromal Targeting Agent in a Novel Drug Combination for Pancreatic Cancer[NCT04241276]	Phase 2	170 participants (Anticipated)	Interventional	2020-04-30	Not yet recruiting
The Combination of Oral All-trans Retinoic Acid and High-dose Dexamethasone vs High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Trial[NCT04217148]	Phase 2	132 participants (Actual)	Interventional	2020-01-01	Completed
Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer[NCT03370367]	Phase 3	189 participants (Actual)	Interventional	1989-05-15	Completed
Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules[NCT02715960]	Phase 2	500 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Double Blinded Vehicle Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Non-inflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients Post Oral Isotretinoin Use[NCT00939133]	Phase 4	20 participants (Actual)	Interventional	2009-07-31	Completed
A Pilot Study to Compare Tretinoin Gel, 0.05% to Tretinoin Gel Vehicle When Dosed Once or Twice Daily in Female Subjects With Classical Rosacea[NCT00621218]	Phase 2	36 participants (Actual)	Interventional	2008-02-29	Completed
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C[NCT04303169]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2020-06-26	Active, not recruiting
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation[NCT00866918]	Phase 3	106 participants (Actual)	Interventional	2009-03-09	Completed
A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks[NCT00823901]	Phase 2/Phase 3	83 participants (Actual)	Interventional	2009-02-28	Completed
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma[NCT00808899]	Phase 2	4 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to Voluntarily closed and terminated by the PI due to lack of feasibility)
Low Dose Oral Isotretinoin Versus Topical Tretinoin for Prevention of Actinic Keratosis in Immunocompetent Patients: a Randomized, Comparative Trial[NCT02278861]	Phase 2	60 participants (Actual)	Interventional	2011-11-30	Completed
A Prospective, Randomized, Double-blind, Vehicle-controlled Study Evaluating the Efficacy, Safety and Patient Satisfaction of Tretinoin 0.05% Lotion (Altreno) for Chest Rejuvenation.[NCT04096742]	Phase 4	40 participants (Anticipated)	Interventional	2019-08-06	Active, not recruiting
An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using a Split-Face Model[NCT00714714]	Phase 4	25 participants (Actual)	Interventional	2008-01-31	Completed
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma: A Phase II Study[NCT01183884]	Phase 2	46 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to Low participant accrual)
Clinical Evaluation of the Photoallergy Potential of Atralin Gel (Tretinoin Gel 0.05%)[NCT00603772]	Phase 1	40 participants (Anticipated)	Interventional	2008-01-31	Completed
A Phase II Double-Blind Study of Topical Tretinoin With or Without Oral 4-HPR (Fenretinide) in Patients With the Dysplastic Nevus Syndrome[NCT00003601]	Phase 2	38 participants (Anticipated)	Interventional	1999-02-23	Completed
Implement Randomized, Controlled, International Multi-center Clinical Trial of Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Non-high-risk Acute Promyelocytic Leukaemia[NCT04175587]	Phase 3	109 participants (Anticipated)	Interventional	2019-12-01	Not yet recruiting
[NCT02620813]	Early Phase 1	32 participants (Actual)	Interventional	2015-10-31	Completed
A Multicenter and Randomized Prospective Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia[NCT02200978]	Phase 4	176 participants (Actual)	Interventional	2011-09-30	Completed
A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris[NCT04724473]	Early Phase 1	1,030 participants (Actual)	Interventional	2019-12-10	Completed
Phase I/II Study of Sensitization of Non-M3 Acute Myeloid Leukemia (AML) Blasts to All-trans Retinoic Acid (ATRA) by Epigenetic Treatment With Tranylcypromine (TCP), an Inhibitor of the Histone Lysine Demethylase 1 (LSD1)[NCT02717884]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2015-05-31	Recruiting
A Clinical, Laboratorial and Quality of Life Study to Evaluate the Efficacy and Safety of Oral Isotretinoin in the Treatment of Cutaneous Photodamage[NCT00842907]	Phase 2	20 participants (Anticipated)	Interventional	2009-05-31	Active, not recruiting
A Randomized Phase II Trial Using Dendritic Cells Transduced With an Adenoviral Vector Containing the p53 Gene to Immunize Patients With Extensive Stage Small Cell Lung Cancer in Combination With Chemotherapy With or Without All Trans Retinoic Acid[NCT00617409]	Phase 2	69 participants (Actual)	Interventional	2007-10-02	Completed
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma[NCT03786783]	Phase 2	42 participants (Actual)	Interventional	2019-01-14	Active, not recruiting
Single-blinded, Multicenter, Randomized, Comparative Study of Efficacy and Safety of Adapalene Gel 0.3% Versus Tretinoin Emollient Cream 0.05% in the Treatment of Cutaneous Photoaging.[NCT01406080]	Phase 3	128 participants (Actual)	Interventional	2013-01-31	Completed
A Phase 1, Open-label, Dose-escalation Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome[NCT00892190]	Phase 1	9 participants (Actual)	Interventional	2011-04-30	Completed
Clinical Evaluation of the Phototoxic Potential of Atralin (Tretinoin) Gel, 0.05%[NCT00604032]	Phase 1	60 participants (Actual)	Interventional	2008-01-31	Completed
Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma[NCT00567567]	Phase 3	665 participants (Actual)	Interventional	2007-11-05	Completed
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS[NCT06020833]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid (ATRA)[NCT05297123]	Phase 1	30 participants (Anticipated)	Interventional	2019-02-03	Recruiting
A Comparative Study of Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream, for the Treatment of Photodamage[NCT00647556]	Phase 3	30 participants (Actual)	Interventional	2008-04-30	Completed
Treatment of Acute Myelogenous Leukemia With the Histone Deacetylase Inhibitor Valproic Cid in Combination With All-trans Retinoic Acid (ATRA) and Low Dose Cytarabine[NCT00995332]	Phase 1/Phase 2	36 participants (Actual)	Interventional	2009-09-30	Completed
Guideline for the Treatment of Newly Diagnosed Patients Eith Acutypromyelocytic Leukemia, Aged > 12 Months (1 Year) and <75 Years, Using All-trans Retinoic Acid in Combination With Idarubicin[NCT01064557]		1,068 participants (Anticipated)	Interventional	1993-10-31	Recruiting
Phase IIA Trial: Tretinoin and Pioglitazone HCL Combination Therapy in Amyotrophic Lateral Sclerosis[NCT00919555]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2008-06-30	Completed
Effect of Home-fortification With Micronutrient Powder Sprinkles in Hematologic and Nutritional Status in Preschool Children in Medellín: a Randomized Clinical Trial.[NCT01917032]	Phase 3	100 participants (Anticipated)	Interventional	2013-09-30	Not yet recruiting
A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over[NCT00005823]	Phase 3	2,000 participants (Anticipated)	Interventional	1998-12-31	Completed
Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leu[NCT00867672]	Phase 2	204 participants (Actual)	Interventional	2011-08-31	Completed
Trans Retinoic Acid (Vesanoid) With Chemotherapy in Non-Small Cell Lung Cancer[NCT00005825]	Phase 2	0 participants	Interventional	1998-09-30	Active, not recruiting
Phase II Study of ATRAGEN (Liposomal Tretinoin) in Patients With Relapsed or Refractory Hodgkin's Disease[NCT00005969]	Phase 2	0 participants (Actual)	Interventional	1999-09-30	Withdrawn(stopped due to Study withdrawn.)
Phase II Study Of Combined Modality Postremission Therapy As Determined By Molecular Response (Adaptive Regulation) In The Treatment Of Acute Promyelocytic Leukemia (APL)[NCT00016159]	Phase 2	35 participants (Anticipated)	Interventional	2000-11-30	Completed
Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients >=60 Years With AML Who Are Refractory to Standard Induction Chemotherapy[NCT02942758]	Phase 2	10 participants (Actual)	Interventional	2017-04-10	Terminated(stopped due to Due to financial reasons.)
Differentiation Induction Therapy for Acute Myelogenous Leukemia[NCT00175812]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2004-11-30	Completed
90Y-DOTA-tyr3-Octreotide With or Without Retinoic Acid for the Treatment of Neuroblastoma and Neuroendocrine Tumors in Children and Young Adults. A Randomized, Placebo Controlled Phase II Trial With Dosimetry Guided Dosing[NCT01048086]	Phase 2	0 participants (Actual)	Interventional	2009-06-30	Withdrawn(stopped due to No patients were enrolled because the company that pledged the drug does not yet have it available.)
A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination With Induction Chemotherapy, or Azacitidine and Idarubicin as Salvage Therapy and Idarubicin With Cytarabine or Azacitidine as Maintenance Thera[NCT01067274]	Phase 3	0 participants (Actual)	Interventional	2010-04-30	Withdrawn(stopped due to Study abandoned)
Guidelines for Treatment of Acute Promyelocytic Leukemia[NCT01064570]	Phase 2	600 participants (Anticipated)	Interventional	2000-05-31	Recruiting
Clinical Study on All-Trans Retinoic Acid (ATRA) Combining High-dose Dexamethasone Versus High-dose Dexamethasone Alone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)[NCT01882127]	Phase 3	0 participants (Actual)	Interventional	2013-02-28	Withdrawn(stopped due to No eligible patient was enrolled.)
A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers[NCT01915758]	Phase 1	64 participants (Actual)	Interventional	2008-11-21	Completed
Pilot Exploratory Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis[NCT03491267]	Early Phase 1	20 participants (Anticipated)	Interventional	2018-01-01	Enrolling by invitation
A Randomized Study to Compare the Acne Relapse Rate After a 3-mo Course of Oral Minocycline, to a 3-mo Course of Oral Minocycline in Combination With a Daily Dose of Topical Tretinoin 0.01% Followed by 3 mo of Topical Tretinoin Alone[NCT00240513]	Phase 4	38 participants (Actual)	Interventional	2004-08-31	Terminated(stopped due to Too much difficulty recruiting and retaining patients, PI decided to stop.)
Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?[NCT04623385]	Phase 4	1,000 participants (Anticipated)	Interventional	2020-11-30	Not yet recruiting
Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study[NCT01987297]	Phase 4	738 participants (Anticipated)	Interventional	2012-06-30	Active, not recruiting
Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML[NCT00005863]	Phase 3	0 participants	Interventional	1998-08-31	Completed
Arsenic Trioxide Alone or With ATRA (Vesanoid) for Resistant Hematologic Malignancy[NCT00006220]	Phase 1/Phase 2	5 participants (Actual)	Interventional	1999-06-30	Terminated(stopped due to Study drug became commercially available.)
Single-Blinded Randomized Controlled Trial: Comparison of Quality of Life in Moderate Acne Vulgaris Patients Based on Acne-QoL-INA Using Standard Therapy With and Without Acne Lesions Extraction[NCT06181838]		40 participants (Actual)	Interventional	2023-08-28	Active, not recruiting
A Study of All-trans Retinoic Acid in the Treatment of Immune Thrombocytopenia[NCT04618328]	Phase 2	80 participants (Anticipated)	Interventional	2020-11-30	Not yet recruiting
Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)[NCT04578236]	Phase 2	360 participants (Anticipated)	Interventional	2020-11-30	Not yet recruiting
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach[NCT04577378]	Phase 2	45 participants (Anticipated)	Interventional	2020-10-20	Not yet recruiting
A Multi-Center, Double Blind, Vehicle Controlled, Study of Retin-A Micro 0.04% in the Treatment of Pediatric Acne Vulgaris in Children, Ages 9 to 11 Years of Age[NCT00907335]	Phase 2	110 participants (Actual)	Interventional	2009-02-28	Completed
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma[NCT02403778]	Phase 2	10 participants (Actual)	Interventional	2015-12-17	Completed
A Prospective, Validation Study to Observe the Effect of House Dust Mite Exposure in an Allergen Exposure Chamber (AEC) Within Dust Mite Allergic Patients Taking an Immune Modulating Dietary Supplement[NCT04477382]		38 participants (Actual)	Observational	2020-01-06	Completed
A Phase 1 Dose Escalation Study of Tranylcypromine (TCP) in Combination With ATRA (Tretinoin) for Adult Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)[NCT02273102]	Phase 1	17 participants (Actual)	Interventional	2015-03-02	Completed
Assessment of the Optimal Timing of Chemotherapy With or After ATRA and the Role of Maintenance[NCT00599937]	Phase 3	576 participants (Actual)	Interventional	1993-01-31	Completed
The Combination of ATRA and Eltrombopag as the Treatment Strategy for Glucocorticoid-Resistant/Relapsed ITP Based on the Stratification of the New Biomarker MSC-C5b-9: A Prospective, Randomized, Open-Label, Multicenter Clinical Trial[NCT05438875]	Phase 3	96 participants (Anticipated)	Interventional	2022-10-12	Recruiting
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion[NCT04234048]	Phase 1	46 participants (Anticipated)	Interventional	2023-12-18	Recruiting
Pilot Study of Tolerability and Effectivity Following Application of Two Combination Topical Acne Products Clindamycin 1% and 0.025% Tretinoin Gel (Acnatac® Gel), Adapalen 0,1% and Benzoyl Peroxide 2,5% Gel (Epiduo® Gel)[NCT02731105]	Phase 4	22 participants (Actual)	Interventional	2015-02-28	Completed
Addition of a Topical Steroid to a Topical Retinoid: a Randomized, Split-face, Placebo-controlled, Double-blind, Single-center Clinical Study[NCT02704507]		20 participants (Actual)	Interventional	2015-06-30	Active, not recruiting
Investigation of the Topical Retinoid, Atralin Gel 0.05% for the Treatment of Erythematotelangiectatic Rosacea[NCT01125930]	Phase 3	68 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to Due to slow recruitment and sponsor request study ended early)
A Clinical Assessment of the Use of RETIN-A MICRO (Tretinoin Gel) Microsphere, 0.04% in a Pump Dispenser and a 5% Benzoyl Peroxide Wash Used in the Morning Compared to the Use of RETIN-A MICRO 0.04% Pump Nightly and a 5% Benzoyl Peroxide Wash in the Morni[NCT00907257]	Phase 4	247 participants (Actual)	Interventional	2009-02-28	Completed
A Pilot Study to Evaluate the Efficacy of Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Alone Versus Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Plus Benzoyl Peroxide 6% Foaming Cloths in the Treatment o[NCT01422785]	Phase 4	40 participants (Anticipated)	Interventional	2011-07-31	Recruiting
Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In The Treatment Of Facial Melasma, Taking As Reference The Product Triluma ® (Hidroquinone, Fluoncinolone And Tretinoin).[NCT00717652]	Phase 2/Phase 3	110 participants (Anticipated)	Interventional	2008-07-31	Suspended
A Pilot Study of Arsenic Trioxide-Based Consolidation Therapy for the Primary Treatment of Acute Promyelocytic Leukemia[NCT00276601]	Phase 2	0 participants	Interventional	2004-10-31	Completed
A Phase I, Dose-Finding Trial of Sodium Phenylbutrate (NSC 657802) in Combination With All Trans-retinoic Acid (ATRA, NSC 122758) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)[NCT00006239]	Phase 1	0 participants	Interventional	2000-12-31	Completed
Multi Centers, Open-trial Phase II Study Evaluating 5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®) in Patients With Acute Myelogenous Leukemia and High Risk Myelodysplasia.[NCT00339196]	Phase 2	25 participants (Actual)	Interventional	2006-07-31	Completed
Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia[NCT00151242]	Phase 2/Phase 3	920 participants (Actual)	Interventional	2004-07-31	Completed
Double-blinded, Single-center, Parallel-arm Comparison Study of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage[NCT01283464]	Phase 2	24 participants (Actual)	Interventional	2010-11-30	Completed
A Phase I Study of ZD6474 (Zactima) Alone and in Combination With Retinoic Acid in Relapsed and Refractory Pediatric Neuroblastoma[NCT00533169]	Phase 1	10 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Lack of enrollment.)
Treatment of Non-high-risk Acute Promyelocytic Leukemia With Realgar-Indigo Naturalis Formula (RIF) and All-trans Retinoid Acid (ATRA)[NCT02899169]	Phase 3	110 participants (Anticipated)	Interventional	2016-09-01	Recruiting
PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation[NCT03933774]		25 participants (Actual)	Interventional	2019-04-29	Completed
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation in Patients With High-Risk Neuroblastoma: A Phase II Study[NCT01183416]	Phase 2	4 participants (Actual)	Interventional	2010-08-31	Completed
ASSESSMENT OF INTERMEDIATE ENDPOINT BIOMARKERS TO 13-CIS RETINOIC ACID WITH OR WITHOUT ALPHA TOCOPHEROL OR OBSERVATION[NCT00002586]	Phase 2	96 participants (Actual)	Interventional	1993-01-31	Completed
An Investigator-Blind, Phase 4 Study Assessing Mitigation of Facial Irritation When Comparing the Use of Two Acne Treatment Products (Retin-A Micro® 0.1 % Pump and Aczone®) With One Treatment Product (Retin-A Micro® 0.1 % Pump) Using a Split-Face Model[NCT01313728]	Phase 4	26 participants (Actual)	Interventional	2010-12-31	Completed
Phase II Trial of Bexarotene (Targretin) Capsules With Tretinoin and Chemotherapy in Patients With Advanced Non-small-cell Lung Cancer[NCT00514293]	Phase 2	39 participants (Anticipated)	Interventional	2007-01-31	Recruiting
An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using A Split-Face Model[NCT00919191]	Phase 4	26 participants (Actual)	Interventional	2009-04-30	Completed
ACUTE MYELOID LEUKAEMIA TRIAL 12[NCT00002658]	Phase 3	2,000 participants (Anticipated)	Interventional	1994-01-31	Active, not recruiting
A Phase 1 Trial of PXD101 in Combination With 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies[NCT00334789]	Phase 1	51 participants (Actual)	Interventional	2006-06-12	Completed
A Randomized Phase II Trial of All-Trans Retinoic Acid and One of Two Schedules of Bryostatin 1 in Patients With Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)[NCT00136461]	Phase 2	40 participants	Interventional	1997-05-31	Completed
Neuroblastoma Protocol 2005: Therapy for Children With Advanced Stage High-Risk Neuroblastoma[NCT00135135]	Phase 2	23 participants (Actual)	Interventional	2005-08-31	Completed
The Pharmacokinetics of a Single Dose of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Moderate to Severe Hepatic Insufficiency[NCT01891526]		20 participants (Actual)	Observational	2010-12-31	Completed
Effectiveness and Safety of Therapy Based on Attenuated Arsenic Trioxide Plus Low Doses of All-trans Retinoic Acid as Remission Induction Therapy in Patients With Acute Promyelocytic Leukemia Phase 1/2 Clinical Trial[NCT05497310]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Treatment of Acute Promyelocytic Leukemia (APL) With All-Trans Retinoic Acid, and Arsenic +/- Idarubicin[NCT00413166]	Phase 2	78 participants (Actual)	Interventional	2006-12-31	Completed
Phase II Study of Combined All-Trans Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy[NCT00528450]	Phase 2	1 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Lack of accrual)
Isotretinoin in Treatment of COVID-19 (Randomized)[NCT04353180]	Phase 3	100,000 participants (Anticipated)	Interventional	2021-08-31	Not yet recruiting
Randomized Phase 2 Trial Comparing Experimental Immunotherapy in Recurrent High Risk Neuroblastoma Patients With Standard Immunotherapy in Patients With Recurrent and Newly Diagnosed High Risk Neuroblastoma[NCT02641782]	Phase 2	3 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to Antibody supply was discontinued by United Therapeutics Corporation.)
A Single Blind, Placebo Controlled Trial to Evaluate Effects of a Study Medication, a Nu Skin Lightening Product With and Without Iontophoresis vs Tretinoin Cream vs Vehicle Control for Facial Hyperpigmentation[NCT01149876]	Phase 4	80 participants (Actual)	Interventional	2010-06-30	Completed
A Phase Ib Dose De-Escalation Study of All-Trans Retinoic Acid (ATRA) and Atezolizumab in Patients With Advanced Non-Small Cell Lung Cancer[NCT04919369]	Phase 1	18 participants (Anticipated)	Interventional	2021-10-18	Recruiting
A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor[NCT00001509]	Phase 2	60 participants	Interventional	1996-07-31	Completed
A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 With and Without ATRA (Tretinoin) in Patients With Advanced Myeloid Malignancies[NCT02842827]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2016-10-06	Completed
Adherence to ZIANA (Clindamycin Phosphate 1.2% With Tretinoin 0.025%)Gel Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris[NCT01047189]	Phase 4	26 participants (Actual)	Interventional	2009-03-31	Completed
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications[NCT04382950]	Phase 1	24 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
Randomized Phase II Trial Of Sequential ATRA Then IL-2 For Modulation Of Dendritic Cells And Treatment Of Metastatic Renal Cancer[NCT00100906]	Phase 2	18 participants (Actual)	Interventional	2004-08-31	Completed
CSP #402 - VA Topical Tretinoin Chemoprevention Trial[NCT00007631]	Phase 3	1,131 participants (Actual)	Interventional	1998-03-31	Completed
Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma[NCT00017225]	Phase 2	0 participants	Interventional	1997-05-31	Completed
High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Rescue for Neuroblastoma: Standard of Care Considerations[NCT01526603]		20 participants (Anticipated)	Interventional	2012-03-28	Recruiting
Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.[NCT04730895]	Phase 1/Phase 2	360 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
Phase III - Study on All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia[NCT00151255]	Phase 3	500 participants (Anticipated)	Interventional	2004-06-30	Completed
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation[NCT00609739]	Phase 1/Phase 2	1 participants (Actual)	Interventional	1999-06-30	Terminated(stopped due to Low accrual)
Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy[NCT01404949]	Phase 2	17 participants (Actual)	Interventional	2011-07-31	Completed
A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia[NCT02061384]	Phase 2	20 participants (Actual)	Interventional	2014-08-31	Completed
Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mer[NCT00003934]	Phase 3	420 participants (Actual)	Interventional	1999-06-30	Completed
Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor[NCT05384821]	Phase 1/Phase 2	28 participants (Anticipated)	Interventional	2022-09-14	Recruiting
Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo[NCT01135069]	Phase 3	480 participants (Actual)	Interventional	2009-10-31	Completed
A Single-center, Prospective, Single-arm Clinical Study of All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma (MM)[NCT06158412]	Phase 2	25 participants (Anticipated)	Interventional	2023-11-22	Recruiting
The Combination of Oral All-trans Retinoic Acid and Danazol vs Danazol as Second-line Treatment in Adult Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial[NCT01667263]	Phase 2	130 participants (Actual)	Interventional	2012-06-01	Completed
Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia[NCT01668615]		35 participants (Actual)	Observational	2011-01-31	Completed
Combination Immunotherapy for Lung Cancer[NCT00601796]	Phase 2	24 participants (Actual)	Interventional	2006-10-31	Completed
A Pilot Phase II Two-Arm, Randomized Clinical Trial of Concomitant Immunotherapy (With Interferon-Alpha and Retinoic Acid) and Radiation Therapy for the Treatment of Advanced Cervical Cancer in India[NCT01276730]	Phase 2	209 participants (Actual)	Interventional	2007-10-31	Completed
A Prospective, Open-label, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of All-trans Retinoic Acid (ATRA) in the Treatment of Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck[NCT04433169]	Phase 2	30 participants (Anticipated)	Interventional	2020-06-03	Recruiting
Phase I Trial of Lithium and Tretinoin for Treatment of Non-Promyelocytic Acute Myeloid Leukemia in Patients Intolerant or Relapsed/Refractory to Standard Chemotherapy.[NCT01820624]	Phase 1	12 participants (Actual)	Interventional	2013-04-30	Completed
Expression of Opsins Receptors in Melasma and Its Modification With UV-Visible Light Sunscreen and 0.05% Retinoic Acid.[NCT04417348]		15 participants (Actual)	Interventional	2019-01-31	Completed
Treatment With Nivolumab and All-trans Retinoic Acid for Patients With Refractory Pancreatic Cancer[NCT05482451]	Early Phase 1	20 participants (Anticipated)	Interventional	2021-03-01	Recruiting
[NCT00000621]	Phase 2	0 participants	Interventional	1999-09-30	Completed
A Pilot Study to Evaluate the Safety and Tolerability of CeraVe® Lotion Followed by Fixed Dose Clindamycin Phosphate 1.2% / Benzoyl Peroxide 2.5% Gel in the Morning in Combination With CeraVe® Lotion Followed by Tretinoin 0.05% Gel in the Evening for the [NCT01448733]	Phase 4	20 participants (Actual)	Interventional	2011-07-31	Active, not recruiting
A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes[NCT00001438]	Phase 2	30 participants	Interventional	1995-06-30	Completed
A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients[NCT00001504]	Phase 1	18 participants	Interventional	1996-05-31	Completed
A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia[NCT02688140]	Phase 3	280 participants (Anticipated)	Interventional	2016-06-30	Active, not recruiting
Randomized Clinical Trial Comparing Treatment of Tretinoin or Superficial Dermabrasion for Recent Stretch Marks[NCT01027793]	Phase 4	32 participants (Actual)	Interventional	2009-03-31	Completed
Retinoids and Intermediate Biomarkers for CIN II and III: Pilot Trial[NCT00003598]		180 participants (Anticipated)	Interventional	1999-01-31	Completed
A Pilot Study of the Combination of 5-azacitidine (5-AZA) and All-trans Retinoic Acid (ATRA) for Prostate Cancer (PCa) With PSA-only Recurrence After Definitive Local Treatment[NCT03572387]	Phase 2	14 participants (Actual)	Interventional	2018-08-20	Completed
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment[NCT04396067]	Phase 2	360 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Tretinoin Gel Microsphere, 0.1% (Taro Pharmaceuticals U.S.A, Inc.) to RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (Valeant) and Both Active Treatments to a P[NCT04883736]	Early Phase 1	973 participants (Actual)	Interventional	2020-08-31	Completed
An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma[NCT00469183]	Phase 4	70 participants (Actual)	Interventional	2006-05-31	Completed
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia[NCT00551460]	Phase 2	78 participants (Actual)	Interventional	2007-11-15	Completed
Formulation of Retinyl Palmitate-loaded Topical Ethosomes for Treatment of Acne Vulgaris: a Split-face Comparative Clinical Study[NCT04080869]	Phase 2	20 participants (Actual)	Interventional	2020-01-06	Completed
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia[NCT03031249]	Phase 1/Phase 2	80 participants (Anticipated)	Interventional	2017-02-08	Recruiting
A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers[NCT01929278]	Phase 1	37 participants (Actual)	Interventional	2008-12-08	Completed
Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo[NCT01243450]	Phase 3	958 participants (Actual)	Interventional	2009-10-31	Completed
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma: A Phase II Study[NCT01183429]	Phase 2	39 participants (Actual)	Interventional	2010-08-12	Completed
INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LE[NCT00002701]	Phase 3	750 participants (Anticipated)	Interventional	1995-10-31	Active, not recruiting
Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19[NCT04568096]	Phase 2	160 participants (Anticipated)	Interventional	2020-11-30	Not yet recruiting
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors[NCT00528437]	Phase 2	46 participants (Actual)	Interventional	2005-10-31	Completed
A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing TRETINOIN CREAM, 0.1% to RETIN-A® (TRETINOIN) CREAM, 0.1% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris[NCT03427554]	Early Phase 1	455 participants (Actual)	Interventional	2017-08-21	Completed
Phase II Single-arm, Single-center Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Refractory Microsatellite Stable Colorectal Cancer[NCT05999812]	Phase 2	21 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination With All-Trans Retinoic Acid (ATRA) in Subjects With Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)[NCT04282668]	Phase 1	80 participants (Anticipated)	Interventional	2020-03-15	Recruiting
A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Azoospermia[NCT03323801]	Phase 2	10 participants (Actual)	Interventional	2017-07-25	Completed
Treatment of Striae Distensae With Fractional Radiofrequency and Topical Tretinoin: An Intra-individual Study With Blinded Outcome Assessment[NCT05461755]	Phase 2	20 participants (Actual)	Interventional	2022-11-22	Completed
Relative Bioavailability and Comparative Pharmacokinetics of 13-CRA Oral Liquid and Extracted Capsule Formulations: a Randomised, Open Label, Multi-dose, Cross-over Clinical Trial in Patients Requiring Treatment Cycles of 13-CRA.[NCT03291080]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2018-04-17	Completed
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma[NCT01711554]	Phase 1	27 participants (Actual)	Interventional	2013-02-04	Active, not recruiting
Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream Before and After 30% Trichloroacetic Acid Chemical Peeling on Aging Skin[NCT05004909]		46 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
An Open-Label Phase I Trial to Evaluate the Safety and Tolerability of ATRA, Celecoxib, and Itraconazole Administered As Maintenance Treatment Post-Autologous Transplantation in Relapsed Multiple Myeloma[NCT02401295]	Phase 1	1 participants (Actual)	Interventional	2015-05-31	Completed
Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19[NCT05077813]	Phase 2	250 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy[NCT01041638]	Phase 3	105 participants (Actual)	Interventional	2009-12-21	Completed
Single Blind Study to Evaluate the Tolerance and Effectiveness of Redermic Versus Rejuva-A™ (0.025% Tretinoin) and Redermic in Combination With Rejuva-A™ (0.025% Tretinoin) Under Normal Conditions in Subjects With Signs of Aging[NCT00974480]		120 participants (Actual)	Interventional	2009-09-30	Completed
Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis - A Human Pilot Study[NCT01456468]	Phase 1	19 participants (Actual)	Interventional	2011-10-31	Completed
Open Label Study to Evaluate the Efficacy and Safety of Sequential Therapy With Fluocinolone Acetonide 0.01%, Hydroquinone (HQ) 4% and Tretinoin 0.05% (TriLuma® Cream) and a Series of Glycolic Acid Peels for the Treatment of Melasma[NCT00472966]	Phase 4	20 participants (Actual)	Interventional	2006-11-30	Completed
Phase II Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia[NCT00326170]	Phase 2	34 participants (Actual)	Interventional	2005-07-31	Completed
Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens[NCT01275274]	Phase 2	0 participants (Actual)	Interventional	2012-01-31	Withdrawn(stopped due to no subject enrolled in nearly 2 years)
[NCT00835198]	Phase 4	163 participants (Actual)	Interventional	2008-12-31	Completed
Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer[NCT05016349]	Phase 3	160 participants (Anticipated)	Interventional	2021-08-31	Not yet recruiting
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies[NCT02712905]	Phase 1/Phase 2	116 participants (Actual)	Interventional	2016-05-05	Terminated(stopped due to Strategic Business Decision)
DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.[NCT03392623]	Early Phase 1	28 participants (Actual)	Interventional	2015-01-01	Completed
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.[NCT05002530]	Phase 4	10,000 participants (Anticipated)	Interventional	2021-11-30	Not yet recruiting
Split-face Tolerability Comparison Between Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Versus Retin-A Micro® (Tretinoin Gel) Microsphere, 0.1% in Subjects With Acne Vulgaris[NCT01522456]	Phase 4	73 participants (Actual)	Interventional	2012-04-30	Completed
A Phase 2 Trial of All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma[NCT05345002]	Phase 2	55 participants (Anticipated)	Interventional	2022-11-16	Recruiting
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia[NCT04793919]	Phase 2	89 participants (Anticipated)	Interventional	2019-10-09	Recruiting
Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel[NCT02249767]	Phase 3	574 participants (Actual)	Interventional	2013-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Complete Response

"CR rate captured up to 8 months~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. SD=stable disease, PD=progression of disease, UE=unevaluable" (NCT03999684)
Timeframe: up to 8 months

Intervention	Participants (Count of Participants)
Tretinoin	0

Intervention	T-Score (Mean)
Regimen A (SPNET Patients)	53.5
Regimen B (SPNET Patients)	75.5
Regimen C (SPNET Patients)	64.5
Regimen D (SPNET Patients)	53.5

Intervention	T-Score (Mean)
Regimen A (SPNET Patients)	56.0
Regimen B (SPNET Patients)	64.0
Regimen C (SPNET Patients)	71.5
Regimen D (SPNET Patients)	53.7

Intervention	T-Score (Mean)
Regimen A (Medulloblastoma Patients)	50.9
Regimen B (Medulloblastoma Patients)	50.2
Regimen C (Medulloblastoma Patients)	50.8
Regimen D (Medulloblastoma Patients)	47.5

Intervention	T-Score (Mean)
Regimen A (SPNET Patients)	53.8
Regimen B (SPNET Patients)	66.7
Regimen C (SPNET Patients)	46.1
Regimen D (SPNET Patients)	64.3

Intervention	Percent Probability (Number)
Regimen A (Medulloblastoma Patients)	57.5
Regimen B (Medulloblastoma Patients)	65.3
Regimen C (Medulloblastoma Patients)	60.3
Regimen D (Medulloblastoma Patients)	70.9

Intervention	Percent Probability (Number)
Regimen A (SPNET Patients)	52.2
Regimen B (SPNET Patients)	52.6
Regimen C (SPNET Patients)	19
Regimen D (SPNET Patients)	63

Intervention	Percent Probability (Number)
Regimen A (Medulloblastoma Patients)	66.0
Regimen B (Medulloblastoma Patients)	75.9
Regimen C (Medulloblastoma Patients)	69.9
Regimen D (Medulloblastoma Patients)	81.6

Intervention	Percent Probability (Number)
Regimen A (SPNET Patients)	60.9
Regimen B (SPNET Patients)	57.9
Regimen C (SPNET Patients)	35.3
Regimen D (SPNET Patients)	77.0

Intervention	Score on a scale (Mean)
Regimen A (SPNET Patients)	83.3
Regimen B (SPNET Patients)	57.5
Regimen C (SPNET Patients)	83.7
Regimen D (SPNET Patients)	88.5

Intervention	score on a scale (Mean)
Regimen A (SPNET Patients)	94.8
Regimen B (SPNET Patients)	48.0
Regimen C (SPNET Patients)	87.0
Regimen D (SPNET Patients)	79.7

Intervention	Score on a scale (Mean)
Regimen A (Medulloblastoma Patients)	96.6
Regimen B (Medulloblastoma Patients)	89.1
Regimen C (Medulloblastoma Patients)	83.5
Regimen D (Medulloblastoma Patients)	94.8

Intervention	Score on a scale (Mean)
Regimen A (SPNET Patients)	84.6
Regimen B (SPNET Patients)	80.3
Regimen C (SPNET Patients)	99.3
Regimen D (SPNET Patients)	90.6

Intervention	Participants (Count of Participants)
	Complete Response	Minor Reponse	Partial Response	Stable Disease	Disease Progression
Phase 1 Group	1	0	1	5	5
Phase 2 Group	0	1	3	4	6

Intervention	Participants (Count of Participants)
	Fatigue : Grade 1	Fatigue : Grade 2	Fatigue : Grade 3	Fatigue : Grade 4	Skin : Grade 1	Skin : Grade 2	Skin : Grade 3	Skin : Grade 4	Xeroderma : Grade 1	Xeroderma : Grade 2	Xeroderma : Grade 3	Xeroderma : Grade 4	Constipation : Grade 1	Constipation : Grade 2	Constipation : Grade 3	Constipation : Grade 4	Cough : Grade 1	Cough : Grade 2	Cough : Grade 3	Cough : Grade 4	Anemia : Grade 1	Anemia : Grade 2	Anemia : Grade 3	Anemia : Grade 4	Anorexia : Grade 1	Anorexia : Grade 2	Anorexia : Grade 3	Anorexia : Grade 4	Neurologic : Grade 1	Neurologic : Grade 2	Neurologic : Grade 3	Neurologic : Grade 4	Diarrhea : Grade 1	Diarrhea : Grade 2	Diarrhea : Grade 3	Diarrhea : Grade 4	Nausea/vomiting : Grade 1	Nausea/vomiting : Grade 2	Nausea/vomiting : Grade 3	Nausea/vomiting : Grade 4	Altered mood : Grade 1	Altered mood : Grade 2	Altered mood : Grade 3	Altered mood : Grade 4	Leukopenia : Grade 1	Leukopenia : Grade 2	Leukopenia : Grade 3	Leukopenia : Grade 4	Fever : Grade 1	Fever : Grade 2	Fever : Grade 3	Fever : Grade 4	Renal : Grade 1	Renal : Grade 2	Renal : Grade 3	Renal : Grade 4	Liver : Grade 1	Liver : Grade 2	Liver : Grade 3	Liver : Grade 4	Thrombocytopenia : Grade 1	Thrombocytopenia : Grade 2	Thrombocytopenia : Grade 3	Thrombocytopenia : Grade 4	Infusion reaction : Grade 1	Infusion reaction : Grade 2	Infusion reaction : Grade 3	Infusion reaction : Grade 4	Pulmonary : Grade 1	Pulmonary : Grade 2	Pulmonary : Grade 3	Pulmonary : Grade 4	Nasal congestion : Grade 1	Nasal congestion : Grade 2	Nasal congestion : Grade 3	Nasal congestion : Grade 4	Hypotension : Grade 1	Hypotension : Grade 2	Hypotension : Grade 3	Hypotension : Grade 4	Cholesterol/TG : Grade 1	Cholesterol/TG : Grade 2	Cholesterol/TG : Grade 3	Cholesterol/TG : Grade 4	Bone pain : Grade 1	Bone pain : Grade 2	Bone pain : Grade 3	Bone pain : Grade 4	Other pain : Grade 1	Other pain : Grade 2	Other pain : Grade 3	Other pain : Grade 4
Phase 1 Group	7	5	0	0	1	0	0	0	11	0	0	0	5	0	0	0	4	2	0	0	3	1	2	0	9	2	0	0	8	3	1	0	5	0	0	0	2	2	0	0	8	0	0	0	2	2	3	0	4	1	0	0	1	1	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Phase 2 Group	8	4	0	0	3	0	0	0	5	0	0	0	4	0	0	0	0	0	0	0	2	5	0	0	6	2	0	0	9	1	0	0	4	0	0	0	6	1	0	0	4	0	0	0	2	1	0	0	5	0	0	0	3	0	0	0	2	0	0	0	3	0	0	0	0	1	0	0	1	0	1	0	1	0	0	0	0	1	0	0	1	0	0	0	1	0	0	0	5	0	0	0

Intervention	percent change from pre-treatment value (Mean)
	Responding patients	Non-responding patients	Overall
Pembrolizumab With All-Trans Retinoic Acid	-48.6	109.7	-7.3

Intervention	percentage of patients (Number)
Post-consolidation Therapy Arm I	96
Post-consolidation Therapy Arm II	100

Intervention	Participants (Number)
	ALT, SGPT (serum glutamic pyruvic transaminase)	AST, SGOT	Acidosis (metabolic or respiratory)	Albumin, serum-low (hypoalbuminemia)	Alkaline phosphatase	Alkalosis (metabolic or respiratory)	Anorexia	Bilirubin (hyperbilirubinemia)	CPK (creatine phosphokinase)	Calcium, serum-low (hypocalcemia)	Cardiac Arrhythmia-Other (Specify)	Cardiac troponin T (cTnT)	Cholesterol, serum-high (hypercholesterolemia)	Coagulation-Other (Specify)	Confusion	Creatinine	DIC (disseminated intravascular coagulation)	Dehydration	Diarrhea	Distention/bloating, abdominal	Dizziness	Dry skin	Dysphagia (difficulty swallowing)	Dyspnea (shortness of breath)	Enteritis (inflammation of the small bowel)	Extremity-lower (gait/walking)	Fatigue (asthenia, lethargy, malaise)	Febrile neutropenia	Fever in absence of neutropenia, ANC lt1.0x10e9/L	Flu-like syndrome	Glucose, serum-high (hyperglycemia)	Hemoglobin	Hemorrhage, CNS	Hemorrhage, GI - Rectum	Hemorrhage, GU - Vagina	Hemorrhage, pulmonary/upper respiratory - Lung	Hemorrhage, pulmonary/upper respiratory - Nose	Hypertension	Hypotension	Hypoxia	Inf (clin/microbio) w/Gr 3-4 neuts - Blood	Inf (clin/microbio) w/Gr 3-4 neuts - Cecum	Inf (clin/microbio) w/Gr 3-4 neuts - Colon	Inf (clin/microbio) w/Gr 3-4 neuts - Dental-tooth	Inf (clin/microbio) w/Gr 3-4 neuts - Lung	Inf (clin/microbio) w/Gr 3-4 neuts - Oral cav-gums	Inf (clin/microbio) w/Gr 3-4 neuts - Sinus	Inf (clin/microbio) w/Gr 3-4 neuts - Skin	Inf (clin/microbio) w/Gr 3-4 neuts - UTI	Inf (clin/microbio) w/Gr 3-4 neuts - Up aerodigest	Inf w/normal ANC or Gr 1-2 neutrophils - Bladder	Inf w/normal ANC or Gr 1-2 neutrophils - Blood	Inf w/normal ANC or Gr 1-2 neutrophils - Catheter	Inf w/normal ANC or Gr 1-2 neutrophils - Gallbladd	Inf w/normal ANC or Gr 1-2 neutrophils - Skin	Inf w/unknown ANC - Oral cavity-gums (gingivitis)	Infection with unknown ANC - Bladder (urinary)	Infection with unknown ANC - Lung (pneumonia)	Infection with unknown ANC - Rectum	Infection with unknown ANC - Skin (cellulitis)	Infection-Other (Specify)	Left ventricular systolic dysfunction	Leukocytes (total WBC)	Lymphopenia	Metabolic/Laboratory-Other (Specify)	Mood alteration - agitation	Mood alteration - anxiety	Mood alteration - depression	Mucositis/stomatitis (clinical exam) - Oral cavity	Mucositis/stomatitis (clinical exam) - Rectum	Mucositis/stomatitis (functional/symp) - Oral cav	Muscle weakness, not d/t neuropathy - Extrem-lower	Muscle weakness, not d/t neuropathy - Extrem-upper	Muscle weakness, not d/t neuropathy - body/general	Myositis (inflammation/damage of muscle)	Nausea	Neuropathy: motor	Neuropathy: sensory	Neutrophils/granulocytes (ANC/AGC)	Opportunistic inf associated w/gt=Gr 2 lymphopenia	Pain - Abdomen NOS	Pain - Back	Pain - Chest/thorax NOS	Pain - Extremity-limb	Pain - Head/headache	Pain - Joint	Pain - Muscle	Pain - Neck	Pain - Rectum	Pain - Scrotum	Pain - Throat/pharynx/larynx	Pericardial effusion (non-malignant)	Pericarditis	Petechiae/purpura (hemorrhage into skin or mucosa)	Phosphate, serum-low (hypophosphatemia)	Photosensitivity	Platelets	Pleural effusion (non-malignant)	Pneumonitis/pulmonary infiltrates	Potassium, serum-low (hypokalemia)	Prolonged QTc interval	Pruritus/itching	Rash/desquamation	Renal failure	Renal/Genitourinary-Other (Specify)	Restrictive cardiomyopathy	Retinal detachment	Retinoic acid syndrome	Sodium, serum-low (hyponatremia)	Syncope (fainting)	Thrombosis/thrombus/embolism	Triglyceride, serum-high (hypertriglyceridemia)	Typhlitis (cecal inflammation)	Uric acid, serum-high (hyperuricemia)	Vasovagal episode	Ventricular arrhythmia - Ventricular tachycardia	Vomiting	Weight gain
ATRA + Ara-C + Daunorubicin	5	2	1	4	1	2	4	7	2	3	1	2	1	2	4	2	11	0	11	2	1	1	0	11	1	1	8	58	1	0	4	37	1	1	1	1	2	3	1	6	10	1	4	1	8	1	0	3	1	1	0	1	0	1	3	1	1	1	1	1	2	0	34	20	1	1	0	1	3	1	0	1	1	2	2	6	1	0	34	0	3	2	0	1	10	0	3	1	0	1	0	1	0	2	7	1	42	1	0	4	3	0	3	7	1	0	1	13	4	3	1	5	3	0	1	1	1	1
ATRA+6-MP+MTX	2	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3	3	7	0	0	0	0	1	0	0	0	0	0	0	1	0	0	4	0	0	0	0	0	6	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0
Consolidation	3	2	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	5	8	1	1	5	4	0	0	0	0	0	1	2	0	1	0	0	0	0	0	0	0	0	0	0	5	1	0	1	0	0	0	0	0	0	3	37	20	0	0	1	0	0	0	1	0	0	0	0	4	0	2	55	1	1	0	2	1	3	4	2	0	1	0	1	1	1	0	1	0	18	0	1	0	6	0	1	1	0	1	0	0	0	0	0	2	0	1	1	1	1	0
Gemtuzumab Ozogamicin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Intervention	Percentage of participants (Number)
	Randomized patients with INSS Stage 4 disease	Eligible patients with persistent disease
Regimen B	59.7	35.1

Intervention	courses per patient (Median)
	Randomized to Regimen B - RA + Immunotherapy	Non-randomly assigned after halting randomization
Regimen B	6	6

Intervention	Percentage of participants (Number)
	Randomized patients	Randomized patients with INSS Stage 4 disease
Regimen A	67.4	64.0
Regimen B	78.8	78.7

tretinoin

Description

Cross-References

Synonyms (336)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (9)

Drug Classes (2)

Pathways (46)

Protein Targets (137)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (644)

Molecular Functions (206)

Ceullar Components (117)

Bioassays (916)

Research

Studies (22,822)

Study Types

Clinical Trials (221)

Trial Overview

Trial Outcomes

Complete Response

Duration Of Therapeutic Response

Partial Response

Progression Free Survival

Best Overall Response Rate

Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 30+/-6 Months Post Diagnosis for SPNET Patients

Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 60+/-12 Months Post Diagnosis for SPNET Patients

Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients

Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 9+/-3 Months Post Diagnosis for SPNET Patients

Percent Probability of Event-free Survival (EFS) for Patients With Medulloblastoma

Percent Probability of Event-free Survival (EFS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)

Percent Probability of Overall Survival (OS) for Patients With Medulloblastoma

Percent Probability of Overall Survival (OS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)

The Estimated Full-scale IQ (FSIQ) at 30+/-6 Months Post Diagnosis for SPNET Patients

The Estimated Full-scale IQ (FSIQ) at 60+/-12 Months Post Diagnosis for SPNET Patients

The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients

The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for SPNET Patients

Tumor Response to Radiation Therapy for Patients With Medulloblastoma

Tumor Response to Radiation Therapy for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)

Melasma Area Severity Assessment (MASI) Score Change From Baseline to Follow Up

Change in Retinoic Acid Receptor Expression on Tissue as Measured by Number of Subjects With the Presence of Peripheral Blood Lymphocytes During the First and Fifth Dose

Best Response as Measured by CT, Bone Scans, and Clinical Progression

Duration of Response (Progression-free Survival) as Measured by CT, Bone Scans, and Clinical Progression From Initiation of Therapy Until an Increase of ≥ 25% From the Smallest Sum of All Tumor Measurements Obtained During the Best Response

Number of Subjects With Toxicity by Clinical Evaluation From First Dose to 30 Days After Last Dose

EFS in High Risk APL Patients

Event-free Survival (EFS) in Standard Risk Acute Promyelocytic Leukemia (APL) Patients

Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12

Change From Baseline in Inflammatory Lesion Counts on the Face at Week 4

Change From Baseline in Inflammatory Lesion Counts on the Face at Week 8

Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12

Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 4

Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 8

Percent Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12

Percent Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12

Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline

Percentage of Participants Achieving at Least a 4-Point Reduction on Item 1 (Pimple) of the Patient-Reported Evaluation of Facial Acne (Pre-Face)

Percentage of Participants Achieving at Least a 4-Point Reduction on Item 5 (Embarrassment) of the Pre-Face

Incidence of Unacceptable Toxicity and Sinusoidal Obstruction Syndrome (SOS), Assessed by Common Terminology Criteria (CTV)v.4.0 for Toxicity Assessment and Grading for I-MIBG

Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131

Percentage of MIBG Avid Patients Treated With MIBG Labeled With Iodine-131 and Bu/Mel Chemotherapy

Maximally Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of All-Trans Retinoic Acid

Maximally Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Pembrolizumab

Number of Patients With a Dose-Limiting Toxicity (DLT) for the Combined Treatment of Pembrolizumab and All-Trans Retinoic Acid